DNA damage response and anti-apoptotic proteins expression in NPMc+ mutated cells in acute myeloid leukaemia by Qutob, Haitham
Qutob, Haitham (2014) DNA damage response and anti-
apoptotic proteins expression in NPMc+ mutated cells in 
acute myeloid leukaemia. PhD thesis, University of 
Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/14209/1/Haitham_Qutob_Thesis_19-05-14.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
  
 
DNA Damage Response and  
Anti-apoptotic Proteins 
Expression in NPMc+ Mutated 
Cells in Acute Myeloid Leukaemia 
 
 
 
 
 
Haitham Mohammed Habib Qutob, BSc, MSc. 
 
 
 
 
 
 
 
Thesis submitted to the University of Nottingham for the 
degree of Doctor of Philosophy 
 
 
 
July 2014 
Qutob, H 
I 
 
Abstract 
Nucleophosmin 1 (NPM1) is a multi-functional phosphoprotein, 
which shuttles between the nucleolus and the cytoplasm. It 
participates in many cellular processes including ribosome 
biogenesis and transport, centrosome duplication, and also 
contributes to the control of genomic stability. NPM1 interacts 
with many proteins including those that participate in DNA 
damage repair processes. C-terminal mutations in NPM1 occur 
in 35% of patients with acute myeloid leukaemia and are 
associated with a good prognosis. They are characterised by 
delocalisation of NPM1 into the cytoplasm. This may have a 
role in the sensitivity of mutant cells to chemotherapy via 
inactivation of the DNA damage response processes. 
Firstly, we aimed to identify potential differences in DNA repair 
in response to double-strand breaks (DSB) and alkylating 
inducers and then assess them through the comet assay in the 
wild-type and mutant NPM1 cell lines. The percentage and 
kinetics of DNA damage in both cell lines was identical, 
indicating that DNA lesions were repaired efficiently in both 
the wild-W\SHDQGPXWDQWFHOOOLQHV7KHǄ-H2AX foci were also 
evaluated which increased to similar levels in mutant and wild-
type cells lines after exposure to DNA damaging agents and 
decreased with similar rates when the cells were allowed 24 
hours to repair the damage. Interestingly, following DNA 
damage, the amount of NPM1 increased significantly in NPMc+ 
cells, both in the nucleus and the cytoplasm, which was not 
seen in NPM1 wild-type cells. 
Next, we determined the subcellular localisation of APE1, 
which is a DNA repair enzyme in the base excision repair 
pathway and a transcriptional co-activator. APE1 has 
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previously been shown to associate with NPM1. Using confocal 
microscopy, we found that the APE1 in both wild-type and 
NPMc+ mutant cell lines is predominately localised in the 
cytoplasm, while it is translocated into the nucleus after the 
cells were exposed to MMS, presumably to play a role in the 
DNA damage repair mechanism.  
As we could find no apparent difference in DNA repair between 
NPM1 mutated and wild type cells we went on to look at 
proteins involved in cell survival - BCL-2 and MCL-1. The 
NPMc+ mutant cell line expressed the highest level of mRNA 
BCL-2 and MCL-1 when compared to the NPM1 wild-type cell 
lines. The NPMc+ mutated cells have previously been shown to 
be sensitive to the effect of all-trans retinoic acid (ATRA). We 
looked to see whether ATRA has an effect on the anti-
apoptotic proteins. The results demonstrate that the BCL-2 
and MCL-1 levels were down-regulated to a greater level in the 
NPM1 mutant cell line than in the NPM1 wild-type cells. In 
patient samples, the BCL-2 and MCL-1 mRNA down-regulation 
was seen in 3/5 and 5/5 NPMc+ samples, respectively. Thus, 
these finding indicate that BCL-2 and MCL-1 mRNA expression 
is down-regulated following ATRA in NPMc+ mutant cells. 
Finally, siRNA was used to decrease levels of either total NPM1 
or mutant NPM1 alone. Results showed that in the NPM1 
mutant cells there was a down-regulation of BCL-2 mRNA, 
while in the NPM1 wild-type cells, no effect on the BCL-2 
mRNA level was found. Furthermore, levels of P53 were up-
regulated in the mutant NPM1 cells after knocking-down the 
total NPM1, whereas the wild-type cell line showed no change 
in the P53 level. These results provide evidence suggesting 
that down-regulation of NPM1 in the NPMc+ cell line increases 
total P53, possibly by interaction of ARF and HDM2, resulting 
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in down-regulation of the BCL-2 in the mutated cells. In 
conclusion, perturbation of NPM1 subcellular localisation in 
NPMc+AML has no effect on the DNA repair mechanisms but 
we found differences in the anti-apoptotic proteins expression 
compared to NPM1 wild-type cells. 
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1.1 Acute myeloid leukaemia: 
Acute myeloid leukaemia (AML), also known as acute 
myelogenous leukaemia, is a haematological malignancy that 
arises from myeloid precursor cells. These cells fail to 
differentiate normally and to activate normal cell apoptosis 
signals leading to abnormal accumulation of immature myeloid 
cells and increase in cell proliferation. The incidence of AML 
varies with age, it is most common in older adults with a 
median age of approximately 68 years and accounts for 80-
90% of acute leukaemia in adults (reviewed in (Konoplev and 
Bueso-Ramos 2006)). In addition, 10% of AML incidences 
affect younger children whose age are less than 10 years, 
while in patients aged between 10 and 15 years AML 
comprises 30% of cases (reviewed in (Konoplev and Bueso-
Ramos 2006)). Males are more likely to suffer from AML than 
females and the incidence of AML is increased in patients who 
suffer with certain genetic disorders such as Fanconi anaemia, 
Kostmann syndrome, Down syndrome and Klinefelter 
(Konoplev and Bueso-Ramos 2006, Shipley and Butera 2009). 
AML is diagnosed by the accumulation of 20% blast cells in the 
bone marrow, and these blasts express surface antigen 
associated with myeloid differentiation such as CD33 and 
CD13 (reviewed in (Estey and Doehner 2006)). AML treatment 
consists of an anthracycline, such as daunorubicin or 
idarubicin, combined with cytarabine and the therapy is based 
on two steps, which are attempt to produce complete 
remission by decreasing the blast cells to reach 5%, and then 
prolong the complete remission (reviewed in (Estey and 
Doehner 2006)).  
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1.1.1 AML heterogeneity: 
AML is an extremely heterogeneous disease and several 
systems have been used to divide AML cases into subgroups. 
AML has been classified into different categories according to 
cell morphological, immunological, cytochemical, and 
cytogenetic features (Konoplev and Bueso-Ramos 2006). The 
most commonly used is the World Health Organisation (WHO) 
classification, which has essentially taken over from the 
French-American-British classification (FAB). The FAB 
classification depends on cell morphology and cytochemical 
features, but a number of subtypes, which are identified by 
high technology methods, were not included in the FAB 
classification (Wakui, et al 2008). Thus, the demand for a 
more precise and comprehensive system was accomplished in 
the WHO classification, which relies on immunological, 
cytogenetical and clinical features, in addition to the FAB 
criteria, and has been cited as being more comprehensively 
useful than the FAB classification (Table 1.1) (Vardiman, et al 
2009). 
1.1.2 AML with cytogenetic abnormalities: 
Chromosomal rearrangements, which include balanced 
translocations, inversions, deletions, additions or trisomies, 
are seen in approximately 55% of AML cases (reviewed in 
(Mrozek, et al 2004)). Cytogenetic analysis contributes 
important information to prognosis in AML and divides cases 
into three groups: favourable, intermediate, and adverse 
(Doehner, et al 2010). The t(8;21), t(15;17) and inv(16) are 
associated with the favourable group, whilst patients with 
abnormalities of 3q, deletion of 5q, or complex karyotype, 
which have 4 or more chromosomal abnormalities other than 
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t(8;21), inv(16) or t(16;16), and t(15;17), are classified with 
the adverse group (Table 1.2) (Grimwade, et al 2010). For 
example, the overall-survival (OS) in a patient with t(8;21) 
and deletion (9q) or other chromosome abnormalities, is not 
significantly different from those patients with only t(8;21) 
(Grimwade, et al 2010). However, the presence of 
t(3;3)/inv(3), del(5q)/-5, and -7 cytogenetic abnormalities are 
predictors of a poor prognosis (Figure 1.1) (Grimwade, et al 
2010). The distributions of cytogenetic abnormalities are 
FRUUHODWHG ZLWK WKH SDWLHQW¶V DJH In younger patients, for 
instance, the balanced rearrangements of t(8;21), t(15;17) 
and inv(16) are more common than in older patients, whilst 
the unbalanced rearrangements occur in older patients 
(Grimwade, et al 2010).  
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Table 1.1: WHO (2008) classifications; Classification of acute myeloid 
leukaemia and related precursor neoplasms, and acute leukaemias of 
ambiguous lineage (Doehner, et al 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
Categories 
Acute myeloid leukaemia with recurrent genetic abnormalities: 
x AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
x AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-
MYH11 
x APL with t(15;17)(q22;q12); PML-RARA 
x AML with t(9;11)(p22;q23); MLLT3-MLL 
x AML with t(6;9)(p23;q34); DEK-NUP214 
x AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
x AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
x Provisional entity: AML with mutated NPM1 
x Provisional entity: AML with mutated CEBPA 
Acute myeloid leukaemia with Myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
 
Acute myeloid leukaemia, not otherwise specified (NOS): 
x Acute myeloid leukaemia with minimal differentiation 
x Acute myeloid leukaemia without maturation 
x Acute myeloid leukaemia with maturation 
x Acute myelomonocytic leukaemia 
x Acute monoblastic/monocytic leukaemia 
x Acute erythroid leukaemia 
x Pure erythroid leukaemia 
x Erythroleukemia, erythroid/myeloid 
x Acute megakaryoblastic leukaemia 
x Acute basophilic leukaemia 
x Acute panmyelosis with myelofibrosis (acute myelofibrosis; 
acute myelosclerosis) 
 
Myeloid sarcoma (extramedullary myeloid tumour; granulocytic 
sarcoma; chloroma) 
Myeloid proliferations related to Down syndrome: 
x Transient abnormal myelopoiesis (transient myeloproliferative 
disorder) 
x Myeloid leukaemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
$FXWHOHXNDHPLD¶VRIDPELJXRXVOLQHDJH 
x Acute undifferentiated leukaemia 
x Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); 
BCR-ABL1 
x Mixed phenotype acute leukaemia with t(v;11q23); MLL 
rearranged 
x Mixed phenotype acute leukaemia, B/myeloid, NOS 
x Mixed phenotype acute leukaemia, T/myeloid, NOS 
x Provisional entity: Natural killer (NK)±cell lymphoblastic 
leukaemia/lymphoma 
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Table 1.2: Cytogenetics-risk group classifications in AML   
(Grimwade, et al 2010). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Impact of cytogenetic entities recognised in 2008 WHO 
classification on survival (Grimwade, et al 2010). *Excluding patients with 
t(15;17), t(8;21), inv(16), t(9;11), t(6;9), inv(3)/t(3;3). **Excluding patients 
with any other abnormalities. 
 
 
Cytogenetic abnormality Comments 
Favourable 
 
t(15;17)(q22;q21)  
t(8;21)(q22;q22)  
inv(16)(p13q22)/t(16;16)(p13;q22) 
 
 
Irrespective 
of additional 
cytogenetic 
abnormalities 
Intermediate 
 
Entities not classified as favourable 
or adverse 
 
Adverse 
 
Abnormal (3q)  [excluding 
t(3;5)(q21_25;q31_35)], 
inv(3)(q21q26)/t(3;3)(q21;q26), 
add(5q), del(5q), _5, 
_7, add(7q)/del(7q), 
t(6;11)(q27;q23), 
t(10;11)(p11_13;q23), 
t(11q23) [excluding t(9;11)(p21_22;q23), and 
t(11;19)(q23;p13)] 
t(9;22)(q34;q11), 
_17/abnormal(17p), 
Complex (> 4 unrelated abnormalities) 
 
 
Excluding 
cases with 
favourable 
Karyotype 
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1.1.3 AML with normal cytogenetic and molecular 
mutations: 
Despite the refinement of the cytogenetic classification by 
Grimwade 2010 (Grimwade, et al 2010), approximately 40 to 
50% of AML cases have a normal karyotype and these cases 
are classified in the intermediate prognosis group based on 
cytogenetics even though some patients with a normal 
karyotype respond very well to treatment and some respond 
very badly (reviewed in (Estey and Doehner 2006). Recently, 
many of these normal karyotype AML cases have been shown 
to harbour specific gene mutations, or deregulation of gene 
expression which may account for the heterogeneity within 
this group of patients (reviewed in (Dohner and Dohner 
2008)). The type of mutations required to result in AML are 
categorised into two different groups: the first group, class I, 
involves the activation of signal transduction pathways causing 
hyper-proliferation and survival of the leukaemic cells, such as 
FLT3-ITD and RAS mutations (reviewed in (Dohner and 
Dohner 2008)). The second group, class II, leads to an 
impaired differentiation and/or irregular gaining of self renewal 
properties, such as CEBPA, MLL-PTD, where the mutations 
affect transcription factors, or its co-activation components 
(reviewed in (Dohner and Dohner 2008)). 
1.1.3.1 Internal tandem duplication of Fms-like tyrosine 
kinase-3 (FLT3-ITD) in AML: 
The most common mutations in normal karyotype AML are 
length mutations in fms-like tyrosine kinase-3 (FLT3) and 
nucleophosmin 1 (NPM1). FLT3 is a member of the class III 
receptor tyrosine kinase, and is normally expressed in 
haematopoietic stem cells but this expression is reduced as 
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these cells differentiate (Lyman, et al 1994). It plays a major 
role in cell survival and proliferation through increase in the 
expression of FLT3 in haematopoietic cells leading to activation 
of the tyrosine kinase activity and stimulate the growth of 
progenitor cells in the bone marrow (Kikushige, et al 2008). 
FLT3 mutations are caused either by internal tandem 
duplication (ITD), which is described by an insertion of 3 to 
hundreds of amino acids into the FLT3 juxtamembrane 
domain, or by point mutation in the activation loop of the 
tyrosine kinase domain of FLT3, which are observed in 
approximately 5% of all patients with AML (Kusec, et al 2006, 
Ponziani, et al 2006, Reindl, et al 2006). FLT3 mutations lead 
to constitutive activation of the receptor and subsequent 
downstream activation of signal transducers and activators of 
transcription 5 (STAT-5), mitogen-activated protein (MAP) 
kinase, and phosphatidylinositol 3 (PI3) resulting in leukaemic 
cell survival and proliferation (Brandts, et al 2005, Mizuki, et al 
2000). The signalling pathways have an effect on a large 
number of related proteins and genes (Seedhouse, et al 2006, 
Tickenbrock, et al 2005). 
Internal tandem duplication (ITD) in the FLT3 gene is a 
common mutation in AML and accounts for 25% of AML and 
patients with an FLT3-ITD are classified as having an adverse 
prognosis because it is correlated with a high risk of disease 
relapse leading to the lowering of the overall survival 
(Grimwade, et al 2010, Kottaridis, et al 2001). One 
explanation for the inferior outcome is due to the resistance of 
the leukaemic cells to chemotherapy, possibly as a result of 
enhancing the DNA damage repair in the cells. Consequently, 
a possibility for this occurrence is due to the increase of 
phosphorylation of STAT-5 (p-STAT-5) and the homologous 
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recombination mechanism (Seedhouse, et al 2006). This 
causes an increase of the RAD51 expression, which has been 
noted to correlate with a poorer clinical outcome in many 
types of tumours and induces anti-apoptotic programmes 
(Helleday 2010). 
In preclinical studies, abnormal over-expression of FLT3-ITD is 
considered to be a useful therapeutic target in AML. Small 
FLT3 tyrosine kinase inhibitors have been developed to block 
the aberrant signal transduction in FLT3-ITD patients and 
these molecules show an ability in inhibition to both the wild-
type and FLT3-ITD auto-phosphorylation and an increase in 
cytotoxicity against the primary FLT3-ITD mutant blast cells 
(reviewed in (Kindler, et al 2010)). These agents were 
classified as high selective to target FLT3, such as AC220, 
intermediate (sunitinib), and less selective (lestaurtinib) and 
all are under investigation as single agents and in combination 
with conventional chemotherapy (Mollgard, et al 2008, 
Schittenhelm, et al 2009, Seedhouse, et al 2006). 
1.1.3.2 Frame-shift mutations of NPM1 in AML: 
On the other hand, the NPMc+AML mutations account for 35% 
of all adult AML and it is characterised by an aberrant 
delocalisation of NPM1 into the cytoplasm (Falini, et al 2005). 
NPMc+AML is associated with a favourable prognosis, 
however, the presence of FLT3-ITD with NPMc+ mutations has 
a negative influence on the prognosis and converts it into an 
intermediate prognosis (Dohner, et al 2005, Schnittger, et al 
2005, Thiede, et al 2006, Verhaak, et al 2005). The precise 
mechanisms connecting the NPM1 mutation to the 
development of AML and the increased risk of patients 
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harbouring the NPM1 mutation and FLT3-ITD has not been 
clarified.  
The subject of this thesis is on NPM1 and therefore the most 
recent insights into the molecular, biological, pathological 
features of NPM1 mutations in AML will be discussed in 
sections 1.2. 
1.1.3.3 Other mutations in cytogenetically normal AML: 
There are other mutations that have been detected in normal-
karyotype AML, such as CEBPA, MLL-PTD, NRAS, WT1, and 
RUNX1. Mutations in &&$$7HQKDQFHU ELQGLQJ SURWHLQ Į
(CEBPA) are detected in 15% of patients with normal-
karyotype in AML (Lin, et al 2005). CEBP protein encodes a 
master regulatory transcription factor in haematopoiesis and it 
up-regulates genes, which are involved in haematopoietic 
stem cell and granulocyte differentiation (Lin, et al 2005). 
CEBPA mutations include mutations in the N-terminal region 
leading to the production of a truncated isoform with negative 
effect, and in-frame mutations in the C-terminal resulting in 
CEBPA proteins with reduced DNA binding (Lin, et al 2005). 
CEBPA mutations in AML are associated with favourable 
prognosis and the overall survival rates are very comparable 
to those patients with NPMc+ without FLT3-ITD (reviewed in 
(Dohner and Dohner 2008)). 
Furthermore, the MLL gene, which is located on chromosome 
11q23, encodes the protein involved in the epigenetic 
regulation of gene expression in haematopoiesis (Whitman, et 
al 2005). MLL partial tandem duplications (MLL-PTD) are 
detected in 7% of AML patients with normal cytogenetics and 
have a short complete remission rate and relapsed-free 
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survival (Whitman, et al 2005). Approximately 25% of MLL-
PTD cases are associated with FLT3-ITD and the prognoses are 
very poor (Zorko, et al 2012). NRAS mutations cause a 
constitutive activation of the RAS protein, which plays an 
important role in the modulation of signal transduction. They 
bind to different membrane receptors leading to the regulation 
of cell growth, differentiation and apoptosis. NRAS mutations 
are found in 14% of younger adult AML patients and the 
disease prognosis is controversial. Some studies found that 
patients with NRAS mutations have poor prognosis, while 
others assumed the prognosis impact is associated with a 
more favourable outcome (Neubauer, et al 1994, Paquette, et 
al 1993). 
1.2 Nucleophosmin 1 (NPM1) gene and protein: 
NPM1, also called nucleolar protein B23, is a multifunctional 
phosphoprotein that resides mainly in the nucleolus. It 
shuttles rapidly between the nucleus and the cytoplasm, and 
transports proteins between the cellular compartments 
(reviewed in (Falini, et al 2007b)). Due to its shuttling role, 
NPM1 is involved in many cellular activities, including both cell 
proliferation and growth-suppressive roles (Grisendi, et al 
2006). The gene mapping of NPM1 has located the gene to 
chromosome 5q35 and it contains 12 exons and encodes a 
protein of 294 amino acids (Chen, et al 2006, Falini, et al 
2005). 
1.2.1 NPM1 structure: 
The genetic structure of NPM1 encodes for three alternative 
nucleophosmin isoforms termed B23.1, B23.2 and B23.3, 
which share N-terminal residues, but, which differ in the last 
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amino acids of the C-terminal domain (Hingorani, et al 2000). 
B23.1 is localised in the nucleolus and is the predominant form 
in all tissues. The composition of NPM1 B23.1 is divided into 
three parts; N-terminal, acidic stretches, and C-terminal 
(Figure 1.2). The N-terminal residue, which is common to the 
NPM1 isoforms, is a hydrophobic region involved in 
oligomerisation and chaperon activity for proteins, nucleic 
acids and histones (Falini, et al 2007b, Hingorani, et al 2000). 
NPM1 is mainly present as an oligomer, a form which is 
adopted during both cell proliferation and resting, and 
accounts for 95% of NPM1 protein (Chan and Chan 1995). The 
N-terminal residues are followed by two acidic stretches that 
act to help in the histone binding activity of NPM1 and, which 
are also required for ribonuclease activity (Falini, et al 2007b, 
Hingorani, et al 2000). The third region of the B23.1 isoform is 
the C-terminal, which is involved in nucleic acid binding and 
ribonuclease activity (Hingorani, et al 2000). It is then 
followed by aromatic short stretches containing two 
tryptophan residues at positions 288 and 290, which assist in 
the localisation of the NPM1 in the nucleolus (Hingorani, et al 
2000, Nishimura, et al 2002). Importantly, the NPM1 contains 
the nuclear-export signal (NES) motifs and bipartite nuclear 
localisation signal (NLS) motifs at the N-terminal domain and 
the acidic region, which are important for its shuttling activity 
(Wang, et al 2005). Moreover, the gene contains numerous 
phosphorylation sites, which are important for specific 
functions including, the regulation of centrosome duplication 
and nucleic acid binding during specific cell cycle stages 
(Hingorani, et al 2000).  
B23.2, which is a truncated isoform, is composed of 257 amino 
acids, while the B23.3 consists of 259 amino acids (Dalenc, et 
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al 2002)). B23.2 is similar to B23.1, but lacks the last 35 C-
terminal amino acid and is expressed in the nucleoplasm and 
found in all tissues, but at a lower level than B23.1 (Dalenc, et 
al 2002, Falini, et al 2007b). 
 
Figure 1.2: NPM1 structure; The N-terminal motif is involved in oligomerisation and 
chaperon activity, followed by the central portion which is important in ribonuclease activity 
and histone binding. The C-terminal domain is involved in nucleic acid binding and contains 
two tryptophan residues which are essential for nucleolar localisation of NPM1 (Grisendi, et al 
2006).  
1.2.2 NPM1 transport in wild-type NPM1: 
NPM1 is a nucleocytoplasmic shuttling protein, which is 
predominantly localised in the nucleolus (Cordell, et al 1999). 
The two highly conserved nuclear export signal (NES) motifs in 
the wild-type NPM1 are located within residues 94 to 102 with 
the sequence I-xx-P-xx-L-x-L, and the other at the N-terminus 
within amino acid 42 to 49 with the sequence L-x-L-xx-V-x-L 
at the N-terminus. These motifs are essential in regulation the 
nuclear export of NPM1 through interaction of the conserved 
export receptor CRM1 with these motifs (Kau, et al 2004). 
Furthermore, the nuclear localisation signal (NLS), which is 
located between the two acidic regions in NPM1, drives the 
NPM1 into the nucleoplasm where it is translocated to the 
nucleolus through its nucleolar-binding domains; tryptophan 
288 and 290 (Nishimura, et al 2002). 
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1.2.3 NPM1 functions: 
Through all of these descriptions of the NPM1 structure, it 
seems that NPM1 serves as an important protein in cellular 
activities (Rau and Brown 2009). It has an ability to bind to 
distinct cellular molecules such as nucleoli factors, 
transcription factors, histones, and other proteins, which are 
involved in cell proliferation (Falini, et al 2007b). NPM1 
functions include involvement in ribosome biogenesis, cell 
proliferation and growth suppression, and it also has a role in 
controlling genetic stability. As a result, it can be considered 
as both an oncogene, and a tumour-suppressor protein, 
depending on the expression level of NPM1. 
1.2.3.1 The role of NPM1 in ribosome biogenesis: 
Ribosomal biogenesis is the process of making ribosomes. 
NPM1 is involved in this process, specifically in the subunit 
assembly and nuclear export of ribosomes. Transportation of 
the ribosome elements between the nucleus, and cytoplasm, is 
a function attributed to NPM1. NPM1 has two leucine residues 
at 42 and 44, which are important in the CRM1-dependent 
nuclear export process (Falini, et al 2006). Ribosomal L5 and 
5S rRNA are transported into the cytoplasm by an interaction 
with NPM1, which therefore regulates the protein translation 
mechanism (Yu, et al 2006). 
Furthermore, NPM1 is found to form complexes with the APE1 
protein, which is a DNA repair enzyme and a transcriptional 
co-activator. Interaction of APE1 with NPM1 occurs via the N-
terminal of both proteins and forms the NPM1-APE1 complex 
(Vascotto, et al 2009). This interaction is essential in the 
production of functional ribosome molecules through 
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regulation of endonuclease activity during the rRNA synthesis 
(Vascotto, et al 2009). NPM1 also prevents protein 
aggregation in the nucleolus during this process because of its 
shuttling function and intrinsic RNAse activity. In contrast, 
inhibition of the ribosomal biogenesis machinery leads to a 
decrease in the protein shuttling and translation, which causes 
the cell cycle to arrest. It was shown by Itahana et al. that 
reduction of NPM1 mRNA, inactivated the pre-rRNA process 
and in murine cells, the ribosome profile changed as a result of 
the down regulation of the NPM1 gene (Itahana, et al 2003). 
1.2.3.2 The role of NPM1 in regulation of cell growth 
and proliferation: 
NPM1 has been associated with the regulation of proliferation 
and cell growth because its over-expression is strongly 
correlated with proliferation rates in many cell types. NPM1 is 
involved in the proliferative response through various 
mechanisms. NPM1 enhances the proliferation of 
haematopoietic stem cell (HSC) and progenitor cells and over-
expression of NPM1 leads to a reduction of protein levels of 
negative cell cycle regulators and induces entry of 
haematopoietic cells into the cell cycle (Li, et al 2006). NPM1 
is involved in enhancing cell proliferation through functioning 
as an effector for numerous positive cell cycle regulators (Du, 
et al 2010). Phosphorylation of NPM1 at the Ser10 and Ser70 
residues promotes the interaction between NPM1 and Cdc25c 
and prevents phosphorylation of Cdc25c at Ser216. Cdc25c is 
a key activator of Cdk1/cyclin-B, which regulates cell cycle 
transition to M phase, and Cdc25c activation is important in 
cell cycle progression, while inhibition of Cdc25c is associated 
with cell cycle checkpoint activation (Du, et al 2010). As a 
result, the interaction between Cdk1 and Cdc25c rises and 
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contributes to enhance the activity of Cdk1, which causes it to 
enhance cell cycle progression and proliferation (Du, et al 
2010). 
Furthermore, the transcription factor c-Myc, which is the most 
frequently activated oncogene, is important for cellular 
proliferation and a high expression of c-Myc enhances cell 
hyperproliferation and transformation (Li, et al 2008). c-Myc 
has a role in the ribosomal biogenesis process by regulation of 
the RNA polymerases during transcription (Boon, et al 2001). 
c-Myc induced proliferation and transformation is mediated by 
NPM1 through interaction with c-Myc target gene promoters 
which are involved in transcriptional activation and repression 
of c-Myc (Li, et al 2008). Moreover, c-Myc subcellular 
localisation in nucleoli is regulated by NPM1 which binds to c-
Myc in the nucleoplasm and mobilises it into the nucleoli to 
induce rRNA synthesis (Boon, et al 2001, Li and Hann 2013). 
It has been shown that the over-expression of both NPM1 and 
c-Myc stimulates rRNA synthesis, whereas c-Myc fails to 
induce rRNA synthesis when NPM1 is down-regulated (Li and 
Hann 2013). Therefore, NPM1 is essential for c-Myc 
localisation in the nucleoli and has the ability to enhance its 
function in the ribosomal assembly and cell hyperproliferation 
(Li and Hann 2013, Li, et al 2008). 
1.2.3.3 The role of NPM1 in regulation of tumour 
suppressor proteins: 
The interaction of NPM1 with P53, ARF and HDM2 provides 
NPM1 with a tumour-suppressor feature (Colombo, et al 2002, 
Kurki, et al 2004b). P53 is stabilised and enhanced via NPM1 
binding to the negative P53 regulator - HDM2, which is a 
nucleoplasmic and nucleolar RING-finger protein (Colombo, et 
Qutob, H  Chapter 1 
17 
 
al 2002, Kurki, et al 2004b). When the cell is damaged by UV, 
cytotoxic drugs, or DNA intercalating agents, NPM1 is 
translocated into the nucleoplasm and interacts with HDM2 
leading to stabilisation of the P53 protein level and activation 
of its functions (Colombo, et al 2002, Kurki, et al 2004a). In 
contrast, other report found that over-expression of NPM1 can 
antagonise P53 by inhibiting the IR-induced P53 
phosphorylation in normal haematopoietic cells and in cells 
treated with chemotherapeutic agents, this can lead to an 
increase in the resistance to apoptosis (Li, et al 2005). 
Moreover, up-regulation of NPM1 with a deletion of the C-
terminal domain, the domain which interacts with P53, had no 
effect on the cellular resistance to apoptosis, whereas 
suppression of NPM1 increased stress-induced apoptosis (Li, et 
al 2005). 
ARF is another tumour-suppressor protein associated with 
NPM1 and plays an essential role in cell cycle arrest and 
proliferation (reviewed in (Grisendi, et al 2006). It acts as a 
positive regulator of P53 by binding to HDM2 and in turn 
resulting in P53 stabilisation and enhancement of its 
transcriptional targets (Gjerset 2006, Khan, et al 2004).  
NPM1 insulates ARF in the nucleoli and hampers its function in 
the activation of the P53-dependant pathway (Korgaonkar, et 
al 2005). In stressed cells, however, a modest decrease in 
NPM1 protein level translocates ARF into the nucleoplasm and 
bind to the P53 negative regulator protein ± HDM2 and 
activate P53-dependent process, whilst in unstressed cells, 
NPM1 prevent ARF from localising in the nucleoplasm and 
blocks the ARF-mediated P53 activation pathway (Korgaonkar, 
et al 2005). In NPM1 knock-down cells, the interaction of ARF 
with HDM2 increases, but the expression of ARF is reduced, 
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which reflects the importance of NPM1 in the stabilisation of 
ARF (Korgaonkar, et al 2005). 
1.2.3.4 The role of NPM1 in maintenance of genomic 
stability: 
NPM1 participates in the control of chromosomal ploidy and 
DNA repair. NPM1 regulates centrosome duplication through 
inhibition of the process by binding to unduplicated 
centrosome (Okuda, et al 2000). In the mitosis process, 
CDK2-Cyclin-E, which is a family of serine/threonine kinases 
and important for centrosome duplication initiation, 
phosphorylate NPM1 leading to a dissociation of the 
centrosome and trigger of the initiation of the centrosome 
duplication process (Okuda, et al 2000).  Aberrant multiple 
centrosomes are detected in NPM1-/- cells, and blocking the 
phosphorylation sites in NPM1 caused repression of 
centrosome duplication (Grisendi, et al 2005). Furthermore, 
NPM1 is a BRCA2-associated protein and required for 
maintaining the numerical integrity of the centrosomes (Wang, 
et al 2011). Detail on the exact mechanism has not been 
identified, but the inhibition of the interaction of NPM1 with 
BRCA2 showed an abnormal amplification of centrosome 
numbers (Wang, et al 2011).  
NPM1 is implicated in DNA damage repair through modulation 
of the function of proliferating cellular nuclear antigen (PCNA). 
This is a necessary component in the nucleotide excision repair 
mechanism (Wu, et al 2002). In a UV-treated cell, the up-
regulation of NPM1 was correlated with a higher level of PCNA 
leading to an increase in cell growth and inhibition of apoptosis 
by increases the activity of NER (Wu, et al 2002). In addition, 
NPM1 is required for normal DNA damage repair by binding to 
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other proteins at the site of DNA damage (Koike, et al 2010). 
In response to irradiation treatment, the formation of 
irradiated±induced foci (IRIF) is initiated and followed by 
phosphorylation of H2AX Ǆ-H2AX) and the mediator of DNA 
damage checkpoint 1 (MDC1). Subsequently, the lysine (K63)-
linked polyubiquitin is catalysed by E3 ubiquitin ligase, which 
is recruited by MDC1, at the site of DSBs. It has been shown 
that phosphorylated NPM1 foci are formed and recruited to the 
DSB sites, where it interacts with K63-linked polyubiquitin 
conjugates and participates in the DSB-induced RNF8-
dependent pathway (Koike, et al 2010). Furthermore, cells 
with mutant NPM1 lacking the phosphorylated domain (T199A-
NPM1) demonstrated an increase in DNA fragments after 12 
and 24 hours of irradiation treatment, whereas in wild-type 
NPM1 the fragments were repaired efficiently (Koike, et al 
2010). In addition, the RAD51-IRIF foci, which are a marker of 
the homologous recombination (HR) pathway, reached a peak 
after 6 hours in wild-type and T199A mutant NPM1. 
Thereafter, the foci was reduced in NPM1 wild-type cells, 
whilst in the mutant cells, the foci continued to increase until 
18 hours after the treatment (Koike, et al 2010). Therefore, 
the role of NPM1 in regulation of centrosome duplication and 
DNA damage repair is critical in the maintenance of genomic 
stability. 
1.3 Mutations in NPM1 in haematological malignancies: 
1.3.1 NPM1 gene translocations in leukaemia and 
lymphoma: 
The NPM1 gene is involved in the pathogenesis of several 
types of cancer. Over-expression of NPM1 has been seen in 
many solid tumours such as gastric, colon, ovarian, and 
Qutob, H  Chapter 1 
20 
 
prostate carcinoma (reviewed in (Grisendi, et al 2006)). In 
haematological malignancies, the NPM1 locus is implicated in 
chromosomal translocations, deletions and mutations. An 
oncogenic fusion protein is formed due to locus translocation 
leading to the induction of an oncogenesis process. The most 
recognised haematological translocation, due to chromosomal 
abnormalities of the NPM1 gene are: lymphoma (NPM1-ALK), 
NPM1-RAR-Į DQG 1301-MLF1, which are all characterised by 
the formation of oncogenic fusion and a decrease in wild-type 
NPM1 (reviewed in (Naoe, et al 2006)). 
Anaplastic large cell lymphoma (ALCL) accounts for 3% of 
adult non-Hodgkin lymphoma due to a chromosomal 
translocation of the 5q35 locus of NPM1 gene with the 2q23 of 
anaplastic lymphoma kinase (ALK) gene t(2;5) (reviewed in 
(Falini, et al 2007a)). As a result, the N-terminal of NPM1 is 
fused to the catalytic domain of ALK causing a constitutive 
activation of the ALK kinase fusion protein (reviewed in (Naoe, 
et al 2006)). The subcellular localisation of the NPM1-ALK 
chimeric kinase is distributed in the cytoplasm and nucleus, 
whereas wild-type NPM1 is localised in the nucleus. In 
leukaemia, a translocation of the NPM1 protein to the RAR-Į
protein, which is a result of the integration of the NPM1 gene 
to a retinoic-acid receptor-ĮJHQHFDXVHVthe translocation to 
form a rare type of acute promyelocytic leukaemia (APL) with 
an NPM1-RAR-Į IXVLRQ SURGXFW UHYLHZHG LQ (Falini, et al 
2007a)). NPM1-RAR-Į W VXSSUHVVHV WKH UHWLQRLG-
responsive transcription, which is restored by ATRA treatment, 
similar to the more common t(15;17) APL disease (reviewed in 
(Naoe, et al 2006)). Another form of NPM1 translocation in 
leukaemia is NPM1-MLF1, where the t(3;5) translocation 
creates the NPM1-MLF1 chimeric protein and, occurs in less 
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than 1% of myelodysplastic syndrome and AML cases 
(reviewed in (Falini, et al 2007a)). Myelodysplasia/myeloid 
leukaemia factor-1 (MLF1) is localised in the cytoplasm and 
plays a negative role in the regulation of MLF11P in 
erythropoietin-induced differentiation (reviewed in (Naoe, et al 
2006)). The MLF1 in the NPM1-MLF1 chimeric protein has been 
shown to be localised in the nucleolus and interrupts the 
function of MLF1 in erythroid differentiation (reviewed in 
(Naoe, et al 2006)). 
1.3.2 NPM1 cytoplasmic mutations in AML (NPMc+AML): 
Nucleotide insertions in NPM1 mutations (NPMc+) were 
discovered in 2005 and they are now considered to be one of 
the genes most commonly mutated in AML (Falini, et al 2005). 
These NPM1 mutations are characterised by the abnormal 
subcellular localisation of the NPM1 protein in the cytoplasm 
(hence the designation NPMc+) and occur in approximately 
60% of adult AML cases with a normal karyotype (Falini, et al 
2005). NPM1 mutations usually occur at exon 12 (Falini, et al 
2005), but mutations in exon 9 and 11 have been reported in 
rare cases (Albiero, et al 2007, Mariano, et al 2006). There are 
55 NPM1 mutations in exon 12 that have identified, but an 
addition of a TCTG tetra-nucleotide at 956 to 959 is the most 
common NPM1 mutation (Falini, et al 2006). This mutation is 
called mutation A and accounts for 75-80% of the NPMc+ 
cases (reviewed in (Falini, et al 2007b, Rau and Brown 2009)). 
NPM1 mutations B and D account for 10% and 5% of cases, 
respectively, whereas other mutations are rare (Chen, et al 
2006, Falini, et al 2007b). All of the NPMc+ mutations cause a 
frame shift in the C-terminus resulting in a replacement of the 
last 7 amino acids with 11 different residues, while the N-
terminal is conserved (Chen, et al 2006, Verhaak, et al 2005). 
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Although the NPMc+ mutations are heterozygous and retain a 
wild-type allele, the wild-type NPM1 is delocalised from the 
nucleoli into the cytoplasm through the N-terminal 
dimerisation domain, which is conserved in all NPM1 mutants. 
The mutant NPM1 therefore forms heterodimers with wild-type 
NPM1 which disrupts the function of NPM1 (Falini, et al 2006, 
Verhaak, et al 2005). 
1.3.2.1 Mechanism of abnormal NPM1 subcellular 
localisation in NPMc+AML: 
The abnormal distribution of NPM1 in NPMc+AML is caused by 
two major changes at the C-terminus and the last 9 amino 
acids are crucial for mutant function because they determine 
the subcellular localisation of the protein (Verhaak, et al 
2005). These are an insertion of an NES motif and the loss of  
tryptophan 288 and 290, or the loss of tryptophan 290 alone 
(Falini, et al 2006). The loss of tryptophan 288 and 290, or 
tryptophan 290 alone, causes delocalisation of the mutant 
NPM1 in the nucleoplasm, where the additional NES motif at 
COOH terminus of NPM1 reinforces the protein to be exported 
into the cytoplasm (Bolli, et al 2007, Falini, et al 2006). A loss 
of tryptophan 290 is observed in all NPMc+AML but the 
highest translocation of mutant NPM1 to the nucleoplasm 
occurs when both tryptophan (288 and 290) are lost; around 
90% of NPMc+AML cases have lost both tryptophan residues 
(Falini, et al 2006). NPM1 is retained in the nucleolus after 
reinsertion of tryptophan 280 and 290 indicating that the 
presence of these residues are essential for nuclear export of 
NPM1 (Falini, et al 2006). The loss of both tryptophan 288, 
and 290 are frequently correlated with the most common NES 
motif in NPMc+ (L-xxx-V-xx-V-x-L). The loss of tryptophan 
290 only shows the same NES motif (L-xxx-V-xx-V-x-L), but 
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the valine in the second position is replaced with leucine, 
phenylalanine, cysteine or methionine leading to an increase in 
the NES export activity (Bolli, et al 2007, Falini, et al 2006). 
Bolli et al. found that the two NES motif in wild-type NPM1 
cannot counterbalance the force of nuclear localisation signal 
(NLS) and tryptophans, which are responsible for NPM1 
subcellular localisation in the nucleolus. However, an insertion 
of NES motif in NPMc+ and a loss of tryptophan 290 showed 
an increase in the nuclear export activity more than the NES 
motif (L-xxx-V-xx-V-x-L) with mutations of both tryptophans 
(Bolli, et al 2007). Furthermore, by combining the NES motif 
(L-xxx-V-xx-V-x-L), which is found in NPM1 mutations (type-
A), with tryptophan 288 only or NES motif (L-xxx-L-xx-V-x-L), 
which is seen in NPM1 mutation (type-E), with a loss of both 
tryptophans, these were not efficient enough to export NPM1 
into the cytoplasm, which indicates that the NPM1 mutants are 
naturally selected to enforce the protein exportation into the 
cytoplasm (Bolli, et al 2007). 
1.3.2.2 Role of NPMc+ in leukaemogenesis: 
The mechanism of leukaemogenesis in NPMc+AML has not 
been elucidated, but there are many suggestions that should 
be considered, particularly in terms of the main 
characterisation of the mutated cells ± that is delocalisation of 
NPM1 into the cytoplasm which also displaces the protein 
partners thereby interfering with a range of functions. At the 
level of tumour suppressor protein regulation, it is known that 
P53 stability and activity is mediated by ARF and NPM1 
through binding to HDM2 (Colombo, et al 2002). In 
NPMc+AML, mutant NPM1 binds to ARF and delocalises into 
the cytoplasm leading to the inhibition of P53 dependent and 
independent pathways (Colombo, et al 2006, Korgaonkar, et al 
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2005). The work of Bonetti et al. (2008) agrees with this and 
demonstrates the role of another factor, which may contribute 
to the development of leukemogenesis in NPMc+AML (Bonetti, 
et al 2008). Specifically, they found that the stability of c-Myc 
is regulated by NPM1 through the interaction with the F-box 
SURWHLQ )EZǄ ZKLFK LV D FRPSRQHQW LQYROYHG LQ WKH
ubiquitination and proteasome degradation of c-Myc (Bonetti, 
et al 2008) ,Q 130F$0/ WKH )EZǄ LV GHORFDOLVHG LQ WKH
cytoplasm by mutant NPM1, which leads to an increase in the 
stability of c-MYC and an increase in the cell proliferation 
(Bonetti, et al 2008). As a result, the hyperproliferation of the 
cells as a result of the increase in the c-MYC activation, 
perturbs ARF and P53 activity and this may result in 
tumorigenesis (Li and Hann 2009). 
Another possible factor which may play a role in NPMc+ 
leukaemogenesis is the impairment of HEXIM1 protein 
subcellular localisation. The NPM1 was found to regulate RNA 
polymerase II transcription through the interaction of 
hexamethylene-bis-acetamide inducible protein 1 (HEXIM1), 
which has an inhibitory effect on RNA polymerase II 
transcription (Gurumurthy, et al 2008). The interaction of 
NPM1 with HEXIM1 results in NPM1 inactivation of HEXIM1 and 
enhances the RNA polymerase II transcription (Gurumurthy, et 
al 2008). In NPMc+AML, the HEXM1 protein has been reported 
to delocalise in the cytoplasm causing an increase in the 
transcription of RNA polymerase II and enhancement of the 
expression of genes that may be related to the leukaemic 
phenotype such as MCL-1 and cyclin D1 (Glaser, et al 2012, 
Gurumurthy, et al 2008). Therefore, it seems that aberrant 
localisation of NPM1 in the cytoplasm effects many proteins, 
which may contribute to leukaemogenesis. 
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In vivo, complete abrogation of NPM1 gene expression (NPM1-
/-) in mouse result in embryonic lethality (Grisendi, et al 
2005). Although the mutant embryos were smaller in size than 
in wild-type and heterozygote NPM1, the heart, neural tube, 
brachial arches and limb buds were comparatively well-
developed (Grisendi, et al 2005). However, the number of 
haematopoietic precursor in the blood islands of the NPM1-/- 
yolk sacs was decreased and their ability to differentiate into 
various lineages was impaired and the blood cells contain large 
multi-nucleated cells with 4 nuclei and copious centrosomes 
due to supernumerary centrosome amplification (Grisendi, et 
al 2005). The apoptosis level was up-regulated in NPM1-/- 
embryos and the level and the activity of P53 was increased 
(Grisendi, et al 2005). Thereafter, the haematopoiesis analysis 
of heterozygous NPM1 (NPM1+/-) demonstrated 
myelodysplastic syndrome (MDS) features and bone marrow of 
NPM1+/- showed dyserythropoiesis and megakaryocyte 
dyspoiesis (Grisendi, et al 2005). As a result, it seems that 
NPM1 is in embryogenesis and the development of 
haematopoiesis, while impairment in NPM1 function by loss its 
function leads to develop tumorigenesis (Grisendi, et al 2005). 
Furthermore, the expression of NPMc+ in transgenic mice and 
in a zebrafish embryonic model, demonstrated myeloid 
proliferation. In the transgenic mice, the mutant NPM1 
localised in the cytoplasm and the mice exhibited features of 
myeloproliferation and an accumulation of myeloid cells in the 
spleen. In addition, it has demonstrated that the NPM1 mutant 
blocked megakaryocytic differentiation leading to an increase 
in the mean platelet number and the number of 
megakaryocyte cells in bone marrow and the spleen (Cheng, 
et al 2010, Sportoletti, et al 2013, Vassiliou, et al 2011). 
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Moreover, The zebrafish model showed the same results as 
the transgenic mice with an increase in the numbers of 
erythro-myeloid progenitors and haematopoietic stem cells 
(Bolli, et al 2010). However, in both models, there was no 
evidence of disease development and this concludes that the 
NPM1 mutant alone itself is insufficient to trigger all the 
characteristics necessary for AML. Vassiliou et al. agreed with 
this and they used human-NPMc+ knock-in mice and 
combined it with insertional mutagenesis in other genes such 
as the Csf2 gene, which encodes GM-CSF and is activated in 
48% of leukaemia, or in the FLT3 gene (FLT3-ITDs are 
common in NPMc+AML) (Vassiliou, et al 2011). They found 
that the presence of mutations in other genes are important in 
the growth of leukaemic cells through the activation of 
proliferating molecules and pathways (Vassiliou, et al 2011). 
1.3.2.3 Clinical features of patients with NPMc+AML: 
Several clinical characterisations have been shown to 
significantly correlate with NPMc+AML. In many studies, NPM1 
mutations cooperate with other gene mutations such as FLT3-
TKD, CEBPA, NRAS and IDH1 mutations (Dohner, et al 2005, 
Schnittger, et al 2005, Thiede, et al 2006, Verhaak, et al 
2005). However, the most common mutation co-expressed 
with NPMc+ is an internal tandem duplication of FLT3 (FLT3-
ITD): FLT3-ITDs occur in about 40% of NPMc+ mutated AMLs 
(Boissel, et al 2005, Falini, et al 2005). Chromosomal 
abnormalities in NPMc+AML are uncommon and account for 
only 19% and 4% of NPMc+ cases in adults and children, 
respectively (Rau and Brown 2009). Karyotype abnormalities 
are considered secondary to NPM1 mutations because; a) the 
chromosome abnormalities arise at relapse in the NK-AML 
patient; b) the cells show a mixture of leukaemic cells 
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harbouring cytogenetic abnormalities and subclones of normal 
karyotype, and c) the feature of NPMc+AML patients with 
chromosomal abnormalities, in terms of type and frequency, 
are similar to secondary chromosomal changes developed in 
AML patients harbouring recurrent karyotype abnormalities 
(Falini, et al 2005). 
The incidence of NPMc+ mutations in AML is higher in adults 
than in paediatric cases, and the risk of NPMc+ mutations is 
more frequent in adult female than in adult male (Chou, et al 
2006, Shimada, et al 2007). Moreover, the frequency of the 
NPMc+ mutations is increased in American and European 
populations compared with Asian populations (Gale, et al 
2008, Shimada, et al 2007). NPMc+ mutations are found in all 
FAB subtypes in adult patients except M3 and M7, whereas M4 
and M5 have the highest frequency of NPMc+. The blast cells 
and platelet counts are elevated in NPMc+ (Dohner, et al 
2005, Falini, et al 2005, Schnittger, et al 2005). 
Although a minor population of CD34 positive cells were 
identified, the NPMc+AML cells are generally CD34 negative 
(Nomdedeu, et al 2011). The minor population of CD34 
positive were transplanted into mice to test their ability to 
initiate leukaemia. CD34 positive cells, which are bearing 
NPM1 wild-type in NPMc+AML, gave rise to normal 
multilineage haematopoiesis after transplantation into mice, 
whilst cells with NPMc+ mutations either CD34 negative or 
CD34 positive initiated leukaemia. Interestingly, the CD34 
expression was lost after re-transplantation of the AML cells 
into the secondary recipients (Taussig, et al 2010). Moreover, 
Martelli et al. found that CD34 positive cells carrying NPMc+ 
mutations generated a leukaemia with the same features as 
seen in the NPMc+AML patients, but they found that CD34 
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negative cells gave rise to different patterns to those observed 
in NPMc+AML (Martelli, et al 2010). Therefore, CD34 positive 
and CD34 negative cells are considered as being leukaemia-
initiated (LIC) cells in NPMc+ AML, but the origin of the 
leukaemia stem cells (LSC) in NPMc+AML still remains to be 
clarified and the question of whether is the disease has arisen 
from early progenitors or long-term repopulating cells is still 
not clear (Martelli, et al 2010, Taussig, et al 2010).  
1.3.2.4 Gene expressions profiling (GEP) in NPMc+AML: 
Gene expression profiling (GEP) assists in identifying the 
pathogenesis of AML through understanding which genes are 
up or down regulated  (Bacher, et al 2009). The Homeodomain 
genes (HOX-A and HOX-B), TALE, PBX3, and MEIS1 are the 
genes whose aberrant regulation is most correlated with NPM1 
mutations; these genes are over-expressed (Andreeff, et al 
2008, Bacher, et al 2009). The HOX genes encode 
transcription factors and regulate the early stages of 
haematopoiesis, including self renewal and haematopoietic 
stem cell, differentiation as well as the proliferation of cells 
(Andreeff, et al 2008). In normal cells, up-regulated HOX 
genes are associated with haematopoietic stem cells and CD34 
positivity, whilst expression is reduced during normal 
differentiation (Alcalay, et al 2005, Bacher, et al 2009). 
NPMc+ causes the activation of many members of the HOX 
family and TALE possibly leading to leukaemogenesis (Bacher, 
et al 2009). NPMc+/FLT3-ITD cells have a higher level of HOX 
than NPMc+/FLT3-wt cells and NPM-wt/FLT3-ITD (Andreeff, et 
al 2008). The reason for this appears to be because the FLT3-
ITD affects a small number of non-clustered HOX genes, 
particularly HOX-B5, which is expressed abnormally (Andreeff, 
et al 2008). Alterations in HOX gene expression have been 
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associated with disease prognosis and responsiveness to 
chemotherapy and it has been noted that decreasing levels of 
HOX-A9 and CD34 are associated with a favourable prognosis, 
as seen in NPMc+AML cases (Bacher, et al 2009, Verhaak, et 
al 2005). 
1.3.2.5 Prognostic impact of NPMc+AML: 
In normal karyotype AML, the prognostic impact of NPMc+ 
varies amongst patients with different AML-associated 
mutations. FLT3-ITD, for example, is associated with an 
adverse outcome after conventional chemotherapy, whereas 
patients carrying CEBPA mutations have been associated with 
a favourable outcome (Shipley and Butera 2009). NPM1 
mutations have been associated with favourable prognosis and 
many studies have found that the complete remission rate is 
higher amongst these patients compared to patients with wild-
type NPM1 (Dohner, et al 2005, Schnittger, et al 2005, Thiede, 
et al 2006, Verhaak, et al 2005). Furthermore, in patients with 
NPMc+/FLT3-ITD, the complete remission rate was lower than 
in the presence of NPMc+ mutations only (Boissel, et al 2005). 
In addition, the event-free survival, overall survival and 
relapse-free survival rates, were noted to be better in 
NPMc+/FLT3-wild-type than other normal karyotype AML 
patients (Figure 1.3) (Dohner, et al 2005, Gale, et al 2008, 
Thiede, et al 2006, Verhaak, et al 2005).  
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Figure 1.3: Survival analysis of NPM1 and FLT3 mutations in AML patients; (A) 
Relapsed-free survival, and (B) Overall Survival according to the combined NPMc+ and FLT3-
ITD mutations status in AML patients younger than 60 years old (Dohner, et al 2005). 
 
1.3.2.6 All-trans retinoic acid (ATRA) treatment in AML: 
All-trans retinoic acid (ATRA), vitamin-A derivative, is used in 
the treatment of acute promyelocytic leukaemia (APL) (Seiter, 
et al 2000). APL is an AML type characterised by chromosomal 
WUDQVORFDWLRQWKDWUHVXOWVLQDFKLPHULFIXVLRQJHQHRI5$5ĮWR
a second gene, most commonly PML in t(15;17), but also 
NPM1 in t(5;17) and PLZF in t(11;17) (reviewed in (Zhang, et 
al 2000)).   
The action of ATRA in the treatment of APL has been 
investigated. In PML-5$5Į SRVLWLYH $3/ $75$ GHJUDGHV WKH
oncogenic PML-5$5Į IXVLRQ SURWHLQ DQG UHVWRUHV WKH QRUPDO
structure of PML oncogenic domains (reviewed in (Zhang, et al 
2000)). Furthermore, ATRA modulates receptors that are 
involved in cell differentiation by affecting the co-repressor 
(CoR) and co-activator (CoA) complexes (reviewed in (Zhang, 
et al 2000)). CoR binds to the chimeric fusion PML-5$5Į RU
NPM1-5$5Į FDXVLQJ LW WR EORFN FHOO GLIIHUHQWLDWLRQ+RZHYHU
in ATRA treatment, CoR is released from the complex and 
recruited to CoA for transcriptional activation and a reverse of 
A B 
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the differentiation block (reviewed in (Zhang, et al 2000)). At 
the gene expression level, many signalling pathways have 
been induced upon ATRA treatment in APL cells. A high 
expression of genes participating in the signal transduction 
pathway such as, cAMP dependent protein kinase A 
(cAMP/PKA), and protein kinase C (PKC) have been reported, 
whereas genes involved in Mitogen-activated protein (MAP) 
kinases particularly P38, ERK3 and JNK are down-regulated 
(Yang, et al 2003b, Zhang, et al 2000). 
Administration of ATRA with chemotherapy to non-APL AML 
patients did not improve clinical outcome (Burnett, et al 2010, 
Milligan, et al 2006). Conversely, other researchers found that 
patients with NPMc+ mutations without FLT3-ITD did benefit 
from adding ATRA to chemotherapy and demonstrated a 
significantly higher complete remission rate and overall 
survival (Schlenk, et al 2011, Schlenk, et al 2009). In vitro, 
treatment of the HL-60 AML cell line with ATRA showed an 
inhibition of cell proliferation and an increase in cell 
differentiation (Jian, et al 2011, Wang, et al 2009). In 
NPMc+AML, the effect of ATRA on the OCI-AML3 (NPMc+) cell 
line was studied and these NPMc+ cells were found to be more 
susceptible to differentiation upon ATRA exposure at a low 
concentration when compared to the HL-60 (NPM1-wt) cell line 
(Kutny, et al 2010). Furthermore, ATRA treatment resulted in 
a reduction in the NPM1 mutant level, causing an activation of 
components involved in apoptosis such as caspase-8, caspase-
3, and BAX, which indicated that the cell death pathway in 
NPMc+AML is affected by ATRA treatment (Martelli, et al 
2007). However, during clinical trials, the administration of 
ATRA to NPMc+AML patients demonstrated variable results. In 
a United Kingdom Medical Research Council (MRC) trial, 
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younger patients with NPM1 mutations had no significant 
increase in complete remission (CR) rate, or overall survival 
(OS) when treated with ATRA (Burnett, et al 2010). On the 
other hand, an Austrian-German study found that patients 
harbouring NPMc+ mutants had a high CR and a better overall 
survival and relapse-free survival when treated with ATRA, 
compared to those patients harbouring other prognostically 
important mutations - FLT3-ITD, FLT3-TKD, and MLL-PTD 
(Schlenk, et al 2011, Schlenk, et al 2009). The conflict 
between the two studies was proposed to be because of 
differences in the treatment protocols; ATRA was 
administrated on the third day of chemotherapy in the 
Austrian-German study, whereas in the MRC study ATRA was 
started on day one (Burnett, et al 2010, Schlenk, et al 2009).  
1.4 DNA damage response (DDR): 
DDR mechanisms are activated because our genome is 
introduced to many different types of DNA damage, both 
endogenous and exogenous, leading to the production of 
thousands of DNA lesions. Genome integrity is maintained by 
many DNA damage response (DDR) mechanisms involving cell 
cycle arrest, DNA repair, and apoptosis (reviewed in (Jackson 
and Bartek 2009). Failure in the activation of the DDR process 
can result in the proliferation of cells harbouring damaged DNA 
leading to develop tumorigenesis (reviewed in (Polo and 
Jackson 2011)). 
1.4.1 Sensing of DNA damage: 
Genomic DNA is packaged into highly condensed chromatin 
structures with histone and non-histone proteins. The DNA 
repair process begins with the re-modulation of the chromatin 
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structure, which facilitates DNA repair enzymes accession to 
chromatin (Wong, et al 2006). The chromatin structure 
alteration can occur either by adjustment of the histone 
composition or by chromatin remodelers, which use the energy 
from ATP hydrolysis to weaken the interactions between 
histones and the surrounding DNA (Fyodorov and Kadonaga 
2001, Jenuwein and Allis 2001). In response to DNA damage, 
phosphorylation the variant histone +$; Ǆ-H2AX) at the 
DNA damage site, is required for formation of irradiated-
induced foci (IRIF), which contain several factors involved in 
the DNA repair process (Burma, et al 2001, Huang, et al 
2004) 7KH Ǆ-H2AX formation is dependent on the 
phosphatidylinositol 3-kinase-like kinases (PI3-KK) family 
proteins - Ataxia telangiectasia mutated (ATM), which is 
mainly activated by DSB, and Ataxia- and Rad-related (ATR), 
which is activated by the formation of RPA-coated ssDNA 
complexes (Burma, et al 2001, Ward and Chen 2001). ATM 
and ATR are phosphorylated and recruited to the site of 
damage by Mre11, RAD50, and NBS1 (MRN) complex, and 
ATR-interacting protein (ATRIP), respectively (reviewed in 
(Yang, et al 2003a)). Furthermore, activation and 
accumulation of PI3-KK family at the site of the DNA damage 
leads to the enhancement of the phosphorylation of other 
proteins that are targeted by ATM, such as BRCA1, MDC1, 
Chk2, and P53, and by ATR, such as Rad17, Chk1, ATRIP, and 
P53 (reviewed in (Shimada and Nakanishi 2006)). 
1.4.2 DNA repair mechanisms: 
DNA is repaired by pathways involving many different steps in 
order to eliminate DNA damage that may threaten genome 
integrity. Different mechanisms are involved in DNA repair, 
and each DNA repair pathway is activated depending upon the 
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specific type of DNA lesion (Table 1.3) (Figure 1.4) (Jackson 
and Bartek 2009). 
Figure 1.4: DNA damage repair mechanisms; The four different pathways that are 
implicated in response to damaging agent and the type of DNA lesions (Hoeijmakers 2001). 
 
 
Table 1.3: DDR mechanisms; Different DDR pathways are available, use depends on 
the DNA lesions type (Jackson and Bartek 2009) 
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1.4.2.1 Double strand breaks: 
DSBs are repaired by either non-homologous end-joining 
(NHEJ), which repairs the DSB without the need for a 
template, or homologous recombination (HR), which use a 
sister chromatid as a homologous template (Jackson and 
Bartek 2009, Wong, et al 2006). NHEJ begins by recognising 
the DSBs through the Ku70 and Ku80 proteins, which binds 
and activates the protein kinase DNA-PK. Thereafter, the DNA-
PK recruits other repair proteins, such as ligase-IV/Xrcc4 
complex, Artemis, PNK and Polymerase X to allow the NHEJ 
repair to proceed (reviewed in (Jackson and Bartek 2009, Polo 
and Jackson 2011)). 
On the other hand, HR uses sister chromatid sequences for the 
repair process, which is instigated through the MRN complex 
(reviewed in (Polo and Jackson 2011)). The first step in the HR 
SDWKZD\ WR UHSDLU WKH '6% LV WKH SURGXFWLRQ RI ¶ VV'1$
overhang through reVHFWLRQ RI ¶ HQG E\ WKH 051 FRPSOH[
Subsequently, a nucleoprotein filament is formed after RAD51 
recruitment, which is the central protein in HR that binds to 
the exposed single-strand tail (reviewed in (Rastogi, et al 
2010)). This step is enhanced by a Rad55/Rad57 protein 
heterodimer, which inactivates the inhibitory effect of ssDNA-
binding complex protein (RPA) coating the ssDNA overhang, 
and Ǆ-H2AX, which recruits more RAD51 to the site of damage 
(Sonoda, et al 2007, Wolner, et al 2003). Thereafter, the 
filament, together with RAD51, and other HR factors explore 
for an intact copy of the broken DNA from the sister chromatid 
template (reviewed in (Rastogi, et al 2010)). After the 
insertion of the strand into the homologous template, the 
extension and ligation process occur via the DNA polymerase 
and ligase I, respectively (Mazon, et al 2010). Finally, the 
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cleavage and resolution of HR intermediates are mediated by 
DNA helicase and resolvase enzymes to form intact and 
repaired DNA molecules (Mazon, et al 2010).  
1.4.2.2 Base excision repair: 
Another mechanism that is involved in DNA repair is the base 
excision repair pathway (BER). BER functions on base lesions 
that are generated from oxidative stress, alkylating agents 
such as MMS and other sources (reviewed in (Jackson and 
Bartek 2009)). The process begins when a specific DNA 
glycosylase recognises and removes a damaged base. Next, 
the apurinic/apyrimidinic endonuclease (APE1), which is an 
essential enzyme in BER, hydrolyses the phosphodiester 
baFNERQH DW WKH ¶ SRVLWLRQ UHYLHZHG LQ (Fishel and Kelley 
2007)6XEVHTXHQWO\DQRUPDO¶-hydroxy group is generated 
and DNA polymerase fills the gap. DNA ligase can then re-join 
the strands (reviewed in (Fishel and Kelley 2007)). The BER 
pathway has two repair sub-pathways, which are short-patch 
and long-patch BER, and are initiated after APE1 action. Short-
patch BER, which is activated in the presence of one 
nucleotide lesion, involves recruitments of poly (ADP-ribose) 
polymerase-1 (PARP-1) (Fortini and Dogliotti 2007). Then, the 
damaged nucleotide is replaced by scaffold protein X-ray 
repair cross-complementing (XRCC1) DQG ǃ-polymerase 
followed by the action of DNA ligase III to seal the nick and 
restore the integrity of DNA (Fortini and Dogliotti 2007). On 
the other hand, long-patch BER, which is implied on DNA have 
two or more nucleotide lesions, recruits proliferating cell 
nucleaUDQWLJHQ3&1$ZLWKǃ-SRO\PHUDVHRU İį-polymerase 
to extend and fill the gap by inserting 2-13 nucleotide (Fortini, 
et al 1998). Thereafter, the ensuing DNA flap is displaced by 
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the flap endonuclease (FEN-1) protein and then the nick is 
ligated by DNA ligase I (Fortini and Dogliotti 2007). 
1.4.2.3 Other DNA repair mechanisms: 
Nucleotide excision repair (NER) is an essential process in the 
removal of DNA lesions, which are produced by ultraviolet light 
(reviewed in (Rastogi, et al 2010)). NER recognises helix-
distorting base lesions and operates through two different sub-
pathways, which are global genome (GG-NER) and 
transcription-coupled NER (TC-NER) (Costa, et al 2003)). GG-
NER is activated in lesions produced in a transcriptionally silent 
area. Whereas, TC-NER targets a transcription blocking lesion, 
which is encountered by the transcription mechanism RNA 
polymerase II (Costa, et al 2003). In a mis-match repair 
(MMR) pathway, an incision of single-strand is introduced to 
the damaged DNA which is produced by insertion, deletion, 
and mismatch bases during DNA replication (reviewed in 
(Jackson and Bartek 2009)). Then, the MMR process is 
achieved by the actions of polymerase and ligase enzymes to 
restores the intact DNA (Jiricny 2006)). 
1.4.2.4 DDR in resistance to therapy: 
In cancer therapy, enhanced DDR can have a negative impact 
on the clinical response to chemotherapies and radiotherapy 
because aggressive activation of DDR may cause an increased 
repair of genotoxic lesions resulting in the resistance of 
tumour cells to the therapy (reviewed in (Helleday, et al 
2008)). In ovarian cancer, for instance, positive expression of 
XRCC1, a protein involved in BER, showed to be correlated 
with aggressive outcome and resistance to platinum therapy, 
whereas cases that showed negative XRCC1 were associated 
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with favourable prognostic impact (Abdel-Fatah, et al 2013). 
In addition, ovarian and gastro-oesophageal cancer cases with 
positive expression of APE1 is predicted to have a negative 
impact in the response to chemotherapy compared to those 
cases with negative APE1 expression (Al-Attar, et al 2010). 
Homologous recombination dysfunction in tumour cells confers 
susceptibility to anti-cancer drugs, while glioma stem cells, 
where the HR is activated, are less sensitive to therapy 
(Helleday 2010). Furthermore, RAD51, which is a protein 
involved in the homologous recombination process, is seen in 
high levels in FLT3-ITD AML samples, a mutation associated 
with an adverse prognosis (Seedhouse, et al 2006). Therefore, 
understanding the DDR mechanism is crucial in therapy 
resistance tumour development and there are potential 
benefits in cancer treatment by developing effective inhibitors 
that inhibit the DNA repair function and increase the sensitivity 
of tumour cells to radiation or chemotherapies (Helleday, et al 
2008, Madhusudan, et al 2005). 
1.4.3 Apoptosis: 
Apoptosis or programmed cell death is an essential process to 
remove infected, unwanted or damaged cells. There are two 
distinct principle pathways which are the extrinsic and intrinsic 
cell death pathways (reviewed in (Gustafsson and Gottlieb 
2007)). The extrinsic pathway is induced by ligands binding to 
a death receptor on the cell surface, these ligands are 
members of the tumour necrosis factors (TNF) family 
(reviewed in (Adams and Cory 2007). Subsequently, the Fas-
associated death domain (FADD) protein activates and recruits 
caspase-8 into a death-inducing signalling complex, then 
downstream caspases are activated (reviewed in (Adams and 
Cory 2007). The intrinsic pathway is enhanced when 
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cytochrome-c is released from the mitochondria causing it to 
activate caspase-9 through an apoptotic protease-activating 
factor (Apaf-1). This leads to the activation of the effector 
caspases (reviewed in (Adams and Cory 2007). The intrinsic 
pathway is regulated by the BCL-2 family, which is composed 
of pro- and anti-apoptotic proteins which share up to four 
conserved domains called BCL-2 homology (BH) domains 
(reviewed in (Tzifi, et al 2012)). 
The anti-apoptotic proteins, BCL-2, MCL-1, contain four BH 
domains, named BH1, BH2, BH3, and BH4, whilst the pro-
apoptotic proteins are divided into two groups: the multi-
domain proteins (BAX and BAK), which have the first three 
domains as present in the anti-apoptotic proteins. The other 
group are the BH3-only proteins such as BAD, NOXA, and 
PUMA (reviewed in (Adams and Cory 2007). BH3-only proteins 
are the sensors of cell death signals and two of these proteins 
± Noxa, and Puma ± are essential in the regulation of 
apoptosis induced by the tumour suppressor protein P53 in 
response to DNA damage, while BID and BIM are the 
activators of BAX and BAK (reviewed in (Gustafsson and 
Gottlieb 2007, Letai 2008)). In normal cells, BAX and BAK are 
maintained in an inactive state by binding to the anti-apoptotic 
proteins ± BCL-2, MCL-1 and BCL-xL. In response to cell 
death, the BH3-only proteins bind to the anti-apoptotic 
proteins BCL-2, MCL-1 and BCL-xL leading to release BAX and 
BAK and initiate intrinsic apoptosis pathway (reviewed in 
(Gustafsson and Gottlieb 2007)). 
In cancer development, there is evidence that the expression 
of anti-apoptotic BCL-2 proteins is perturbed and the 
resistance of tumour cells to cytotoxic drugs is elevated 
(Bradbury, et al 1996, Glaser, et al 2012). In t(14;18) 
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lymphoma cells, which is distinguished by translocation of the 
BCL-2 from 18q21 to the 14q32 locus an increase in BCL-2 
levels are seen which promotes cell survival (Graninger, et al 
1987). Moreover, in FLT3-ITD AML, MCL-1, which is an anti-
apoptotic protein and is critical for AML cell survival, has been 
shown to be up-regulated to a greater extent than in normal 
hematopoietic stem cells (Yoshimoto, et al 2009). Therefore, 
developing drugs to target the anti-apoptotic proteins are 
under investigation for effective treatment of tumour cells 
(Adams and Cory 2007, Glaser, et al 2012, Shore and Viallet 
2005). 
1.4.4 Interaction of NPM1 with proteins involved in DNA 
damage response: 
The main function of NPM1 is shuttling between the nucleus 
and the cytoplasm, but NPM1 interacts with many proteins, 
particularly those involved in the DNA damage response 
mechanisms such as ARF, P53, HDM2, and APE1. NPM1-ARF 
complex is formed by binding of the C-terminal of NPM1 to the 
N-terminal of ARF in the nucleus. The C-terminal region of 
NPM1 is essential for a complex formation, as well as nucleic 
acid binding properties (Korgaonkar, et al 2005). The NPM1-
ARF complex disappears after the cell has been exposed to a 
DNA damage response, such as UV. ARF is then translocated 
to the nucleoplasm where it binds to HDM2, resulting in the 
stabilisation and activation of P53 (Lee, et al 2005). In 
addition, NPM1 binds to HDM2 using the same domains as 
ARF, which leads to the formation of the NPM1-HDM2 complex 
(Korgaonkar, et al 2005, Kurki, et al 2004b). The NPM1-HDM2 
complex is usually formed during the later stages of the DNA 
damage response, which indicates that NPM1 interacts with 
newly synthesised HDM2, or when it is released from P53 
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(Colombo, et al 2002, Korgaonkar, et al 2005). ARF-HDM2 and 
NPM1-HDM2 disappear after the DNA is repaired and, the ARF-
NPM1 complex is reformed and relocated in the nucleus. This 
process suggests that NPM1 contributes in controlling DNA 
damage response mechanisms through interaction with the 
tumour-suppressor proteins (Colombo, et al 2005, Colombo, et 
al 2002, Kurki, et al 2004a). Moreover, the APE1 protein is an 
essential enzyme in the DNA base-excision repair pathway and 
functions as a redox factor modulating many transcription 
factors such as, AP-1, NF-ǉ% DQG 3 (Fishel and Kelley 
2007). NPM1 interacts with the N-terminal residues of APE1 in 
the nucleus and translocates it into the nucleolus. This 
interaction is essential in controlling the APE1 endonuclease 
activity, and results in an increase in the enzyme activity 
(Vascotto, et al 2009). The importance of NPM1 in regulation 
of proteins, which are involved in DNA repair pathway, gave 
an attention to the DNA damage response mechanisms in 
NPMc+AML.  
1.5 Aim of the study: 
AML harbouring NPMc+ mutations is a disease with distinct 
clinical features and diagnosis. Patients with NPMc+ mutations 
have a favourable prognosis and the complete remission rate 
is higher than those patients with wild-type NPM1. The exact 
role of NPMc+ in tumorigenesis and the reasons behind the 
favourable prognosis of patients with NPMc+ mutations have 
not yet been precisely determined. However, it is assumed 
that the role of NPM1 in the regulation of tumour-suppressor 
proteins including P53, ARF, and HDM2, is significant 
(Colombo, et al 2005, Kurki, et al 2004b). In NPMc+AML, the 
NPMc+ mutations cause delocalisation of ARF to the cytoplasm 
with NPM1, which could lead to a disturbance of the DDR 
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functions and increase the sensitivity of tumour cells to 
chemotherapies (Colombo, et al 2006). In addition, NPM1 is 
required for APE1 subcellular localisation in nucleoli and the 
modulation of the APE1 endonuclease activity during rRNA 
synthesis. Thus, we aimed to investigate the effect of 
delocalisation of NPM1 into the cytoplasm on DNA damage 
repair function and on APE1 subcellular localisation in an 
NPMc+AML cell line and to compare with AML cell lines bearing 
wild-type NPM1. 
Clinically, the benefits of ATRA administration in NPMc+AML 
patients are controversial. An MRC trial failed to show the 
benefit of adding ATRA to standard chemotherapy in patients 
with NPMc+AML and non-APL AML cases, whilst the Austrian-
German AML study group demonstrated an improvement in 
overall survival in NPMc+ patients receiving ATRA in 
combination with chemotherapy (Burnett, et al 2010, Schlenk, 
et al 2011, Schlenk, et al 2009). In vitro, the treatment of an 
NPMc+ cell line with ATRA showed down-regulation of NPM1 
mutant protein, and activation of the apoptosis process 
(Martelli, et al 2007). Previously, the anti-apoptotic protein 
BCL-2 has been demonstrated to be more sensitive to cells 
that do not express CD34, which is the main feature of NPMc+ 
cells, than to CD34 positive cells (Bradbury, et al 1996). 
Therefore, the status of the anti-apoptotic proteins BCL-2 and 
MCL-1 in NPMc+AML cell line will be undertaken alongside the 
evaluation of the influence of ATRA on BCL-2 and MCL-1 levels 
in NPMc+AML and wild-type NPM1. 
An extra level of complexity is the relationship between FLT3 
and NPM1 mutations. Many patients have both mutations and 
the co-expression of the FLT3-ITD mutation with NPMc+ 
effects patient outcome by converting the prognosis from 
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favourable to intermediate. The risk stratification of NPM1-
wt/FLT3-ITD is classified into the adverse prognostic group 
(Dohner, et al 2005, Gale, et al 2008, Thiede, et al 2006, 
Verhaak, et al 2005). Whilst the presence of FLT3 mutations 
on clinical outcomes are well documented, little is known 
about the biological mechanisms and more effort is required in 
understanding the pathology of these mutations. Hence, we 
aimed to target NPMc+ and FLT3-ITD mutations by adding 
FLT3 inhibitor (AC220) and ATRA, and then assess the effect 
of these drugs on the levels of anti-apoptotic BCL-2 and MCL-1 
in NPMc+/FLT3-ITD cells. 
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2. Materials and 
Methods 
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2.1 Chemicals: 
Reagents were purchased from Sigma-Aldrich unless otherwise 
stated. Glycine, Tris-Base, Sodium azide and 
paraformaldehyde were provided by Fisher Scientific Ltd 
(Loughborough, UK). AC220 - FLT3 inhibitor - was obtained 
from Selleck Chemicals (Munich, Germany). All trans-retinoic 
acid (ATRA), Etoposide and AC220 were dissolved in 100% 
DMSO (dimethyl sulfoxide) to a stock concentration of 100mM 
and then aliquoted and frozen at -20°C. Further dilution was 
made in cell culture medium. 
2.2 Antibodies: 
Negative control mouse IgG1 (X093101), negative mouse 
IgG1-FITC (x0927), monoclonal mouse anti-human NPM1 
clone 376 (M7305), monoclonal mouse anti-human BCL-2 
oncoprotein clone 124 (F7053), polyclonal goat anti-mouse 
IgG-FITC (F0479), and rabbit polyclonal anti-mouse IgG-FITC 
(F0313) were obtained from Dako. Rabbit polyclonal anti-
APE1-N-Terminal (ab82859), mouse monoclonal anti-MCL-1 
DEPRXVHPRQRFORQDOǃ-actin antibody (ab6276), and 
goat polyclonal CY-3 secondary antibody to rabbit IgG 
(ab6939) were from Abcam. PE mouse anti-STAT5 (pY694) 
(612567) and PE mouse IgG1-ǉLVRW\Se control (555749) were 
purchased from BD biosciences. Secondary goat anti-mouse 
IgG-HRP (SC-2005), secondary goat anti-rabbit IgG-HRP (SC-
2054) and mouse monoclonal anti-IgG2b Lamin A/C antibody 
(SC-7292) were obtained from Santa Cruz Biotechnology. 
Rabbit polyclonal anti-APE1 (NB100-101), and mouse 
monoclonal anti-phospho-histone H2AX (ser139) antibody 
clone JBW301 (05-636) were purchased from Novus biological 
and Upstate-Millipore, respectively. 
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2.3 Cell culture: 
Five different AML cell lines were used in the project (Table 
2.1). OCI-AML3, MOLM-13 and M-07e were obtained from the 
German Collection of Microorganisms and Cell Cultures (DSMZ, 
Germany), whilst the MV4-11 cell line was obtained from the 
American Type Culture Collection (ATCC; USA) and HL-60 
were from European Collection of Animal Cell Cultures 
(ECACC; Health Protection Agency Culture Collections, UK). 
OCI-AML3, MOLM-13, MV4-11, and HL-60 were maintained in 
RPMI-1640 medium supplemented with 10% foetal calf serum 
(FCS; First Link, UK), 2mM L-glutamine, 100U/ml penicillin 
and 10µg/ml streptomycin. 10ng/ml of GM-CSF (A gift from 
Novartis, Switzerland) was added to M-07e cell line because it 
is dependent on this cytokine for growth. All cell lines were 
grown in a humidified 5% CO2 incubator at 37°C, and 
refreshed every two or three days by feeding and diluting 
them to prevent an overgrowth of the cells. All experiments 
were performed with cell lines in log phase, and used for a 
specific number of passages to minimise the chances of any 
genetic drift. In addition, these cell lines were regularly 
analysed with short tandem repeat (STR) to verify that the 
experiment results belong to the selected cell line with a 
specific genotype. 
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Table 2.1: The characterisations of Leukaemic cell lines; List of Leukaemic cell lines 
which are used in the experiments. 
 
2.4 Patient samples: 
Peripheral blood (PB) or bone marrow (BM) samples were 
obtained from AML patients presenting to Nottingham City 
Hospital. Samples were obtained after written informed 
consent from AML patients. Use of these samples was 
approved by the Nottingham 1 Ethics Committee (reference 
06/Q2403/16) and the Nottingham University Hospitals NHS 
Trust. Mononuclear cells were isolated from PB or BM by 
standard density gradient techniques using Histopaque and 
were either frozen in RPMI-1640 medium with 20% foetal calf 
serum, and 10% of DMSO in liquid nitrogen or used directly in 
an experiment. The frozen sample were thawed at 37°C and 
then added to RPMI-1640 supplemented with 10% FCS, and 
1% heparin. After pelleting the thawed cells, the supernatant 
was removed and cells were resuspended in rest medium 
which comprised 40% FCS, and 2mM L-glutamine for 90 
minutes in a humidified 5% CO2 incubator at 37°C. The cell 
Cell Line Origin P53/NPM/FLT3 Genotype 
M-07e 
Established from the peripheral blood 
of a 6-month old girl with acute 
megakaryoblast leukaemia 
Wild-Type FLT3 
Wild-Type NPM 
Wild-Type P53 
OCI-AML3 
Established from the peripheral blood 
of a 57-year old man with acute 
myeloid leukaemia 
Wild-Type FLT3 
Mutant NPM Type A 
Wild-Type P53 
MOLM-13 
Established from the peripheral blood 
of 20-year old man with acute 
myeloid leukaemia 
Heterozygous FLT3-ITD 
Wild-Type NPM 
Wild-Type P53 
MV4-11 
Established from the blast cells of a 
10-year old man with biphenotypic 
B-myelomonocytic leukemia 
Homozygous FLT3-ITD 
Wild-Type NPM 
Wild-Type P53 
HL-60 
Established from a 36-year old 
Caucasian woman with acute 
promyelocytic leukaemia 
Wild-Type FLT3 
Wild-Type NPM 
Mutant P53 
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viability was assessed by 7-AAD (7-amino-actinomycin D) (see 
section 2.5.3). During experiments, the patient samples were 
incubated in RPMI-1640 supplemented with 10% FCS, 2mM L-
glutamine, 100U/ml penicillin, 10µg/ml streptomycin, 10ng/ml  
GM-CSF (Novartis, Switzerland), 25ng/ml G-CSF (NEUPOGEN, 
Amgen Inc), 20ng/ml IL-6 (PeproTech EC Ltd, UK), 20ng/ml 
IL-3 (a gift from Novartis, Switzerland), 20ng/ml SCF (255-SC, 
R&D system, USA), and 0.07µl/ml ǃ-mercaptoethanol in a 5% 
CO2 incubator at 37°C. 
2.5 Cell viability assays: 
2.5.1 Cell counting by haemocytometer: 
The cells were resuspended in a known volume of medium 
were mixed thoroughly and then 10µl was transferred into an 
eppendorf tube. 10µl of sterile Trypan-Blue (1:1 volume) was 
mixed with the cells. Thereafter, 10µl was introduced into the 
V-shaped well of a haemocytometer to totally cover the whole 
area with the cell suspension. The counting chamber was then 
placed under a microscope. The viable cells in the four corner 
squares in the chamber were counted. Finally, the number of 
cells/ml was calculated by multiplying the average count per 
square by the dilution factor and 104. 
2.5.2 Alamar blue assay: 
5×105/ml OCI-AML3, MV4-11, M-07e and HL-60 cells were 
prepared in medium and then 100µl was transferred into 96 
well plates. Thereafter, the cells were treated with etoposide 
or methyl methanesulfonate MMS at different concentrations 
and incubated at 370C in a humidified 5% CO2 incubator for 24 
hours.  After 20 hours, 10µl of Alamar Blue reagent was added 
to the wells and the plate incubated for another 4 hours. The 
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resulting fluorescence was then read at 560/590nm using a 
plate reader (FluoStar-Optima, BMG Lab Technology, 
German). The percentage of viable cells was calculated by 
dividing the treated cells by the untreated cells. In addition, 
cells were treated with DMSO at the highest concentration in 
which it had been used as a drug diluent in the experiment to 
ensure that the cell viability was not affected by DMSO. 
2.5.3 7-AAD cell viability assay: 
The patient cells, or the cell lines, were mixed with fixed 
stained cells (FSC), which were collected from a normal donor, 
in 1:1 volume. Subsequently, 50µl of 25µg/ml of 7-AAD was 
added and incubated for 15 minutes on ice, and then the cells 
were analysed by flow cytometry, and BD FACSCanto software 
was used (FACS; BD FACSCanto II). The number of viable 
cells was quantified by excluding dead cells and multiplying by 
the number of FSC, which is added with the patient cells or cell 
lines and counted by the haemocytometer (Pallis, et al 1999). 
2.6 Molecular methods: 
2.6.1 RNA extraction: 
RNA extraction was performed using a QIAamp blood RNA 
isolation kit (cat# 52304; Qiagen, Crawley, UK). However, a 
DNase digestion (cat#79254, Qiagen) was added to the 
standard procedure. The concentration of RNA was measured 
by a Thermo Scientific nanodrop 2000 (Labtech International 
Ltd, UK). Thereafter, cDNA was prepared from 2µg RNA which 
was heated to 650C to denature it and then placed on ice for 5 
minutes. Subsequently, it was mixed with 21.5µl of reverse 
transcription master mix, containing 200µl of 5x first strand 
buffer (Y02321; Invitrogen, Life Technologies Ltd, UK), 40µl of 
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25mM dNTPs (10297-018; Invitrogen), 100µl of 0.1M DTT 
(Y00147; Invitrogen), 33µl of random primer concentration 
3µg/µl (12097-018; Invitrogen), and 65µl of DEPC-treated 
water, 1µl of 40u/µl RNasin (N251B; Promega, UK) and 1.5µl 
of MMLV reverse transcriptase concentration 200u/µl (28025-
013; Invitrogen). The cycles were run in two stages at 370C 
for 60 minutes, then 950C for 10 minutes and then put on hold 
at 40C. Finally, the cDNAs were stored at -200C. 
2.6.2 Polymerase chain reaction (PCR) optimisations: 
Genomic DNA was extracted from the above cell lines using 
QIAamp blood DNA isolation kit (cat# 51104; Qiagen) 
DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V SURWRFRO 7KHUHDIWHU WKH
optimal condition for the amplification of NPM1 or APE1, which 
was done on cDNA, was determined by assessing different 
annealing temperatures and MgCl2 concentrations. The 
annealing temperature was set between 540C and 650C; 
54.90C, 55.20C, 55.90C, 57.00C, 58.20C, 59.40C, 60.50C, 
61.70C, 62.90C, 64.00C, 64.70C, and 65.00C and the MgCl2 
concentrations tested were 1.0, 1.5, 2.0 and 2.5mM, Other 
PCR components are shown in Table 2.2. The primer 
sequences were: NPM1 [F-
CTTAACCACATTTCTTTTTTTTTTTTTCCA, R-
GGACAACATTTATCAAACACGGTAG] (Invitrogen)(Gale, et al 
2008) and APE1 [F-ATATTGCTTCGGTGGGTGAC, R-
CTTGGAACGGATCTTGCTGT] primers (Invitrogen). The APE1 
primers were designed by using primer3 input version 4.0 
(http://primer3.sourceforge.net) (Rozen and Skaletsky 2000). 
Thereafter, the PCR products were loaded on an agarose gel 
(1x TBE, 2% (weight by volume) of agarose, and 0.5µg/100ml 
ethidium bromide and run for 1 hour at 200 volts following 
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which products were visualised under UV light and compared 
to a DNA ladder of known sizes (Invitrogen) 
Table 2.2: PCR optimisation conditions; The four different conditions of MgCl2 
used in the PCR optimisation.   
Content A B C D 
DNA 1µl 1µl 1µl 1µl 
Taq polymerase (Amplitaq Gold) 0.2µl 0.2µl 0.2µl 0.2µl 
10x PCR Buffer 2.5µl 2.5µl 2.5µl 2.5µl 
MgCl2 (25mM) 1µl 1.5µl 2µl 2.5µl 
Forward primer (20pmol) 1.25µl 1.25µl 1.25µl 1.25µl 
Reverse primer (20pmol) 1.25µl 1.25µl 1.25µl 1.25µl 
dNTPs (200µM) 1µl 1µl 1µl 1µl 
H2O 16.8µl 16.3µl 15.8µl 15.3µl 
Total Volume 25µl 25µl 25µl 25µl 
 
2.6.3 NPM1 and FLT3-ITD mutations analysis: 
The genomic PCR amplification of NPM1 and FLT3-ITD to 
assess length mutations was performed as follows: 1x buffer 
PCR (Applied Biosystems, Warrington, UK),  2mM, and 1.5mM 
MgCl2 (Applied Biosystems), for NPM1 and FLT3-ITD 
correspondingly, 2 units of Taq-polymerase (Amplitaq Gold, 
Applied Biosystems), 200µM dNTPs (Amersham Pharmacia 
Biotech), 1.25µl of 20pmol/µl NPM1 forward and reverse 
primers or FLT3-ITD forward (F-
GCAATTTAGGTATGAAAGCCAGC) and reverse (R-
CTTTCAGCATTTTGACGGCAACC-3) primers (Invitrogen) (Kiyoi, 
et al 1999, Seedhouse, et al 2009b), 1µl of DNA, with the  
volume being made up to 25µl with water. The NPM1 and FLT3 
reverse primers were labelled with Carboxyfluorescein (FAM). 
The fluorescent-PCR cycles started with a Taq activation stage 
at 950C for 10 minutes, then, 30 cycles of 950C for 1 minute, 
630C or 520C for 1 minute for NPM1 or FLT3, correspondingly, 
and 720C for 1 minute. The 30 cycles were followed by a final 
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extension step at 720C for 10 minutes (Biometra, T-Gradient, 
Germany). The products were subsequently loaded onto a 
3130 Genetic analyser (Applied Biosystems) for size 
separation and analyzed by GeneMapper ID software V3.2 
(Applied Biosystems). 
2.6.4 Gene expression measurements: 
NPM1, BCL-2, and MCL-1 expressions were measured using 
quantitative real-time PCR. Quantitative PCR was completed 
on an ABI prism 7500-Fast machine (Applied Biosystems) 
using real-time mastermix with SYBR Green (Applied 
Biosystems). The PCR master-mix contained 0.8µl of diluted 
cDNA (1:15), 5µl sybr green PCR master-mix (4309159; 
Applied Biosystems), and 1pmol of the specific primers for the 
UHOHYDQWJHQH7DEOHǃ2-0LFURJOREXOLQǃ0(Pallisgaard, 
et al 1999), BCL-2 (Pattyn, et al 2003), NPM1, and MCL-1 
(Qiagen; Table 2.3). The volume was then made up to 10µl 
with molecular grade water. cDNA from the KG1a cell line was 
used to make up a standard curve with doubling dilutions 
giving concentrations 125ng to 1.9ng. The cycle conditions 
were 500C for 2 minutes, 950C for 10 minutes, then, 40 times 
at 950C for 15 seconds, 600C for 1 minute, and 750C for 10 
seconds. Consequently, the products were heated from 600C 
to 950C over 20 minutes to allow melting curve analysis to be 
performed to assess the product specificity and ensure the 
absence of primer-dimers. Template-free reactions were 
included in each experiment as a negative control and all 
reactions were done in triplicate. The standard curve was used 
to assign values to the samples and the housekeeping gene 
ǃ0ZDVXVHGWRFDOFXODWHWKHUHODWLYHH[SUHVVLRQOHYHOVRIWKH
selected genes. 
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 Table 2.3: Primers used in real-time PCR. 
Gene Primer Sequences Code Source 
ǃ0 F-GAGTATGCCTGCCGTGTG 
R-AATCCAAATGCGGCATCT  
------------ Invitrogen 
BCL-2 
F-ATGTGTGTGGAGAGCGTCAACC 
R-TGAGCACAGTCTTCAGAGACAGCC 
------------ Invitrogen 
NPM1 Custom primers QT00091875 Qiagen 
MCL-1 Custom primers QT00094122 Qiagen 
 
2.6.5 Sequencing: 
PCR products from OCI-AML3, HL-60, and M-07e were purified 
using QIAquick PCR Purification kit (Qiagen). Thereafter, each 
sample has two reactions; one for the forward primer and the 
second for the reverse. 1µl of the PCR product was mixed with 
3.2pmol of forward or reverse primers, 3µl of sequence mix 
(BigDye Terminator V3.1±Cycle Sequencing Kit, cat# 
4337455, AB Applied Biosystems), 5µl 2.5x buffer with the 
volume being made up to 20µl by H2O. The sequencing cycles 
were repeated 25 times as follows; 960C for 1 minutes, 960C 
for 10 seconds, 500C for 5 seconds, and 600C for 4 min by 
using T-Gradient Thermocycler (Whatman Biometra). 
Thereafter, 20µl of the sequenced products were purified using 
2µl of sodium acetate (3M at pH5.2) and 50µl 100% ethanol, 
and then incubated on ice for 20 minutes. After centrifugation 
for 20 minutes at 14000 rpm, the liquid was discarded and 
150µl 70% ethanol was added to wash the pellet. The tubes 
were spun again, 5 minutes 14000 rpm and the supernatant 
was removed. Thereafter, the pellets were left to air dry for 5 
minutes and stored at -200C until ready for analysis. The 
sequencing products were resuspended in HiDye (Applied 
Biosystems) and run on ABI Prism 3130 Genetic Analyser 
(Applied Biosystems). Sequencing analysis was performed 
using Applied Biosystems Sequencing Analysis software 5.2. 
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2.7 Assessing the interaction of NPM1 and APE1 in the 
leukaemic cell lines: 
2.7.1 Preparation of slides: 
2.7.1.1 LiquiPrep cytology system: 
5×105 cells were mixed with 5ml cell preservative solution 
(Vector Labs, UK) and incubated for 30 minutes with 
occasional mixing. The cells were pelleted by centrifugation for 
5 minutes at 200g, and then the supernatant was removed 
and the cell pellet resuspended by adding 50µl of cellular base 
solution (Vector Labs). After mixing the cells, one drop of cell 
preparation was applied onto the centre of a labelled slide and 
left to dry for approximately 1 hour. The cells were fixed by 
4% paraformaldehyde for 15 minutes. 
2.7.1.2 Coverslip technique: 
5×105 cells were transferred to a cover slip and incubated for 
24 hours in a humidified 5% CO2 incubator at 37°C. On the 
next day, the medium was aspirated carefully from the cover 
slip and the cells were fixed in 4% paraformaldehyde 
(Colombo, et al 2002). 
2.7.1.3 Cytospin technique: 
5×105 cell suspension was dispensed into a cytospin tube and 
then centrifuged at 1000 rpm for 5 minutes. Thereafter, the 
slides were left to air dry for 30 minutes and the cells fixed 
with 4% paraformaldehyde (Gruszka, et al 2010). 
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2.7.1.4 Fibronectin coating technique: 
Fibronectin solution was prepared at 20µg/ml in PBS. 400µl of 
the solution was added to a slide and incubated overnight at 
40C. On the next day, the slides were washed twice with 
filtered PBS and then incubated for 2 hours at 370C in a closed 
box. Thereafter, the slides were left to air dry for one hour in a 
safety hood to prevent contamination. Subsequently, 5×105 
cells were added to the slides and incubated for one hour at 
room temperature in the safety hood and then were fixed with 
4% paraformaldehyde. 
2.7.2 Indirect immunofluorescence method for 
detection of subcellular localisation by confocal 
microscopy: 
NPM1 and APE1 localizations were observed using an 
immunofluorescence technique.  After the cells were fixed by 
4% paraformaldyhyde for 15 minutes at room temperature, 
they were permeabilized for 5 minutes in PBS containing 0.2% 
(wt/vol) Triton X-100 and 2% normal goat serum albumin and 
then incubated for 30 minutes in 2% normal goat serum in 
PBS at room temperature to block non-specific binding of the 
antibodies. Cells were incubated with rabbit polyclonal anti-
APE1 diluted 1:150 in blocking solution overnight at 4oC. After 
washing, cells were incubated for 1 hour with goat polyclonal 
secondary antibody to rabbit IgG (CY-3 labelled, pre-
adsorbed) (1:250). For NPM1 subcellular localization detection, 
the permeabilized cells were incubated with monoclonal mouse 
anti-NPM1 1:80 overnight at 4oC. Thereafter, the slides were 
washed twice with PBS and then incubated with polyclonal 
rabbit anti-mouse IgG FITC 1:100 for 1 hour in the dark.  
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The slides were then washed in PBS and the nuclei were 
stained by 4,6-diamidino-2-phenylindole dihydrochloride 
(DAPI) (VectaShield Mounting Medium with DAPI, Cat# H-
1200, Vector Laboratories, USA). The slides were visualized 
through 100× oil objective using a NIKON C2 confocal 
microscope system and captured by NIS-elements imaging 
software.  
2.7.3 Cytoplasmic-nuclear extracts: 
2.7.3.1 Preparation of cytoplasmic-nuclear extracts: 
The cytoplasmic and nuclear extraction was performed using a 
nuclear extract kit (Active Motif, cat# 40010, Belgium). 
8.8×106 cell line cells (treated with/without drugs) were 
washed with cold PBS/phosphatise inhibitors and then 
centrifuged at 500 rpm for 5 minutes at 40C. Supernatant was 
removed and the pellet was resuspended in 1x hypotonic 
buffer, which was supplied in the kit, then incubated on ice for 
15 minutes, thereafter, ǋORIWKHGHWHUJHQWVXSSOLHGE\WKH
kit was added and vortexed for 10 seconds. Consequently, the 
suspensions were centrifuged at high speed for 30 seconds 
and the resulting cytoplasmic fraction was transferred into a 
clean 1.5ml tube. The nuclei were collected by resuspending 
the nuclear pellet in complete lysis buffer, which is supplied in 
the kit (Active Motif), and votexing at high speed for 10 
seconds. After 30 minutes of incubation on ice, the suspension 
was centrifuged at 10000 rpm for 10 minutes at 40C. Finally, 
the supernatant was collected as a nuclear protein extract and 
used for western blot and co-immunoprecipitation or stored at 
-800C. 
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2.7.3.2 Determination of protein concentration: 
Protein concentration was determined using BioRad dye 
reagent (Bio-Rad protein assay, cat# 500-0006, Bio-Rad Lab 
GMBH, German). 1ml of the BioRad protein buffer was diluted 
in 4ml distilled water, and then 100Pl was transferred into 
wells of a 96 well plate. Bovine Serum Albumin (BSA) was 
used to establish a standard curve at 4, 2, 1, 0.5, 0.2, 
0.1mg/ml in lysis buffer. 2Pl of BSA standard or sample was 
added to the plate. The absorbance was measured at 590nm. 
The protein concentrations of samples were calculated from 
the BSA standard curve by the software provided with the 
plate reader (FluoStar-Optima, BMG Lab Technology, 
German). 
2.7.4 Western blot analysis: 
10µl of molecular weight marker (Amersham High-Range 
Rainbow Molecular Markers, code# RPN756E, GE Healthcare 
Life Sciences) and 40µl of the protein solutions, which were 
mixed with an electrophoresis sample buffer in a 1:1 ratio (2x 
Laemmli buffer: 4% SDS, 10% 2-mercaptoehtanol, 20% 
glycerol, 0.004% bromophenol blue, 0.125M Tris HCl, pH:6.8), 
and added to 10% SDS±PAGE for separation in migration 
buffer (25mM Tris base, 190mM Glycine, 0.1% SDS, pH:8.3) 
at 200V for 1 hour. The resolved proteins were transferred 
from the gel to a PVDF membrane for 45 minutes at 100V in 
transfer buffer (25mM Tris base, 190mM Glycine, 20% 
methanol). The membranes were blocked by 5% non-fat free 
milk (Blotting Grage Blocker, cat# 170-6404, USA) for 1 hour 
at room temperature. After three washing steps with 1x TBST 
buffer (10x TBST buffer: 24.2g Tris base, 87.6g NaCl, 1000ml 
dH2O, 10mls Tween 20, pH 7.4 ± 7.6), 1:1000 of rabbit anti-
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APE1, 1:4000 of mouse anti-NPM1 were incubated overnight 
at 40C, while the loading control of 1:10000 of mouse anti-ǃ-
actin or 1:700 of mouse anti-Lamin A/C was incubated for 1 
hour at room temperature or overnight at 40C, respectively. 
After three washes with 1x TBST, goat anti-rabbit-HRP 
(1:2500) or anti-mouse-HRP (1:3000) secondary antibodies 
were applied. The binding of antibodies was detected using 
enhanced chemiluminescence (ECL Western Blotting Detection 
Reagents; code#RPN2209, GE Healthcare Life Sciences) and 
the densitometry of the bands was performed by using Image-
J analysis software (NIH) (Schneider, et al 2012). 
2.7.5 Co-immunoprecipitation: 
100µg of cellular protein was mixed with 2µg of primary 
antibody (NPM1 or APE1); and incubated for 1 hour at 40C; 
these were the same antibodies as had been previously used 
in subcellular localisation detection and in western blotting. 
20µl of well mixed protein A/G plus-agarose (cat# sc-2003, 
santa cruz biotechnology) was then added and incubated at 
40C on a rocker platform overnight. The immunoprecipitate 
was collected by centrifugation at 2500 rpm for 5 minutes at 
40C, and then the supernatant was discarded. The pellet was 
washed 4 times with PBS. Finally, the pellet was resuspended 
in 40µl of 1x electrophoresis sample buffer, and the proteins 
were separated as described previously (section 2.7.4). 
2.7.6 MMS cytotoxicity assay: 
Methyl methanesulfonate (MMS) sensitivity was investigated 
using wild-type and mutated NPM1 cell lines. 5×105 cells were 
treated with different concentrations of MMS (0.8µM, 1µM, 
2µM, 3µM, 4µM, 5µM, 10µM, 15µM, 20µM and 25µM) for 1 
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hour. Then, the cells were washed 3 times with RPMI medium 
and incubated for 72 hours in drug-free medium. The growing 
medium was replenished every 24 hours. Cell viability was 
tested by flow cytometry using the 7-AAD assays (section 
2.5.3). 
2.8 DNA damage response: 
2.8.1 Comet assay: 
2.8.1.1 Preparation of slides: 
Neutral and alkaline comet assays were performed on the 
selected leukaemic cell lines OCI-AML3, M-07e, and MV4-11 
using commercially available comet assay slides (Trevigen, 
USA). Both basal levels of DNA damage and drug-induced 
damage were assessed. In the neutral comet assay, 1x105 
cells were suspended in PBS then mixed with cooled molten 
low-melting-point agarose (Trevigen) at a ratio of 1:10 (v/v). 
75µl of the mixture was added to the comet slides (Trevigen) 
which were then placed in the dark at 40C for 10 minutes to 
improve the adherence of samples in agarose in a high 
humidity environment.  
The slides were immersed overnight in pre-chilled lysis 
solution (Trevigen) at 40C. After removing the excess buffer 
from the slides, they were gently washed twice by placing in 
neutral buffer (1x TBE; 89mM Tris-base, 89mM boric acid, 
2mM EDTA, pH 8.0) for 30 min at room temperature to 
remove the lysis solution and to enable DNA to unwind.  
The slides were then placed in a horizontal electrophoresis 
tank which contained a neutral buffer, and electrophoresis was 
conducted for 15 min at 22V (1 V/cm, 400mA). After removing 
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excess electrophoresis buffer from the slide, they were rinsed 
briefly in distilled water, and then the cells were fixed through 
immersion in 70% ethanol for 5 minutes and air dried at room 
temperature in the dark overnight. The sample slides were 
stained for approximately 5 minutes with the green fluorescent 
DNA-binding dye, SYBR Green I (Sigma). The migrated DNA 
(comet) was observed under an epifluorescence microscope at 
20x magnification (BX61, Olympus Tokyo, Japan) and 
analysed as described in section 2.8.1.2. The steps of the 
comet assay are summarised in Figure 2.1. 
The alkaline comet assay used the same protocol except for 
the unwinding and electrophoresis steps, where the neutral 
buffer was replaced by an alkaline buffer (300mM NaOH, 1mM 
EDTA, pH >13.0) ± unwinding proceeded for 10 minutes and 
electrophoreses for 20 minutes. Thereafter, the slides were 
washed gently three times with a neutralisation buffer to 
remove excess alkali. 70% ethanol was used to fix the cells, 
which were then left to air dry at room temperature in the 
dark overnight. Finally, SYBR Green I was added to the slides 
and DNA migration was observed under an epifluorescence 
microscope. 
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Figure 2.1: Comet assay protocol steps; 
(http://www.amsbio.com/Comet-Assays.aspx) 
 
2.8.1.2 Analysis of comet assay: 
DNA damage was assessed using an automatic image analysis 
system (CometAssay IV software, Perceptive Instruments, UK) 
to measure the olive tail moment (Sigurdson, et al 2005). This 
is defined as the amount of DNA in the tail and the 
displacement between the centre of mass of the comet head 
and the centre of mass of the tail (tail length) (Kumaravel, et 
al 2009). Duplicate agarose spots were prepared for each 
experimental condition, and 50 cells in each spot were 
randomly selected and analysed.  
Ǆ-H2AX immunocytochemistry assay: 
Ǆ-H2AX foci in OCI-AML-3 and MV4-11 cell lines were 
evaluated by immunofluorescence. 3x105 cells were fixed with 
20µl of reagent-A (ABD Serotec, Bio-Rad) for 15 minutes at 
room temperature in the dark. Subsequently, 2ml of 100% 
methanol was added and the cells incubated for 10 minutes on 
ice. The cells were then washed twice in phosphate buffered 
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saline with sodium azide (1% bovine serum albumin/0.5% 
sodium azide in PBS) (PBS-AA) and 20µl of reagent B (ABD 
Serotec) was added for permeabilisation. The cells were 
incubated with 200µl of primary antibody anti-Ǆ-H2AX (1:500) 
at room temperature in the dark for 2 hours, while in the 
control tube 200µl of negative control mouse-IgG (1:50) was 
added. After two washing steps with PBS-AA, the cells were 
incubated with 3µl of appropriate secondary antibodies, anti-
mouse IgG-FITC, for an hour in the dark at room temperature, 
before being washed. Thereafter, cells were resuspended in 
20µl PBS-AA and mounted in mounting medium with 4',6'-
diamidino-2-phenylindole (DAPI) (cat# H-1200, Vectashield 
Mounting Medium with DAPI, Vector Laboratories, USA). Foci 
were visualized in 100 cells by using fluorescence microscope 
at 100x magnification. As the number of foci varied per cell, 
these were quantified using an H score system (Katz, et al 
1990, Seedhouse, et al 2009a). According to the number of 
foci in each cell, the results are divided into five groups: N (no 
foci), L (1-6 foci), M (7-12 foci), H (>13), C (completely 
damaged). The H score was calculated as follows: N + 2L + 
3M + 4H + 5C. 
2.9 Anti-apoptotic protein levels in NPMc+AML cells and 
response to ATRA: 
2.9.1 ATRA and AC220 concentration optimisations: 
2×105 cells/ml of the cell lines were treated with different 
concentrations of ATRA (5nM, 10nM, 50nM, 100nM, 250nM, 
500nM, 1000nM) and the highest concentration of DMSO, 
which was used in ATRA dilution, was used in a control 
condition to test for the effect on cell survival. After 72 hours, 
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the viable cells were counted by the haemocytometer method 
(section 2.5.1).  
For AC220, the same procedure was followed but the drug 
concentrations ranged between 0.5nM-15nM for MV4-11 and 
MOLM-13 cell line, and 0.5nM-1000nM for the OCI-AML3 and 
M-07e cell lines. 
2.9.2 Blood cell morphology: 
The different cell lines were incubated for three days with 
ATRA at 500nM. Then, 1×105 cells were prepared by the 
cytospin method at 400rpm for 5 minutes and left to air dry 
for 30 minutes. After this, the slides were placed in methanol 
for 30 seconds, and then immersed in Wright-Giemsa stain for 
1 minute. Subsequently, the slides were removed from the 
stain and placed in de-ionized water for 10 minutes and then 
rinsed briefly in running de-ionized water and left to air dry. 
Cellular morphology was observed by light microscopy and 
signs of differentiation were evaluated.  
2.9.3 CD11b differentiation marker analysis: 
2×105 cells were washed twice with PBS-AA and incubated 
with 2.5µl of normal mouse serum for 30 minutes. Thereafter, 
2.5µl of anti-CD11b was added and incubated for another 30 
minutes. After two washing steps with PBS-AA, the cells were 
resuspended in 300µl of PBS-AA and analysed by flow 
cytometry.  
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2.9.4 Apoptosis detection by Annexin-V: 
Evaluation of apoptosis in the cell lines treated with ATRA, or 
AC220 was carried out by annexin-V FITC assay (cat#4830-
01-K, TACS Annexin-V kit, Trevigen). After 72 hours ATRA 
treatment, 2×105 of cells were washed twice with cold PBS. 
Then, 100µl of mixed annexin-V (84.5µl dH2O, 0.5µl Annexin-
V, 5µl Propidium Iodide, 10µl 10X binding buffer) was added 
and incubated for 1 hour at room temperature in the dark. 
Thereafter, 400µl of 1x binding buffer (TACS Annexin-V kit, 
Trevigen) was added to the tubes and they were processed by 
flow cytometry. 
2.9.5 BCL-2 and MCL-1 protein levels detection: 
1×106 of untreated and ATRA treated OCI-AML3, M-07e, 
MOLM-13, and MV4-11 cell lines were fixed with 4% 
paraformaldehyde for 15 minute at room temperature. After 
two rinsing steps with PBS-AA, the cells were resuspended in 
fresh saponin buffer (0.1% saponin, 0.5% BSA in PBS) and 
200µl was transferred to a tube. For MCL-1, 10µl of negative 
mouse IgG and anti-MCL-1 (1:10; diluted in saponin buffer) 
was added in different tubes. They were incubated for one 
hour at room temperature in the dark and then washed twice 
in PBS-AA. Thereafter, the tubes, which have primary 
antibodies in, were incubated with 80µl of normal rabbit serum 
for 30 minutes and then 5µl of rabbit anti-mouse FITC was 
added and incubated for 30 minutes at room temperature in 
the dark. Consequently, the cells were washed two times with 
PBS-AA and resuspended in 300µl of the saponin buffer. For 
BCL-2, 5ul of negative mouse IgG1-FITC and anti-BCL-2 
(1:10; diluted in saponin buffer) was added to the prospective 
tube and incubated at room temperature for an hour in the 
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dark. Subsequently, the cells were washed in PBS-AA and 
resuspended in saponin buffer. Finally, the proteins levels 
were measured by Flow cytometry (FACS; BD FACSCanto II).  
2.9.6 Total P53 protein measurement: 
1×106 cells were fixed with 4% paraformaldehyde for 15 
minutes at room temperature. After two washing steps with 
PBS-AA, the cells were resuspended in fresh saponin buffer. 
2×105 of the cells were incubated with 2µl of negative mouse 
IgG and 2µl (2µg) of anti-P53 in different tubes for one hour at 
room temperature in the dark and followed by two rinsing 
steps with PBS-AA. Thereafter, the tubes were incubated with 
80µl of normal rabbit serum for 30 minutes and then 5µl of 
rabbit anti-mouse FITC was added and incubated for another 
30 minutes at room temperature in the dark. Consequently, 
the cells were washed two times with PBS-AA, resuspended in 
300µl of saponin buffer and analyzed by flow cytometry. 
2.9.7 RNA Interference of NPM1: 
NPMc+AML and NPM1 wild-type cell lines were nucleofected 
with 15nM siRNAs targeting both the wild-type and mutant 
NPM1 (AAAGGTGGTTCTCTTCCCAAA) (Hs_NPM1_7, 
SI02654960, Qiagen). siRNA NPM1_7 was found to be more 
effective in knocking-down NPM1 than Hs_NPM1_1 
(SI00300979). Moreover, a siRNA species was designed to 
knockdown only the mutated NPM1 allele [NPM1-A (sense 
VWUDQG ¶-UCAAGAUCUCUGUCUGGCAtt-¶@ FDW 6
Applied Biosystems) via Cell Line Nucleofector Kit-T (cat# 
VCA-1002, Lonza, Switzerland) with the programme X-001 in 
a Nucleofector-2b device (Lonza). The nucleofection 
programme was selected and a lot of work went into 
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optimising the nucleofection conditions for the cell lines 
(unpublished work by Shili Shang). 1×106 cells were 
nucleofecWHG DFFRUGLQJ WR WKH PDQXIDFWXUH¶V SURWRFRO 
Thereafter, the cells were maintained in RPMI-1640 with the 
required supplements and incubated for 48 hours. 2µg of 
pmaxGFP vector (Lonza) was used as a positive transfection 
control and cells nucleofected with 15nM of AllStars negative 
control siRNA (cat# 1027281, Qiagen) was also included in the 
experiment. The transfection efficiency and the cell viability 
were assessed by flow cytometry via mixing 2×105 of the cells 
with 12.5µg/ml of 7-AAD. RNA from the negative control, and 
the cells with the total NPM1 or the mutant NPM1 knocked-
down, were extracted as previously described (section 2.6.3). 
The cDNA was used in real time PCR to measure the 
expression of NPM1, BCL-2, and MCL-1. In addition, the 
differentiation marker (CD11b) and P53 protein levels (see 
sections 2.9.3 and 2.9.6, respectively) were also evaluated in 
the OCI-AML3 and M-07e after knocking-down the total NPM1. 
2.9.8 Preparation of lysate from cell culture: 
Protein was extracted from different cell lines following 
different conditions according to nuclear extract kit (Active 
Motif). Approximately 3.2×106 OCI-AML3 cells were washed 
two times with ice-cold PBS containing 1:20 of phosphatase 
inhibitors. The cells were pelleted, and resuspended in 
complete lysis buffer, which is supplied in the kit (Active 
Motif), and vortexed for 10 second. The suspensions were 
incubated on ice for 30 minutes and then sonicated for 10 
seconds at 30% power setting (Bandelin Sonopuls ultrasonic 
homogenizer HD2070) and left on the shaker in the cold room 
for another 30 minutes. The sonicates were centrifuged at 40C 
at high speed for 10 minutes, then the supernatants were 
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transferred into a new pre-cooled eppendorf and assessed by 
western blot (section 2.7.4) or stored at -800C. 
2.10 Statistical analysis: 
Statistical analysis was performed using SPSS version 21 
(SPSS Inc., USA). All experiments were repeated at least three 
times and the data are presented as mean + standard 
deviation (SD). A p-value < 0.05 was considered statistically 
significant. 
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3. DNA Damage 
Repair Activity in 
NPMc+AML Cells 
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3.1 Introduction: 
DNA damage response is essential for the maintenance of 
genomic stability through the repair of DNA damage or the 
initiation of programmed cell death. A reduction in DNA repair 
activity could lead to an accumulation of mutations and DNA 
breaks, whilst an elevation of the DNA activity may inhibit cell 
apoptosis and enable highly damaged cells to attempt repair 
and survival with mis-repaired DNA damage (reviewed in 
(Seedhouse and Russell 2007)). Therefore, aberrant activity of 
DNA repair mechanisms is susceptible to the development of 
genetic instability that causes tumorigenesis. In clinical trials, 
extreme activation of DNA damage repair has been 
documented and associated with poor phenotype tumours. 
Moreover, the reduction, or absence of DDR and its factors, 
correlate with a favourable outcome (reviewed in (Helleday 
2010, Madhusudan and Middleton 2005)). For instance, a 
positive expression of APE1 corresponds with a poor prognosis 
because the resistance to chemotherapy and radiation is 
increased, meanwhile the reduction in APE1 expression 
enhances the cytotoxicity of the cells in response to the 
therapy (Al-Attar, et al 2010, Fishel and Kelley 2007, Zhang, 
et al 2009). Thus, inhibition of DNA repair function plays an 
essential role in the response of the tumour cells to 
chemotherapy. 
There are several types of DNA lesion and each group of DNA 
damage is repaired by a distinct DNA repair mechanism. For 
example, double-strand breaks are repaired by either 
homologous recombination (HR) or non-homologous end 
joining (NHEJ) mechanisms, whereas  single-strand breaks, or 
abnormal DNA bases, are repaired by the base excision repair 
mechanism (reviewed in (Jackson and Bartek 2009)). 
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Numerous kinds of tumours have developed due to mutations 
in genes that are involved in DNA damage repair, such as 
mutations in ATM lead to Ataxia-telangiectasia in which 
individuals are predisposed to cancer, and mutations in the 
BRCA1 or BRCA2 genes significantly increase the risk in 
women of developing breast or ovarian cancer (reviewed in 
(Kastan 2008)).   
In NPMc+ cells, disruption of NPM1 subcellular localisation 
from the nucleus into the cytoplasm causes the delocalisation 
of some of the proteins that are involved in the activation of 
the P53-mediated response to DNA damage, such as ARF 
(Colombo, et al 2006, den Besten, et al 2005). In addition, it 
has been reported that interaction of NPM1 with 
apurinic/apyrimidinic endonuclease-1 (APE1), which is an 
essential protein in the base excision repair (BER) pathway, is 
important for APE1 subcellular localisation and for regulating 
the rRNA process ((Vascotto, et al 2009)).  
It is well known that NPMc+ AML on its own has a favourable 
prognosis (Dohner, et al 2005, Schnittger, et al 2005, Thiede, 
et al 2006). We proposed that the delocalisation of NPM1 into 
the cytoplasm in NPMc+ mutated AML cells may result in a 
reduction in DNA damage repair mechanisms leading to an 
increase in the sensitivity of such cells to chemotherapy. 
Hence, we aimed to evaluate the DNA damage repair function 
within NPMc+AML cells. 
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3.2 Results: 
3.2.1 NPM1 and FLT3-ITD mutations detection: 
The status of NPM1 and FLT3-ITD mutations in haematological 
cell lines was determined by fluorescent PCR with detection of 
products on the 3130 genetic analyser. Firstly, the reaction 
containing the NPM1 primers, which had previously been used 
by Gale et al. (Gale, et al 2008), was optimised for use in our 
laboratory by using different MgCl2 concentrations and 
annealing temperatures and 30 cycles of amplification were 
performed. As shown in figure 3.1, the PCR products at 2mM 
of MgCl2 and the annealing temperature is at 63
0C were 
chosen due to the presence of a single, tight, and bright band.  
 
Figure 3.1: PCR optimisation for NPM1 primers; The NPM1 primers 
were optimised at 4 different MgCl2 concentrations, which are (A) 1mM, (B) 
1.5mM, (C) 2mM, and (D) 2.5mM, and at different annealing temperatures: 
54.90C, 55.20C, 55.90C, 57.00C, 58.20C, 59.40C, 60.50C, 61.70C, 62.90C, 
64.00C, 64.70C, and 65.00C. A 1000bp-loading marker was used in the 2% 
agarose gel. A negative template control was included in the experiments. 
 
Thereafter, we assessed the genetics status in M-07e, OCI-
AML3, MV4-11, and MOLM-13 cell lines for NPM1 mutation, 
using the conditions determined above, and FLT3-ITD which 
was already being routinely used to screen samples in the 
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laboratory (Seedhouse, et al 2006). Figure 3.2A, shows the 
mutation status of NPM1 in MOLM-13 and OCI-AML3 cell lines, 
a single peak at 198 base pairs in the MOLM-13 cell line was 
detected indicating wild-type NPM1, whereas in the OCI-AML3 
cell line there were two peaks, which indicate a wild-type allele 
and a product with a 4 base pair addition. This is the result of 
a heterozygous NPMc+ mutation in the OCI-AML3 cell line 
(Quentmeier, et al 2005). The presence of FLT3 internal 
tandem duplication mutations was also detected in these cell 
lines and results showed that the MV4-11 cell line harbours a 
356bp of FLT3-ITD, with no wild-type peak compared to the 
MOLM-13 cell line, which has a wild-type FLT3 peak and a 
347bp of FLT3-ITD (Figure 3.2B). In contrast, the wild-type 
FLT3 was detected in the OCI-AML3 and M-07e cell lines. 
These findings are consistent with the published findings on 
FLT3-ITD status among cell lines (Quentmeier, et al 2005, 
Quentmeier, et al 2003). Minor peaks, which are stutter 
bands, were seen before the main allele. The stutter bands are 
characterised by the presence of fewer repeat units compared 
to the main allele band which is caused by strand slippage 
during the extension step of the PCR.  
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Figure 3.2: NPM1 and FLT3 length mutations in AML cell lines; NPM1 
and FLT3-ITD mutations were detected by PCR using fluorescence primers. 
(A) A homozygous peak at 193bp in MOLM-13 indicates wild-type NPM1, 
while two peaks in OCI-AML3 one at 193bp for wild-type NPM1 and the 
second at 197bp for the mutated NPM1 indicates the heterozygosity of 
OCI-AML3 for the NPMc+ mutation. (B) Wild-type FLT3 at 326pb and 
FLT3-ITD at 347bp were detected in MOLM-13, whereas in OCI-AML3 was 
only one peak is seen at the wild type position (326bp). In the MV4-11 cell 
line one peak was detected at 356bp which indicates homozygosity of this 
cell line for FLT3-ITD. All the samples were run twice. 
 
3.2.2 DNA damage repair activity in response to a DSB-
inducing agent: 
3.2.2.1 Assessment of DNA damage repair activity by 
the comet assay: 
In this chapter we aimed to evaluate DNA damage repair in 
the OCI-AML3 cell line, which harbour NPM1 mutations and 
wild-type P53, and compare it with other leukaemic cell lines 
that bear both wild-type NPM1 and P53. The comet assay or 
single cell gel electrophoresis assay (SCGE) is used to detect 
  
 
B 
 
A 
1 
1 
Qutob, H  Chapter 3 
74 
 
the DNA damage at the level of the individual cell (reviewed in 
(Kumaravel, et al 2009). It is based on the ability of 
negatively charged DNA to migrate to the anode in the 
presence of an electric field after unwinding the DNA through 
agarose gel in either a neutral or alkaline buffer. Neutral 
comet assay detects primarily double-strand breaks, whereas 
alkaline comet detects DNA single-strand breaks (SSB), 
double-strand breaks (DSB), and alkali labile sites (reviewed 
in (Collins 2004)). 
It is known that NPM1 plays a critical role in P53 activation 
through binding to ARF and HDM2 (Colombo, et al 2002, 
Gjerset 2006); thus, the delocalization of NPM1 in the mutated 
NPM1 cell line was suggested to impair the DSB repair 
pathway. Therefore, neutral and alkaline comet assays were 
used for assessing the DNA repair as loss of damage over time 
in M-07e, OCI-AML3 and MV4-11 cell lines. The cell lines were 
treated with etoposide at different concentrations for 24 hours 
to choose the optimal drug concentration, which caused 30% 
of cell death to ensure the cells had been damaged but not 
reach the point where all cells were undergoing to apoptosis 
(Figure 3.3A,B). Thereafter, M-07e, OCI-AML3 and MV4-11 cell 
lines were exposed to etoposide at 6µM, 4µM, and 0.4µM, 
respectively, for 24 hours. Following incubation with etoposide, 
the cells were incubated in drug-free medium and aliquots of 
cells were removed at different time points over 2 days to 
investigate the DNA damage/repair process. 
In neutral comet analysis, the tail moment increased after 24 
hours of treatment in all cell lines. During recovery process, 
the tail moment reduced by 20% after 24 hours in OCI-AML3 
cell lines and followed by a further reduction to reach about 
60% after 48 hours (p-value: 0.010), as the same percentage 
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as detected in MV4-11 and M-07e cell lines (p-values, which  
represent the difference in tail moment between 24 hours 
treated condition and after 48 hours of recovery process, in 
OCI-AML3, MV4-11 and M-07e cells are: 0.01, 0.068, and 
0.092, respectively) (Figure 3.4A). On the other hand, the 
alkaline comet analysis demonstrated that the level of damage 
after 24 hours of recovery had reached the basal level in all 
three cell lines but the OCI-AML3 cells has a significant 
reduction when we compared with the 24 hours treated 
condition (p-value in OCI-AML3: 0.021, while in M-07e and 
MV4-11 p-value is around 0.346) (Figure 3.4B). 
The percentage of cell survival during the comet assays was 
evaluated in all cell lines during the 48 hour repair phase and 
showed that cell survival was reduced to approximately 25% 
during recovery indicating that the majority of cells were lost 
via apoptosis and the damaged cells had died, while the 
undamaged cells had survived (Figure 3.5). 
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Figure 3.3: Viability of AML cell lines in response to etoposide; Cell lines were treated 
with etoposide at different concentrations for 24 hours. (A) M-07e and OCI-AML3 were 
treated with etoposide with concentrations range between (0.5µM to 10µM), while (B) MV4-
11 cell line was between (0.05µM to 1µM). The cell viability was measured by Alamar Blue 
assay and the percentage of cell survival was calculated by dividing treated cells by the 
untreated cells. The experiment was performed once. 
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Figure 3.4: Comet Assay in response to DSB agent; Cell lines were treated with 
etoposide at concentrations of 6µM, 4µM, and 400nM for OCI-AML3, M-07e and MV4-11, 
respectively. The tail moment was measured as described in the materials and method 
section. The data shown represents the mean and standard deviation of triplicate 
experiments: (A) tail moment of the neutral comet assay, (B) tail moment for the alkaline 
comet assay. (* indicates p-value <0.05 when the tail moment after 48 hours of recovery 
compared with 24 hours of treated condition) 
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Figure 3.5: Cell viability in parallel with comet assay upon etoposide treatment; The 
viability of M-07e, OCI-AML3, and MV4-11 cell lines were evaluated after 6 hours and 24 
hours of etoposide treatment at the respective concentration, then the drug was washed out 
and the cell viability was tested during the recovery process. An aliquot of cells were mixed 
with 7-AAD and the cell viability was measured using the flow cytometry method. The 
experiment was performed once. 
 
,PPXQRF\WRFKHPLVWU\GHWHFWLRQRIǄ+$; 
3KRVSKRU\ODWLRQ RI +$; Ǆ-H2AX) in the response to DNA 
damage is essential in the response of a cell to double strand 
breaks (DSB) (Huang, et al 2004). Phosphorylation of H2AX is 
considered to be an early step in response to DSBs and is 
therefore considered to be a biomarker of the initiation of 
DNA-DSB repair process (Burma, et al 2001, Rothkamm, et al 
2003)0HDVXUHPHQWVRIǄ-H2AX foci were evaluated by use of 
the H-score system which was originally developed to 
determine oestrogen receptor status in breast carcinomas 
(Katz, et al 1990). A total of 100 cells per condition was 
assessed and the number of foci present in each cell was 
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calculated as follows: N+2L+3M+4H+5C, and the differences 
of H-score between the untreated cells and treated cells were 
calculated (Katz, et al 1990, Seedhouse, et al 2009a).   
7KH Ǆ-H2AX immunocytochemistry assay indicated that the 
percentage of H score in OCI-AML3 and MV4-11 cell lines 
reached around 40% after 24 hours of treatment with 
etoposide compared with untreated cells (Figure 3.6). In the 
OCI-AML3 cell line, the percentage of H score persisted after 1 
hour of recovery in drug-free medium, but then decreased 
significantly over 24 hours, to reach 15% of the baseline (p-
value: 0.03). In contrast, after 1 hour of recovery in the MV4-
11 cell line, the H score reduced to 20% and remained stable 
at that level even after 24 hours of recovery (Figure 3.6). 
7KHVHUHVXOWV LQGLFDWHWKDW ORVVRIǄ-H2AX was delayed in the 
OCI-AML3 cell line during the first hour of DNA recovery 
compared to MV4-11 cells (p-value: 0.061), but after 24 hours 
it was hugely reduced to reach a same level to that seen in 
MV4-11 cells. 
 
Figure 3.6: Ǆ-H2AX Immunocytochemistry analysis; Ǆ-H2AX was examined in MV4-11 
and OCI-AML3 upon etoposide treatment and followed by 1hour, and 24 hours drug-free 
incubation to allow UHFRYHU\7KHSHUFHQWDJHRIǄ-H2AX cells was calculated after dividing H 
score in a specific cell condition by the H score in untreated cells value. The results presented 
are the means of two experiments and the error bars are SD. (* indicates p-value <0.05 
when compared with 1 hour of repair condition) 
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3.2.3 Assessment of DNA damage repair function in 
response to an alkylating agent: 
Methyl methanesulfonate (MMS) is a DNA alkylating agent 
which is known to generate DNA damage, particularly in the 
form of base adducts which are predominantly repaired by the 
base excision repair pathway. Following MMS treatment DNA 
damage was assessed by the alkaline comet assay which 
facilitates the detection of alkali label sites, single strand and 
double strand breaks via unwinding the DNA at pH greater 
than 12 after cell lysis at a high salt concentration. In order to 
assess the DNA repair function in response to MMS in wild-
type and mutated NPM1 cell lines, M-07e, OCI-AML3 and MV4-
11 cell lines were treated with MMS at a concentration of 
700nM, 700nM and 400nM, respectively, which caused around 
30% of cell death after 24 hours (Figure 3.7A,B). Thereafter, 
the drug was washed out and the cells were incubated in drug-
free medium to investigate the repair process at different 
times over 48 hours. The results showed that the tail moment 
among these cell lines increased during the drug treatment, 
whereas during recovery the tail moment reduced by 
approximately 30% after 6 hours in M-07e and OCI-AML3 cell 
lines, but additional reductions in tail moment did not occur 
after 24 hours of recovery (p-value: 0.123, and 0.131, 
respectively) (Figure 3.8). After 48 hours of recovery process, 
M-07e and OCI-AML3 cell lines showed a further reduction in 
the tail moment (Figure 3.8). In two these cell lines the 
percentage of cell survival was reduced from 60% after 24 
hours of MMS treatment to 40% after 48 hours of cell recovery 
which indicates that the damaged M-07e and OCI-AML3 cells 
underwent apoptosis (Figure 3.9). In the MV4-11 cell line, the 
tail moment showed a steady decrease during the 48 hours of 
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incubation in a drug-free media, and reached around the same 
value as seen in untreated cells (Figure 3.8). In addition, the 
percentage of cell survival in MV4-11 cells was 80% after 24 
hours of drug treatment and viability remained high during the 
recovery process suggesting that the DNA damage was 
repaired efficiently and the cells survived (Figure 3.9). 
 
 
Figure 3.7: Viability of AML cell lines upon MMS treatment; (A) M-07e and OCI-AML3 
cell lines were treated with etoposide with concentrations range between (0.5µM to 1µM) for 
24 hours,  while (B) MV4-11 cell line was between (250nM to 450nM) for 24 hours. The cell 
viability was measured by the Alamar Blue assay and the percentage of cell survival was 
calculated by dividing the treated cells by the untreated. The experiment was performed one 
time. 
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Figure 3.8: Alkaline comet assay in response to MMS; Measuring repair of MMS was 
assessed by the alkaline comet assay in OCI-AML3, M-07e and MV4-11. The tail moment was 
measured in untreated cells at 6 hours and 24 hours of MMS treatment, followed by 6 hours, 
24 hours and 48 hours in drug-free medium to evaluate DNA repair. The mean and standard 
deviation of three independent experiments are shown. However, the 48 hour timepoint was 
performed only once. 
 
 
Figure 3.9: Cell viability in parallel with comet assay upon MMS; Viability of cells used 
in the comet assay was tested at different time during the drug exposure and through 48 
hours of recovery. M-07e, OCI-AML3, and MV4-11 were treated with the respective 
concentration of MMS. An aliquot of cells were mixed with 7-AAD and then the cell viability 
was measured using the flow cytometry method. The experiment was performed once. 
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3.2.4 Expression of NPM1 in AML cell lines upon DNA 
damage inducing agent: 
We investigated the mRNA and protein levels of NPM1 in OCI-
AML3 and M-07e cell lines before and after the cell lines were 
treated with MMS or etoposide. OCI-AML3 and M-07e cell lines 
were treated with 4µM, and 12µM etoposide, respectively, or 
2µM MMS for both cell lines for 4 hours. As NPM1 shuttles 
between the nucleus and cytoplasm and there are differences 
in the subcellular localisation between cells expressing wild-
type or mutated NPM1 protein detection of NPM1 by western 
blot was done on cytoplasmic and nuclear lysates.  
In OCI-AML3, as expected for a cell line expressing mutant 
NPM1, the western blot showed that NPM1 was mainly 
observed in the cytoplasmic lysate fraction in untreated cells. 
However, after exposure to MMS or etoposide, NPM1 levels 
increased in the nuclear lysates relative to the loading control 
(p-value: 0.046 and 0.089, respectively) (Figure 3.10A). In 
contrast, the NPM1 localisation in the untreated M-07e cells 
was mainly in the nucleus and this reduced after the cells were 
treated with MMS or etoposide (p-value: 0.020 and 0.018) 
(Figure 3.10B).  
NPM1 mRNA levels were also assessed in these cell lines, 
using the same conditions, to verify whether NPM1 transcript 
expression could be altered in response to the DNA damage 
inducer. Figure 3.11, shows that there was no significant 
difference in the expression of NPM1 mRNA in the OCI-AML3 
NPMc+ cell line following treatment with MMS or etoposide (p-
value: 0.244). NPM1 mRNA expression was also not altered 
among the three different conditions in the NPM1 wild-type cell 
line M-07e (p-value: 0.200).  
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Figure 3.11: The level of NPM1 mRNA upon DNA damage inducers; The NPM1 mRNA 
expression was measured by real-time PCR after RNA was extracted from the cell lines treated 
with MMS or etoposide for 4 hours ǃ0 ZKLFK LV D KRXVHNHHSLQJ JHQH ZDV XVHG WR
normalise the gene expression. The mean of 3 experiments was calculated and the error bars 
represent the SD. 
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3.3 Discussion: 
This chapter focuses on the DNA damage response in a  
NPMc+ mutated AML cell line with comparisons made to  
haematological cell lines with wild-type NPM1. The genotyping 
of the haematological cell lines demonstrated a PCR product 
with an additional 4 bases pairs, in addition to a product of the 
expected size, in the NPM1 mutated OCI-AML3 cell line, this is 
characteristic of the heterozygous duplication of TCTG tetra-
nucleotide position 956 to 959 in this cell line as demonstrated 
by Quentmeier et al. (Quentmeier, et al 2005). 
One of the earliest events in the response to DSBs is the 
phosphorylation of ATM at the site of DNA damage which leads 
to the phosphorylation of H2AX, another early step in the 
cellular response to DSB (Burma, et al 2001, Rothkamm, et al 
2003). This is subsequently followed by a rapid induction of 
numerous proteins and signalling pathways in response to the 
damage, eventually leading to the repair of the DNA damage 
or apoptosis. One important signalling pathway in the cellular 
response to DNA damage is the P53 pathway, which promotes 
cell cycle arrest and repair or apoptosis. It has been 
established that NPM1 plays a vital role in P53 stabilization by 
re-locating the tumour suppressor protein ARF to the 
nucleoplasm which result in the inactivation of HDM2, the 
negative regulator of P53 (Colombo, et al 2002, Gjerset 2006, 
Kurki, et al 2004b). In response to UV-damage or DNA 
intercalating agents such as daunorubicin, the NPM1 protein is 
translocated from nucleoli into the nucleoplasm where it binds 
to HDM2 which releases P53 leading to an increase in P53 
stability and activity (Kurki, et al 2004a). In NPMc+AML 
mutations, we proposed that delocalisation of NPM1 into the 
cytoplasm leads to inactivate ARF function by altering its 
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subcellular localisation from the nucleus into the cytoplasm. As 
a result, the activity of P53 is reduced causing to perturb DNA 
repair functions and increase in sensitivity of NPMc+ cells to 
chemotherapy. 
In the experiments reported in this chapter, the results 
suggest that the delocalisation of NPM1 into the cytoplasm in 
the NPM1 mutated cell line OCI-AML3, has not impaired the 
DNA damage response when compared to two cell lines 
harbouring wild type NPM1. The reason for this is because the 
comet assays showed that the tail moment was reduced 
efficiently after the cells were exposed to a DNA damage 
inducer ± etoposide - and the percentage of cell survival 
decreased during the recovery process. This indicates that 
some of the cells were undergoing apoptosis. Moreover, we 
FRQILUPHG RXU ILQGLQJV E\ PHDVXULQJ Ǆ-H2AX foci following 
etoposide treatment; a reduction in the foci, after 24 hours of 
drug-free cell recovery in the OCI-AML3 and MV4-11 cell lines, 
suggests that the DSBs are being repaired efficiently. 
With respect to DNA damage repair, it has been shown that 
APE1 proteins interact with NPM1 and this complex is 
responsible for the subcellular localization of APE1 in HeLa cell 
line (Vascotto, et al 2009). APE1 is considered to be a vital 
enzyme in the BER pathway, where it functions to remove AP 
VLWHVDQGFOHDYHVWKH'1$VWUDQG¶WRWKH$3VLWHSURGXFLQJD
'1$SULPHUZLWKD¶-hydroxyl end (Fishel and Kelley 2007). 
Due to the association of NPM1 with APE1 we proposed to look 
at the repair of damage caused by the alkylating agent MMS; 
this agent induces damage in the form of base adducts which 
are primarily removed by the BER pathway (Fishel and Kelley 
2007). When comparing the NPMc+AML cell line to the wild 
type cell line, the loss of damage over time was no different 
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between the two cell lines indicating that the NPM1 aberrant 
cytoplasmic localisation in NPMc+AML did not affect the 
response of the cell to methylation damage. As a result, we 
have not looked at the pathways in more detail in patient 
samples, because the results did not show a difference in the 
DDR between the wild-type NPM1 and NPMc+ cell lines.  
A number of papers have reported that the subcellular 
localisation of NPM1 is affected in response to DNA 
intercalating agents and UV damage when it translocates from 
nucleoli into the nucleoplasm to participate in DDR via 
activation of the P53-dependent pathway (Colombo, et al 
2002, Kurki, et al 2004a, Kurki, et al 2004b). In our work, 
albeit in cells damaged by drugs which induce different types 
of damage to that induced by UV, damage did not alter the 
mRNA expression of NPM1 in the wild-type or mutant NPM1 
cells. Conversely, NPM1 protein level was significantly 
increased in the mutant OCI-AML3 cell line in the nuclear 
fraction, but in the wild-type NPM1 cell line NPM1 decreased 
upon drug exposure. 
It is known that NPM1 targets ARF to nucleoli in a dose-
dependent manner; hence moderate to low NPM1 levels 
induces ARF activity by relocation of ARF into the nucleoplasm, 
whereas normal to slight elevation of NPM1 expression 
represses ARF to bind to HDM2 by locating it in the nucleoli 
(Korgaonkar, et al 2005). In western blot densitometry, 
strikingly, we showed a reduction trend in the protein level of 
NPM1 in the wild-type NPM1 cell line, whereas the level of 
NPM1 protein in the OCI-AML3 was raised approximately to 
the same level as detected in the M-07e cells. It seems that in 
the presence of DNA damage, the increased level of NPM1 
protein in the nuclear compartment in OCI-AML3 cells reaches 
Qutob, H  Chapter 3 
89 
 
the same levels seen in wild-type NPM1 cells and this 
contributes to the activation and stabilisation of P53 by 
increasing the NPM1 production and relocating the NPM1 in the 
nucleus. Once there it binds to ARF and HDM2. Moreover, the 
amount of NPM1 protein, which is present in the nucleus of 
OCI-AML3, could be enough to initiate the DDR processes. 
Consistent with this, Koike et al. found that a small fraction of 
NPM1 and phosphorylation at Threonin-199 is employed to 
'6%VLWHVDORQJVLGHWKHǄ-H2AX and BRCA1 foci to participate 
in the DSB-induced repair process (Koike, et al 2010). 
Therefore, it seems that the NPMc+AML cells do not appear to 
affect the DDR during the DNA damage repair because our 
comet assay results and other repair assays demonstrated no 
difference between NPMc+ and wild-type NPM cells. 
There are some aspects, which should be considered in our 
results. The experiments were performed on one cell line 
bearing NPMc+AML and compared to cell lines with wild-type 
NPM1 and P53. In addition, the western blot and the 
expression of NPM1 mRNA were tested after treatment with 
the cell lines by DNA inducer agent for 4 hours. While, in the 
comet anGǄ-H2AX assays, the cells were treated for 24 hours 
at a specific concentration of DNA inducer agent to produce 
30% loss of cell viability. In order to produce consistency in 
the results, the cells in western blot and NPM1 expression 
should be maintained in the same condition as the comet 
assays cells were treated. 
To summarise the findings in this chapter, we proposed that 
DDR in NPMc+ cells is impaired due to the delocalisation of 
NPM1 from the nucleus into the cytoplasm leading to perturb 
the function of some proteins involved in the activation DNA 
damage response (DDR). Our results suggest that 
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delocalisation of NPM1 into the cytoplasm in NPMc+AML cells 
does not impair the function of DDR in response to DNA 
damage drugs. In addition, the NPM1 protein level in NPMc+ 
cells increased in the nucleus upon the DNA damage inducers 
which is suggested that it may contributes in the regulation of 
the proteins involved in the DDR pathways. However, 
providing confirmation of these finding are required to be 
investigated particularly at the protein and mRNA levels of 
NPM1 during the DNA repair mechanisms and the importance 
of NPM1 in the DNA repair process in NPMc+AML cells. 
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4. The Effect of 
NPMc+AML on 
APE1 Subcellular 
Localisation 
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4.1 Introduction: 
APE1 (Apurinic/apyrimidinic endonuclease-1) is a multi-
functional protein that plays a vital role in the repair of 
damaged and mismatched bases and therefore is integral to 
the cellular response to oxidative and alkylation responses. It 
is involved in the base excision repair (BER) pathway and also 
in the transcriptional regulation of gene expression by acting 
as a redox co-activator of transcription factors such as NF-ǉ%
and P53 (Fishel and Kelley 2007). 
APE1 consist of two distinct functional domains, which are the 
N-terminal and C-terminal regions (Xanthoudakis, et al 1994). 
The N-terminal domain, which contains a nuclear localisation 
signal sequence, is responsible for redox activity and interacts 
with other proteins such as NPM1, whereas the C-terminal is 
employed to release its enzymatic activity on the abasic sites 
of DNA in the BER pathway (Fantini, et al 2010, Xanthoudakis, 
et al 1994). The subcellular localization of APE1 distribution is 
variable and depends on the cell type. In most cell types, APE1 
is predominantly found within the nucleus, the location where 
it performs its DNA repair and co-transcriptional functions 
(Tell, et al 2005). However, in some cells, for example 
fibroblasts, lymphocytes and hepatocytes, APE1 is 
predominantly found in the cytoplasm (Tell, et al 2009).  
With respect to the focus of this thesis, a paper was published 
showing that APE1 interacts with NPM1 in the nucleus with a 
subsequent translocation into the nucleolus (Vascotto, et al 
2009). We therefore hypothesised that in NPMc+AML the 
delocalisation of NPM1 to the cytoplasm may also affect the 
subcellular localisation of APE1, this in turn might inhibit the 
APE1 DNA repair activity leading to increased sensitivity of 
Qutob, H  Chapter 4 
93 
 
NPMc+ cells to chemotherapy agents which produce DNA 
adducts that rely on BER for repair. Thus, the aim of the work 
in this chapter was to examine the effect of cytoplasmic NPM1 
on APE1 subcellular distribution and DNA repair following 
alkylating damage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Qutob, H  Chapter 4 
94 
 
4.2 Results: 
4.2.1 NPM1 and APE1 subcellular localization by 
immunofluorescence: 
In order to perform the immunofluorescence staining, the cells 
were adhered on to slides by different methods. The LiquiPrep 
cytology and coverslip techniques (described in section 2.7.1) 
did not effectively coat the cells on the slides, whereas the 
cytospin procedure caused damage to intracellular organelles 
resulting in an artifactual NPM1 staining pattern in the OCI-
AML3 cells ± specifically nucleolar staining appeared 
unaffected but cytoplasmic staining disappeared (Figure 4.1). 
However, the use of fibronectin-coated slides was successful in 
maintaining the cells on the slides without affecting the 
subcellular localisation of the proteins. 
 
Figure 4.1: NPM1 Subcellular localisation after cytospin centrifugation; 
the subcellular localisation of NPM1 was detected in (A) OCI-AML3, (B) HL-60, 
and (C) M07e cell lines. The cells were prepared by cytospin and the NPM1 was 
detected by indirect immunofluorescence using FITC. The nuclei are stained in red 
with propidium iodide. The arrows indicate the localisation of NPM1 in the cell 
lines. 
Anti-NPM1 antibodies were used to detect NPM1 for the 
purpose of investigating the subcellular localization of NPM1 
protein in OCI-AML3, HL-60 and M-07e cell lines. 
Immunostaining revealed the aberrant expression of NPM1 in 
the cytoplasm of the OCI-AML3 cell line, while the HL-60 and 
M-07e AML cell lines, bearing wild-type NPM1, demonstrated 
staining restricted to the nucleoli (Figure 4.2). Therefore, 
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these results confirmed the cytoplasmic delocalisation effect of 
the mutation in NPM1 in the OCI-AML3 cell line (the presence 
of mutation had previously been confirmed by PCR (see 
section 3). As can be seen in Figure 4.2a, in OCI-AML3 cells 
NPM1 staining is predominantly seen in the cytoplasm.  
 
Figure 4.2: Immunofluorescent subcellular detection of NPM1; Subcellular 
localization of NPM1 was detected in (A) OCI-AML3, (B) HL-60, and (C) M07e cell 
lines. The cells were fixed and stained with anti-NPM1 antibody. NPM1 was visualised 
by indirect immunofluorescence using FITC whilst the nucleus was stained with DAPI, 
images were captured using a confocal laser microscope. The green fluorescence, 
where the arrows are, indicates the localisation of NPM1 in the cells. 
When APE1 localisation was studied, immunofluorescence 
analysis showed a predominantly cytoplasmic localisation of 
the protein both in wild-type NPM1 and NPMc+ cell lines 
(Figure 4.3). Differences in APE1 subcellular localization were 
examined after induction of DNA damage by an alkylation 
agent to establish whether NPM1 affected the localisation of 
APE1 under these conditions. When the cells were treated with 
MMS, APE1 was found to accumulate in the nucleus in the 
wild-type and mutant NPM1 cell lines (Figure 4.3). In addition, 
OCI-AML3 showed a translocation of NPM1 from cytoplasm 
into the nucleus (Figure 4.3) and the results were confirmed 
by western blot as described in chapter 3 (section 3.2.4 ± 
Figure 3.10A). As a result, NPM1 and APE1 proteins are 
restricted in the cytoplasm of the NPMc+ cell line, but in 
response to DNA damage they are re-localised in the 
nucleolus. 
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Figure 4.3: Immunofluorescent subcellular detection of APE1, 
Subcellular localization of APE1 was detected in (A) OCI-AML3, (B) HL-60 and 
(C) M-07e cell lines. The APE1 protein was examined under two different 
conditions: untreated or treated with MMS at 2µM for 4 hours. The cells were 
fixed and stained with anti-APE1 antibodies and visualized by indirect 
immunofluorescence using CY-3 with a confocal laser microscope. The red 
colour indicates the APE1 localization, while the blue is the DAPI nucleus stain. 
A 
B 
C 
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Figure 4.4: Immunofluorescent subcellular detection of NPM1 after MMS 
treatment; Subcellular localization of NPM1 was detected in MMS-treated OCI-
AML3, HL-60, and M07e cell lines. The antigen-antibody interactions were 
observed by a confocal laser microscope using secondary FITC-antibodies. 
 
4.2.2 NPM1 and APE1 subcellular localization by 
western blot: 
The subcellular localization of both proteins was also analysed 
using western blotting. The cytoplasmic and nuclear extracts 
for OCI-AML3, HL-60 and M-07e cell lines were subjected to 
SDS-PAGE. As shown in Chapter 3, in OCI-AML3 cell line, 
larger amounts of NPM1 protein were present in the 
cytoplasmic fraction than in nuclei, but after cell treatment 
with MMS, the protein was visualised equally in both fractions 
with more in the nuclei extract following MMS treatment 
compared to the nuclear fraction from untreated OCI-AML3s 
(Figure 4.5A). In contrast and also as shown in Chapter 3, the 
NPM1 protein was mainly present in the nuclei fraction of M-
07e cell line in both conditions (Figure 4.5B). In the HL-60 cell 
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line, it was present in the cytoplasmic fraction and in the 
nuclei of untreated and MMS-treated HL-60 cells (Figure 4.5C). 
The OCI-AML3 and Mo7e NPM1 protein expression results are 
shown here, in addition to Chapter 3, for easy comparisons to 
be made with the APE1 results.   
Following western blotting of the APE1 protein, the OCI-AML3 
cell line showed a band at 37KDa, which is the expected size 
of APE1, was present in the cytoplasmic and nuclear fractions 
of both untreated and treated cells, whilst in the cytoplasmic 
fraction a lower band was also present in both the untreated 
and treated cells (Figure 4.5A). However, in the HL-60 and M-
07e cell lines, APE1 was observed as a single band at 37KDa in 
both the nuclear and cytoplasmic fractions of untreated and 
treated cells (Figure 4.5B,C).  
A detailed literature search was undertaken to try and find out 
what the lower band may be. The APE1 antibody (NB100-101) 
recognises the C-terminus domain of APE1 and two proteins 
may be detected with 37-KDa and 34-KDa molecular masses. 
Later, the 34-KDa band was identified as a truncated form of 
APE1 lacking the N-terminal 33 amino acids (Yoshida, et al 
2003). As a consequence, in an attempt to identify the lower 
band present only in the OCI-AML3 cells, the blot was 
incubated with an APE1 antibody which only binds to the N-
terminal domain of APE1, which should therefore not detect an 
N-terminally truncated protein. In OCI-AML3, the lower band 
remained when the N-terminal APE1 antibody was used 
(Figure 4.5A). In the other cell lines, the N-terminal APE1 
antibody detected the band at the same molecular weight as 
seen previously with APE1 antibody (Figure 4.5B,C). The 
lysates were checked for purity by using specific antibodies for 
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detectiQJ ǃ-actin that can only be found in cytoplasm and 
Lamin A/C which is only found in the nucleus (Figure 4.5). 
4.2.3 Detection of potential NPM1 and APE1 interaction 
by co-immunoprecipitation: 
The possible interaction between NPM1 and APE1 proteins was 
investigated by immunoprecipitation assays. Cytoplasmic 
extracts were isolated from OCI-AML3 and HL-60 cell lines, 
and then the cellular lysates were incubated with anti-NPM1 or 
anti-APE1, and immunoprecipitated with protein A/G-agarose 
beads. As shown in Figure 4.6, in OCI-AML3 and HL-60 cell 
lines, the NPM1 protein was present in the immunocomplexes 
precipitated by the anti-NPM1 and blotted by anti-NPM1, while 
it was absent in the immunocomplexes precipitated by anti-
APE1 (Figure 4.6A). The results were confirmed when the 
immunocomplexes were immunoprecipitated and blotted by 
APE1 antibodies (Figure 4.6B). Whilst, in the HL-60 cell lines, 
there was a band in the complex precipitated by anti-NPM1 
and detected by APE1 antibody, this is most likely non-specific 
since it was not observed when the complexes were 
precipitated by anti-APE1 and detected by anti-NPM1 (Figure 
4.6B). 
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Figure 4.5: NPM1 and APE1 subcellular localization by Western Blot; Western blotting 
was used to investigate the subcellular localization of NPM1 and APE1 in (A) OCI-AML3, (B) 
HL-60, and (C) M-07e cell lines. The cytoplasmic and nuclear extracts of cell lines, untreated 
and treated with MMS, were extracted as described in the materials and method section (see 
section 2.7.3). 10µg was added to SDS-PAGE gel for the detection of NPM1 (37 KDa), APE1 
(34kDa/37KDa). Anti-ǃ-actin (40 KDa), and anti-lamin A/C (70KDa) were used as loading 
controls for cytoplasmic and nuclear extraction. The bands were quantified by densitometry 
using Image J analysis software (NIH). The ratio was calculated by dividing density of the test 
band by the density of the loading control. The experiment was performed three times 
independently, and the error bars represent the SD.  
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Figure 4.6: Detection of NPM1 and APE1 interaction by co-
immunoprecipitation; The cytoplasmic protein was prepared from OCI-
AML3 and HL-60 cell lines and immunoprecipitated with anti-NPM1 or anti-
APE1 (section 2.7.5). The immunocomplexes were analysed using the 
Western Blot technique  (section 2.7.4). (A) The immunocomplexes were 
detected by anti-NPM1, while (B) used anti-APE1. 
 
4.2.4 Detection of possible APE1 alternative splicing 
variants: 
In an attempt to identify the lower molecular weight product 
detected with the anti-APE1 antibodies we looked to see if we 
could detect alternatively spliced variants of APE1. Forward 
and reverse PCR primers were designed using Primer3 
programme against APE1 mRNA to detect aberrantly sized 
transcription products. The PCR was optimized using different 
annealing temperatures and four different MgCl2 
concentrations. As shown in Figure 4.7A, the best PCR 
reaction, as determined by a single bright band, was in 
condition B, where the concentration of MgCl2 was 1.5mM, and 
the annealing temperature was at 62.90C. Using these 
conditions, cDNA from OCI-AML3, M-07e and HL-60 cell lines 
were amplified and loaded to 1.7% agarose gel. The results 
showed that all the cell lines have one product at 963bp 
(Figure 4.7B), this was confirmed by sequencing the PCR 
products (Appendix 3.1) which demonstrated full length APE1 
and suggests that the lower band is not likely to be a result of 
splicing variant of APE1. 
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Figure 4.7: Detection of APE1 spliced variant in AML cell lines; APE1 mRNA 
was converted into cDNA and then amplified by PCR. (A) The APE1 primers were 
optimized at different annealing temperatures: 54.90C, 55.20C, 55.90C, 57.00C, 
58.20C, 59.40C, 60.50C, 61.70C, 62.90C, 64.00C, 64.70C, and 65.00C and four 
different concentration of MgCl2 were used. The Gene-Ruler 100bp DNA ladder 
which range between 100bp-1000bp, was used in the 1.7% agarose gel. (B) The 
PCR products from OCI-AML3, M-07e and HL-60 cell lines and the Gene-Ruler 
100bp plus DNA ladder which range between 100bp to 3000bp, were loaded onto 
the 1.7% agarose gel.  A negative no template control was included in the 
experiments. 
4.2.5 MMS cytotoxicity assay in wild-type and mutant 
NPM1 AML cell lines: 
It has been demonstrated that knocking-down APE1 or 
inhibiting APE1 DNA repair activity causes an increase in 
sensitivity of tumour cells to chemotherapy (McNeill and 
Wilson 2007, Wang, et al 2004). Thus, we investigated the 
sensitivity of NPMc+ and wild-type NPM1 cell lines to MMS and 
looked for possible differences in the sensitivity of the cells 
harbouring the NPM1 mutation by comparing the OCI-AML3 
cell line to two different wild-type NPM1 cell lines (both with 
wild type P53). MMS cytotoxicity was determined after the 
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cells treated with MMS at different concentrations for 1 hour 
and then the cells were incubated for 72 hours in drug-free 
medium. In figure 4.8, the MMS sensitivity test showed that 
survival of the OCI-AML3 cell line at 4µM was around 7% 
compared to untreated cells. It then decreased further at 
10µM and there were no viable cells at higher concentrations. 
In the same way, the M-07e cell line showed a similar pattern 
to the OCI-AML3 cells, whereas MV4-11 cell line showed that 
the cells did not survive at a concentration higher than 4µM. 
At the statistical level, there was no significant difference 
between OCI-AML3 and wild-type NPM1 cell lines (MV4-11, 
and M-07e) at 4µM (p-value: 0.295, and 0.114, respectively) 
and at 2µM (p-value: 0.333, and 0.230, respectively). In 
conclusion, the differences in the sensitivity to MMS among 
these cell lines indicates that the NPM1 mutated cell line does 
not have a different sensitivity to MMS compared to cell lines 
containing wild-type NPM1. 
 
Figure 4.8: The cytotoxic sensitivity assay on wild-type and mutated NPM1 cells in 
response to MMS; The cells were treated with MMS at different concentrations for an hour, 
then washed and incubated for 72 hours in a drug-free medium. The cell viability was 
assessed by flow cytometry as described in section 2.5.3. The percentage of cell survival was 
calculated by dividing the number of cells in the treated condition by those counted in the 
untreated control. The mean and standard deviation of three independent expriments are 
shown. 
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4.3 Discussion: 
APE1, which is a critical protein in the BER pathway, has been 
shown to associate with NPM1 in the nucleus which modulates 
its activity and function (Vascotto, et al 2009). A physical 
interaction between APE1 and NPM1 through the N-terminal 
was observed leading to a translocation of APE1 into the 
nucleolus in order to contribute in the rRNA processes 
(Vascotto, et al 2009). To date, any effect that the NPMc+ 
mutation may have upon the NPM1-APE1 interaction has not 
been studied and so this was the aim of the work in this 
chapter. 
Firstly, we determined the subcellular localisation of NPM1 in 
OCI-AML3, M-07e and HL-60. As expected, the NPM1 
subcellular localisation in NPMc+ cells was delocated in the 
cytoplasm, whilst in the wild-type NPM1 cell lines NPM1 was 
localised in nucleoli. Confirmatory experiments using the 
western blotting technique demonstrated the same findings 
which are consistent with previous findings (Falini, et al 2005). 
The APE1 subcellular localisation in haematological cell lines is 
predominantly located in the cytoplasm as identified in our 
results and as has been previously shown in HL-60 and U937 
cell lines (Yoshida and Ueda 2003, Yoshida, et al 2003). It has 
been suggested that APE1 cytoplasmic localisation is 
associated with high proliferative rates and the function of 
APE1 as a redox may be required to keep newly synthesised 
transcription factors in a reduced state during their 
translocation to the nucleus (Duguid, et al 1995, Fung, et al 
2001, Tell, et al 2009). 
Previous work has demonstrated that APE1 is relocated in the 
nucleus after wild-type NPM1 haematological cell lines, HL-60 
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and U937, were exposed to an oxidative agent (Yoshida and 
Ueda 2003, Yoshida, et al 2003). In NPMc+AML cells, the APE1 
translocation into the nucleus was not perturbed by the 
presence of mutant and wild-type NPM1 in the cytoplasm and 
we were unable to show an interaction between APE1 and 
NPM1 in the cytoplasmic fractions. In addition, the sensitivity 
of the mutated NPM1 cell line to MMS, an alkylating agent 
which causes the production of AP sites, was not perturbed by 
the delocalisation of NPM1 into the cytoplasm. These results 
suggest that APE1 subcellular localisation has not been 
affected by the mutant NPM1 in NPMc+AML and it seems that 
APE1 is translocated into the nucleus, where it may participate 
in the DNA repair process, in response to the DNA damage 
inducer. 
The APE1 protein consists of two domains, which are the N-
terminal and C-terminal domains (Xanthoudakis, et al 1994). 
APE1 has its own nuclear localisation signal in the N-terminal 
of the protein (Fantini, et al 2010, Vascotto, et al 2009), which 
is responsible for localising the protein in the nucleus, which 
could be a suggested reason for APE1 not being affected by 
delocalisation of NPM1 to cytoplasm ± that is, its own nuclear 
localisation signal is stronger than any effects of an interaction 
with cytoplasmic NPM1.  
In our study, certain technical issues had to be considered 
during the preparation of the coated slides with cells. Four 
different techniques were used to coat the cells on the slides in 
order to preserve their morphology and subcellular 
components. In the literature some groups have used a 
coverslip technique to grow cell lines on overnight (Colombo, 
et al 2002), while researchers, who have studied NPM1 
subcellular localisation in the OCI-AML3 cell line, performed 
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the immunofluorescence on paraffin sections, which is the 
optimal method in the detection of NPMc+AML in patient 
samples (Falini, et al 2011, Falini, et al 2005). In addition, it 
has been demonstrated that blood smears, or air-drying 
methods, are not suitable for the detection of NPMc+AML by 
immunohistochemisty or immunofluorescence, due to artefact 
diffusion leading to false positive or negative results 
(Mattsson, et al 2010). Moreover, we showed that the 
cytocentrifugation preparation method causes a false negative 
of NPMc+AML detection due to the re-localisation of NPM1 into 
the nucleus in the OCI-AML3 cell line. Vascotto et al. found a 
physical interaction between NPM1 and APE1, while our results 
did not show any evidence of interaction. However, in their 
H[SHULPHQWV 9DVFRWWR¶V JURXS KDYH XVHG D +HOD FHOO OLQH
where APE1 is localised in the nucleus. Furthermore, the 
interaction between APE1 and NPM1 was detected by co-
localisation analysis using an immunofluorescence confocal 
microscope and confirmed by mapping the domain of NPM1, 
which is involved in the interaction with APE1 by using 
Glutathione-S-transferases (GST) pull-down method. On the 
other hand, our work was performed on haematological cell 
lines, where APE1 is predominantly found in the cytoplasm, 
and APE1 and NPM1 interaction was performed using co-
immunoprecipitation methods on the cytoplasmic lysates. 
In the western blot, we identified a lower band that ran 
beneath the 37KDa APE1 in the cytoplasmic fraction of the 
OCI-AML3 cell line, whereas in the wild-type NPM1 cell lines 
this was not observed. Subcellular localisation of an N-terminal 
WUXQFDWHG IRUP RI $3( 1Ʃ$3( KDV SUHYLRXVO\ EHHQ
detected in the cytoplasm and in mitochondaria 
(Chattopadhyay, et al 2006, Fantini, et al 2010). In 
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heamatological cell lines, this truncated form of APE1 was 
detected in HL-60 after being exposed to 50µM etoposide 
(Yoshida, et al 2003). Therefore, we blotted the membrane 
with an APE1 antibody that binds to the APE1 protein at the N-
terminal region, to elucidate whether the lower band is a 
1Ʃ$3( LI WKH 1-terminal is missing then we would not 
expect a band with this antibody). However, the lower band 
was also detected with the N-terminal APE1 antibody 
VXJJHVWLQJ WKDW WKDW WKH VPDOOHU SURGXFW LV QRW 1Ʃ$3(
Thereafter, reverse-transcription PCR was used to examine 
whether the lower band protein resulted from alternative 
splicing of APE1 mRNA. However, we did not detect any 
splicing variants in the OCI-AML3 cell line and the sequence of 
the cDNA was the same as in the wild-type NPM1 cell lines. 
The next step would be to purify the lower band and subject it 
to peptide sequence analysis and compare this to the full APE1 
amino acid sequnce. 
In summary, we confirmed the cytoplasmic localisation of 
NPM1 in OCI-AML3, whereas in the wild-type cell lines this was 
found in the nucleus, specifically in the nucleoli. Thereafter, we 
reported the subcellular localisation of APE1 in the cytoplasm 
in the heamatological cell lines tested. In response to an 
alkylating agent, the sensitivity of mutant NPM1 cell line to 
MMS was similar to the wild-type NPM1 cell lines indicating 
that APE1 is likely not interpreted by the cytoplasmic NPM1 by 
its translocation into the nucleus in order to participate in DNA 
repair. However, a lower band which was detected by APE1 
antibody still needs to be identified. 
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5. The Effect of 
Down-regulation 
of NPM1 on BCL-2 
and MCL-1 Anti-
apoptotic Levels 
in NPMc+AML 
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5.1 Introduction: 
Programmed cell death (apoptosis) is an essential process for 
removal of unwanted or damaged cells and it is regulated by 
several genes including the BCL-2 family of genes. The 
members of BCL-2 are considered to be vital in the cell 
survival pathway of normal and tumour cells. They have been 
classified into two groups according to their function: pro-
apoptotic (such as BAX, and BAK) and anti-apoptotic proteins 
(such as BCL-2, BCL-xL, MCL-1) (reviewed in (Tzifi, et al 
2012)). The anti-apoptotic BCL-2 is expressed in normal and 
malignant cells (Andreeff, et al 1999), whereas MCL-1 is 
expressed in haematopoietic stem cells (HSCs) and is 
necessary for maintenance of cell survival (Glaser, et al 2012). 
In AML, expression of both MCL-1 and BCL-2 is extremely 
variable but 90% of AML samples taken at diagnosis have a 
high expression of BCL-2, whereas high levels of MCL-1 have 
been reported in human lymphoid leukaemia and FLT3-ITD cell 
lines (Kaufmann, et al 1998, Tothova, et al 2002, Yoshimoto, 
et al 2009). Moreover, MCL-1 expression correlates with 
mutant NPM1 in primary AML samples (unpublished results 
IURP$PLQD¶VZRUN - MSc student in University of Nottingham 
2011). 
In NPMc+AML, activation of RNA polymerase II transcription 
by delocalisation of HEXIM1 into the cytoplasm by the mutant 
NPM1, leads to an enhancement of gene expression, which 
may be associated with an increase in cell growth and 
proliferation (Gurumurthy, et al 2008). Therefore, The aim of 
this study was to examine the level of BCL-2 and MCL-1 in 
wild-type NPM1 and NPMc+ cell lines and examine the 
consequences of NPM1 down-regulation by siRNA, targeting 
either total or just mutant NPM1, on BCL-2 and MCL-1 levels in 
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these cell lines. Parts of this work were performed by an MSc 
student who I co-supervised both at the bench level and with 
respect to the directions the research project took; these parts 
are acknowledged in the text.   
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5.2 Results: 
5.2.1 Knock-down of total NPM1 or mutant NPM1 by 
siRNA in OCI-AML3 and M-07e: 
We aimed to knock-down total NPM1 in both OCI-AML3, which 
harbour a type A mutation in NPM1, and M-07e, which is a 
wild-type NPM1, cell lines and to knock-down just the mutated 
NPM1 allele in OCI-AML3. Cells were nucleofected with siRNAs 
designed to either total NPM1 or mutant NPM1 state and 
compared to cells transfected with the AllStars negative 
control, which detects potential non-specific effects of siRNA 
transfection. The antisense strand of NPM1-A siRNA was 
complimentary with NPM1-A allele, whilst with NPM1 wild-type 
allele there were five mismatches found (Figure 5.1). 
Figure 5.1: Custom designed NPM1-A siRNA; NPM1-A has identical sequence matches 
with NPM1-A allele (AY740634) but not with NPM1 wild-type allele (NM_002520). * denotes a 
sequence match. (K Liang, MSc dissertation, University of Nottingham 2011) 
 
Transfection efficiency, cell viability, and NPM1 expression 
were measured to confirm the success of the nucleofection 
technique and the effect of the siRNAs. Several different total 
NPM1 siRNAs were tested and the one which consistently gave 
the most knock-down, NPM1_7, was taken on to further 
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experiments. In OCI-AML3, the transfection efficiency and the 
cell viability were achieved 50% and 75%, respectively at 48 
hours post-transfection. Moreover, in M-07e, the transfection 
efficiency was approximately 95% and the cell viability 
reached to 70% after 48 hours post-transfection. The NPM1 
expression in OCI-AML3 and M-07e cell lines after 48 hours of 
knocking-down NPM1 reached a level of approximately 15% of 
the control level (OCI-AML3 p-value: <0.05, M-07e p-value: 
<0.05), whereas after knocking-down the mutant NPM1 in the 
OCI-AML3 cell line the level of total NPM1 was 60% of the 
control (p-value: 0.015) (Figure 5.2A). Furthermore, the 
western blot, which was performed during an MSc project (K 
Liang, MSc dissertation, University of Nottingham 2011), 
showed that NPM1 protein was also knocked-down after siRNA 
NPM1 (Figure 5.2B). 
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Figure 5.2: NPM1 expression following siRNA designed to either total NPM1 or the 
mutant NPM1 only; Total NPM1 in OCI-AML3 and M-07e were knocked-down by siRNA 
NPM1_7, whereas the mutant NPM1 was down-regulated in OCI-AML3 by siRNA NPM1-A. After 
48 hours, (A) the NPM1 mRNA was studied by real-time PCR. The gene expression was 
QRUPDOL]HG E\ WKH ǃ0 KRXVH NHHSLQJ JHQH DQG WKHQ WKH SHUFHQWDJH RI WKH 1301 siRNA 
expression compared to AllStars negative control cells was calculated. (B) The protein was 
extracted from OCI-AML3 cell line and then western blot was used to confirm the protein 
reduction after siRNA (the picture was taken from Liang, K. dissertation, 2011). The 
experiment was performed 3 times for the NPM1 expression by real-time PCR, while the 
western blot was done 2 times, and the bars represent the SD. (* indicates p-value <0.05 
when compared with AllStars negative control) 
0 
20 
40 
60 
80 
100 
120 
AllStars Negative 
Control 
NPM1_7 Total NPM1-A mutant 
N
PM
1 
re
la
tiv
e 
ex
pr
es
si
on
 
(%
) 
M-07e 
OCI-AML3 
A 
B 
* 
* * 
Qutob, H  Chapter 5 
114 
 
In the previous work, measurements of NPM1 transcripts had 
been determined using primers designed to exons 9, 10, and 
11 which amplified both wild-type and mutant transcripts. We 
wanted to quantify the mutant allele alone and therefore 
primers were purchased, one of which binds to the NPM1-A 
mutation site resulting in specific amplification of mutant 
WUDQVFULSWV 7KHVH SULPHUV KDG EHHQ GHVLJQHG E\ *RUHOOR¶V
group (Gorello, et al 2006). Total and mutant levels were 
consequently measured in the OCI-AML3 cell line.  
Figure 5.3 shows the expression of total NPM1 was 
approximately 15% after 48 hours exposed to NPM1_7 siRNA 
in OCI-AML3. In contrast, the expression of NPM1 in OCI-AML3 
cell line nucleofected with the mutant NPM1 siRNA was around 
60%, while the expression of mutant NPM1 declined to 40% 
indicating that NPM1-A siRNA induced silencing of the mutant 
NPM1 allele. We also looked at the distribution of the wild-type 
and mutated NPM1 alleles in OCI-AML3 cells by relative 
fluorescent quantitation on capillary electrophoresis system 
(Figure 5.4). As shown in table 5.1, the ratio of NPM1-A/wild-
type NPM1 in cells transfected with either AllStars negative 
control or NPM1_7, which down-regulates total NPM1, was 
close to one indicating that both wild-type and mutant 
transcripts had been similarly decreased, while the mutant 
specific siRNA reduced the mutant transcripts. 
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Figure 5.3: Total NPM1 and mutant NPM1 expressions after siRNA; Total NPM1 
expression or mutant NPM1 expression only was measured in OCI-AML3 cell line. The cells 
were nucleofected with NPM1_7 or NPM1-A siRNA to knock-down total NPM1 or mutant NPM1, 
respectively. After 48hrs, the RNA was extracted and converted into cDNA. The total NPM1 or 
mutant NPM1 only levels were measured by real-time PCR. The gene expression was 
normalized by the house keeping gene and then the percentage of the expression to control 
siRNA treated cells was calculated. The Columns represent the mean of 3 independent 
experiments and the bars are the SD. 
 
 
Figure 5.4: Relative fluorescent quantification of NPM1-A and NPM1-wt alleles; It 
was performed by capillary electrophoresis-based analysis of an NPM1 fluorescently labelled 
RT-PCR product. The experiment was done once (K. Liang, MSc dissertation). (A) The RNA 
was extracted from non-nucleofected OCI-AML3 cell lines. (B) The OCI-AML3 was 
nucleofected with siRNA targeting total NPM1, whereas (C) nucleofected with NPM1-A which 
down-regulates mutant NPM1 only. 
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Table 5.1: The ratio of NPM1-A/ wild-type NPM1; The peak height, which was detected 
by GeneMapper ID software v3.2, was calculated to compare the reduction in wild type and 
mutant NPM allele expression in the OCI-AML3 cell line after siRNA nucleofection. 
 
 
5.2.2 Basal anti-apoptotic levels in wild-type and 
mutant NPM1 cell lines: 
Members of the anti-apoptotic BCL-2 family are over-
expressed in AML and appear to play an essential role in 
leukaemogenesis (reviewed in (Tzifi, et al 2012)). The basal 
levels of BCL-2 and MCL-1 mRNA in the leukaemic cell lines 
were analyzed by real-time PCR. The level of BCL-2 and MCL-1 
mRNA were significantly higher in OCI-AML3, which harbour 
mutant NPM1, specifically when compared to M-07e levels 
both MCL-1 and BCL-2 were increased approximately 3 fold in 
the OCI-AML3 cell line (p-value: <0.005). When comparing 
the OCI-AML3 cell line to the other wild-type NPM1 cell lines 
that co-express FLT3-ITD (MV4-11, and MOLM-13), BCL-2 
mRNA was increased by 1.5 fold which is also statistically 
significant (p-value: 0.014 and 0.003, respectively) and MCL-1 
mRNA in OCI-AML3 cells was 1.5 fold higher than in MV4-11 
and MOLM-13 cells (p-value: 0.003 and <0.005, respectively) 
(Figure 5.5A). However, there was no significant difference in 
the BCL-2 protein at the basal level between the four different 
cell lines (p-value: >0.05). Similar to the mRNA results, MCL-1 
protein level was highest in OCI-AML3, however this was only 
significant when compared to M-07e and MOLM-13 cell lines 
(p-vale: 0.001 and 0.013, respectively) (Figure 5.5B). These 
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results indicate that the expressions of BCL-2 and MCL-1 
transcripts in OCI-AML3 are significantly higher than in the 
other selected haematological cell lines. 
 
 
Figure 5.5: Detection of BCL-2 and MCL-1 mRNA expression and protein levels in the 
different leukaemic cell lines. (A) RNA was extracted from M-07e, OCI-AML3, MV4-11 and 
MOLM-13 and cDNA was prepared. Quantitative real-time PCR was performed with primer sets 
specific to BCL-2 or MCL-1. (B) The cells were fixed and incubated with the respective 
antibodies, and were analysed by flow cytometry for BCL-2 and MCL-1 protein levels. The 
mean fluorescence index (MFI) was calculated by dividing the mean of positive fluorescence to 
the negative control. Columns represent the mean of 3 independent experiments and the bars 
are the SD. (* indicates p-value <0.05, while ** represent p-value <0.005) 
0 
1 
2 
3 
4 
5 
6 
7 
BCL-2 MCL-1 
R
el
at
iv
e 
ge
ne
 e
xp
re
ss
io
n 
M-07e 
OCI-AML3 
MV4-11 
MOLM-13 
0 
5 
10 
15 
20 
25 
30 
BCL-2 MCL-1 
M
FI
 
M-o7e 
OCI-AML3 
MV4-14 
MOLM-13 
A 
B 
** 
** 
  * 
** 
  ** 
* 
  ** 
** 
Qutob, H  Chapter 5 
118 
 
5.2.3 BCL-2 and MCL-1 mRNA levels in wild-type and 
mutant NPM1 cell lines following down-regulation of 
NPM1 with siRNA: 
The transcript expression levels of BCL-2 and MCL-1 were 
evaluated in OCI-AML3 and M-07e after down-regulation of 
NPM1 with siRNA. Figure 5.6 shows that following transfection 
of OCI-AML3 with total NPM1 siRNA a down-regulation of BCL-
2 and MCL-1 levels of around 60% and 40%, respectively, 
occurs (p-value: 0.025 and 0.034). However, after the mutant 
NPM1 was knocked-down, the level of BCL-2 and MCL-1 was 
75% and 90%, respectively, when compared to the control 
cells (p-value: 0.049 and 0.096). The reduction of BCL-2 and 
MCL-1 upon NPM1 mutant siRNA was less than seen in cells 
nucleofected with NPM1 total siRNA. Interestingly, knockdown 
of NPM1 in the wild-type cell line (M-07e) showed no 
difference in the level of BCL-2 (p-value: 0.901) or MCL-1 
expressions (p-value: 0.113) after NPM1 siRNA transfection. 
These results suggest that NPM1 may play a role in the 
regulation of BCL-2 and MCL-1 levels in OCI-AML3 cells.  
However, knocking-down the mutant NPM1 was not used in 
detecting the level of BCL-2 and MCL-1 because after a while 
the mutant NPM1 allele was not targeted and it seems that the 
NPM1-A siRNA had degraded. Furthermore, the detection of 
P53 and CD11b levels in OCI-AML3 and M-07e cell lines after 
silencing the mutant NPM1 allele was not performed for the 
same reason.  
 
 
Qutob, H  Chapter 5 
119 
 
 
 
Figure 5.6: BCL-2 and MCL-1 mRNA level after siRNA total NPM1 or the mutant NPM1 
only. (A) The BCL-2 and (B) MCL-1 mRNA level in OCI-AML3 and M-07e were measured by 
real-time PCR after total NPM1 knocked-down. The relative transcript level was determined by 
dividing the gene level to the house keeping gene, then the percentage to control cells was 
calculated. The experiment was performed 3 times and the bars represent the SD. (* 
indicates p-value <0.05 when compared with AllStars Negative Control) 
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5.2.4 P53 levels in M-07e and OCI-AML3 after total 
NPM1 knock down:  
It is known that NPM1 is involved in the stabilization and 
activation of P53 (Wu, et al 2001). Therefore, P53 protein 
levels were measured in the cell lines after NPM1_7 siRNA 
transfection. Interestingly, a decrease in levels of total NPM1 
was associated with an increase in total P53 in OCI-AML3 of 
approximately 50% (p-value: 0.035) (Figure 5.7), whereas in 
M-07e the level of P53 showed no evidence of change (p-
value: 0.651). 
 
Figure 5.7: The protein level of P53 in the leukaemic cell lines upon NPM1_7 siRNA; 
Flow cytometry were used to detect the total level of P53 in OCI-AML3 and M-07e following 
treatment with siRNA to total NPM1. After 48 hours of nucleofection with NPM1 siRNA, the 
total P53 was analysed using flow cytometry. The MFI was used to calculate the level of 
protein and then the percentage of P53 was calculated by comparing to the AllStars negative 
control. The experiment was performed 3 times and the bars represent the SD. (* indicates p-
value <0.05 when compared with AllStars Negative Control) 
 
 
0 
20 
40 
60 
80 
100 
120 
140 
160 
180 
M-07e OCI-AML3 
 
M
FI
 (%
) AllStars Negative 
Control  
NPM1_7 Total 
* 
Qutob, H  Chapter 5 
121 
 
5.2.5 Measurement of the differentiation marker 
(CD11b) in M-07e and OCI-AML3 after total NPM1 knock 
down: 
We next determined the effects of NPM1 down-regulation on a 
differentiation marker of AML cells. As shown in figure 5.8, 
CD11b was slightly elevated in OCI-AML3 but it is not 
statistically significant (p-value: 0.19). In contrast, the level of 
CD11b in M-07e nucleofected with total NPM1_7 siRNA was 
the same level as measured in cells transfected with AllStars 
negative control (p-value: 0.491) (Figure 5.8). 
 
Figure 5.8: Expression of the differentiation marker CD11b after leukaemic cell lines 
were nucleofected with siRNA NPM1_7; Flow cytometry was used to detect CD11b in 
OCI-AML3 and M-07e following treatment with siRNA to total NPM1. After 48 hours of 
nucleofection with NPM1 siRNA, The CD11b differentiation marker was detected using an anti-
CD11b PE-labelled antibody. The percentage of expression was calculated by comparing to the 
AllStars negative control. The experiment was performed 3 times and the bars represent the 
SD.  
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5.3 Discussion: 
Impairment in regulation of the cell death process is 
associated with cancer development and resistance to 
chemotherapy. In this chapter we have analysed and 
described the expression of BCL-2 and MCL-1 in different 
human leukaemic cell lines and have then investigated the 
effect of the down-regulation of NPM1 on the levels of BCL-2 
and MCL-1 in wild-type and mutant NPM1 cell lines. The OCI-
AML3 cell line is the only one to represent a model of 
NPMc+AML among the haematological cell lines, however it is 
important to note that whilst it differs in NPM1 mutation status 
it will also differ with respect to many other genetic and 
phenotypic abnormalities. However, as our interests were in 
DNA repair and apoptosis we did, at least, choose only those 
cell lines that are P53 wild-type. Ideally a series of isogenetic 
cells would be used in this work but were unfortunately not 
available. 
It has previously been reported that in AML cell lines, the BCL-
2 and MCL-1 anti-apoptotic proteins were found to be over-
expressed in HL-60, KG1a, and ML-1 cell lines (Kaufmann, et 
al 1998). In addition, MCL-1 was highly expressed in the MV4-
11 cell line, which harbours a homozygous FLT3-ITD mutation 
(Yoshimoto, et al 2009). However, in this study, we found that 
the BCL-2 and MCL-1 mRNA levels were highest in the NPMc+ 
cell line when compared to the other three cell lines studied.  
The protein level of MCL-1 was also higher in OCI-AML3 than 
in NPM wild-type cells, however, there were no significant 
differences in the levels of BCL-2 protein amongst the four cell 
lines, contradictory to the mRNA levels. This contradictory has 
been previously seen in lymphoid tissue and is suggested to 
be a result of suppression of the post-transcriptional process 
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of BCL-2 gene (Kondo, et al 1992). In addition, BCL-2 and 
MCL-1 protein levels were only measured by flow cytometry 
and it would be useful to measure levels by western blotting to 
check these results correlate. 
Delocalisation of NPM1 in the cytoplasm may participate in the 
up-regulation of anti-apoptotic gene expression. This 
observation was confirmed when the total NPM1, or the 
mutant NPM1, was knocked-down in OCI-AML3. The levels of 
BCL-2 and MCL-1 mRNA were reduced in OCI-AML3 upon the 
nucleofection, whereas in M-07e the levels of BCL-2 and MCL-
1 did not change. These findings suggests that mutant NPM1 
plays a role in NPMc+AML cells leading to an increase in the 
level of BCL-2 and MCL-1. 
Previously, Balusu et al. found that the P53 level increased in 
OCI-AML3, but not in HL-60 cell lines after down-regulation of 
total NPM1 (Balusu, et al 2011). Furthermore, the 
differentiation marker levels (CEBP-Į 3 3 DQG &'E
were also elevated in OCI-AML3 (Balusu, et al 2011). 
Consistent with this, the results presented here demonstrate 
that the level of P53 has increased in the NPMc+ cell line only 
following knockdown of total NPM1, but the differentiation 
marker (CD11b) illustrated a non-significant increase. 
However, the work in this chapter measured parameters 48 
hours after NPM1 knock-GRZQZKLOH%DOXVX¶VJURXSSHUIRUPHG
experiments after 96 hours of siRNA NPM1 introduction. 
During this work, we attempted to knock-down NPM1 for 72 
hours but levels of NPM1 started to increase and so this time 
point was not continued with.  
In NPMc+AML, the mutant NPM1 delocalises into the 
cytoplasm leading to a perturbance in other NPM1 protein 
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partners, such as ARF (Gjerset 2006, Lee, et al 2005).  ARF is 
a positive regulator of P53 through an interaction with HDM2 
allowing an increase in P53 stability and activity (Kurki, et al 
2004b). The activity of ARF is regulated by NPM1 through 
targeting the protein into the nucleoli in a dose-dependent 
manner. For instance, high expression of NPM1 leads to 
inactivation of ARF by translocation of the protein into the 
nucleolus and thereby blocking ARF-mediated P53 activity, 
while modest reductions in NPM1 levels would cause some ARF 
fraction to relocate in the nucleoplasm and bind to HDM2 with 
subsequent activation of the P53-dependent pathway 
(Korgaonkar, et al 2005). Furthermore, P53 is a negative 
regulator of BCL-2 and it has previously been observed that a 
lack of P53 function leads to an up-regulation of BCL-2 
(summarised in Figure5.9A) (Wu, et al 2001). The precise 
mechanism by which the BCL-2 is up-regulated in OCI-AML3 
was not elucidated, but it is possible that delocalisation of ARF 
by the mutant NPM1 in NPMc+ cells leads to a decrease in P53 
stability and prevents the P53-mediated suppression of BCL-2 
activity (Figure 5.9B). However, down-regulation of wild-type 
and mutant NPM1 in OCI-AML3 cells results in ARF being 
translocated into the nucleoplasm and enables its binding to 
HDM2. As a result, the stability and activity of P53 is increased 
which leads to inhibit BCL-2 activity (Figure 5.9C). In this 
respect, it has been shown that a slight reduction in NPM1 
expression causes a partial localisation of ARF into the 
nucleoplasm and binds to HDM2 which acts to stabilise P53 
(Korgaonkar, et al 2005). 
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Figure 5.9: Models of BCL-2 regulation in NPMc+AML cells; (A) ARF localises with NPM1 
in nucleolus, but in a stress response, it translocates into nucleoplasm where it binds to HDM2 
and which allows stabilisation of P53, whereas over-activation of P53 leads to activate the 
negative feedback loop by promoting NPM1 to relocate ARF in the nucleolus. (B) In NPMc+ 
cells, ARF is delocalised in the cytoplasm with NPM1 leading to inhibition of P53 and an 
increase in BCL-2 levels. (C) down-regulation of total NPM1 leads to translocation of ARF in 
the nucleoplasm and continuously activates P53 resulting in BCL-2 inhibition. 
 
Apoptosis is regulated by two different pathways, which are 
the intrinsic and extrinsic pathways. The intrinsic pathway is 
mediated by BCL-2 family proteins which are composed of pro- 
and anti-apoptotic proteins (Andreeff, et al 1998). The BCL-2 
anti-apoptotic proteins interact with the pro-apoptotic proteins 
(BAX, BAK) and inactivate their function. In response to death 
stimulation, BH3-only proteins bind to BCL-2, BCL-xL, and 
MCL-1 and activate BAX and BAK (Shore and Viallet 2005). In 
addition, it has been noted that the up-regulation of BCL-2 
and MCL-1 prevents translocation and activation of BAX and 
BAK, respectively (Letai 2008). This suggests that in NPMc+ 
cells delocalisation of NPM1 in the cytoplasm could lead to 
anti-apoptotic proteins binding to BH3-only domain pro-
apoptotic proteins and prevention of the activation of BAX and 
BAK. In contrast, the extrinsic pathway is initiated by 
recruitment of pro-caspase-8 and other specific adaptor 
proteins into a death-inducing signalling complex. It has been 
demonstrated that NPM1 acts as a caspase inhibitor through 
direct interaction with caspase-6 and caspase-8 (Leong, et al 
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2010). In OCI-AML3, the impairment of caspase-6 and -8 
signals would be by the aberrant localisation of NPM1 in the 
cytoplasm which further leads to suppression of cell death 
signalling (Leong, et al 2010). 
In summary, the expression of the anti-apoptotic proteins 
BCL-2 and MCL-1 were up-regulated in the OCI-AML3 cell line 
compared to M-07e cell line. It seems that NPMc+ plays a 
crucial role in the regulation of these proteins by modulating 
other proteins through their interactions. However, further 
studies are required to understand the function of cytoplasmic 
NPM which will be discussed later in chapter 7. 
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6. The Impact of 
ATRA on BCL-2 
and MCL-1 Levels 
in NPMc+AML 
Cells 
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6.1 Introduction: 
All-trans-retinoic acid (ATRA) is used in the treatment of acute 
promyelocytic leukaemia (APL) which is characterised by a 
chromosomal translocation resulting in rearrangement of 
retinoic acid (RA) receptor, most commonly with PML t(15;17) 
(Redner, et al 1996). As a result, the myeloid differentiation 
process is arrested at the promyelocytic stage due to 
disruption of the RA signalling pathway (Zhang, et al 2000). 
However, addition of ATRA to APL cells restores the wild-type 
RA receptor pathway and enhances the transcriptional 
expression of downstream genes (see section 1.5) (Zhang, et 
al 2000). 
Many clinical trials have studied the addition of ATRA in 
combination with chemotherapy in non-APL AML but the 
results were variable (Burnett, et al 2010, Schlenk, et al 2011, 
Schlenk, et al 2009). However, the OCI-AML3 cell line, which 
harbours the NPMc+ mutation, exerts growth inhibition upon 
ATRA treatment suggesting that mutant NPM1 may confer 
sensitivity to ATRA (Martelli, et al 2007). The response of the 
NPMc+ cell line to ATRA was more sensitive than the wild-type 
NPM1 cell lines (Kutny, et al 2010). At low doses of ATRA, the 
percentage of cell viability in OCI-AML3 cells was 
approximately 50% and there were signs of differentiation, in 
contrast, in the HL-60 cell line, which harbours wild-type NPM1 
(and also, conversely to OCI-AML3 bears a P53 mutation), 
approximately 90% of cells were viable following treatment 
with ATRA and there was no evidence of differentiation (Kutny, 
et al 2010). 
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FLT3-ITD mutations are one the most common genetic 
alterations in AML and are caused either by an internal tandem 
duplication in the juxtamembrane domain or, by a point 
mutation in the activation loop of the tyrosine kinase domain 
(Kusec, et al 2006, Ponziani, et al 2006, Reindl, et al 2006). It 
accounts for 25% of AML cases and patients with FLT3-ITD 
mutations have a significantly higher relapse rate and a poorer 
overall survival rate than AML patients lacking FLT3-ITD 
(Grimwade, et al 2010, Kottaridis, et al 2001). It has been 
demonstrated that FLT3-ITD express high levels of MCL-1, 
which is the most essential anti-apoptotic molecule for 
haematopoietic stem cell survival, and induces the survival of 
leukaemic cells (Glaser, et al 2012, Yoshimoto, et al 2009). 
FLT3 inhibitors have been introduced in preclinical studies 
through targeting the aberrant signal transduction that 
contributes to tumour cell development. AC220 is one of the 
FLT3 inhibitors for the treatment of FLT3-ITD AML. AC220 has 
shown to inhibit FLT3 activity and induce terminal 
differentiation of FLT3-ITD AML cells (Sexauer, et al 2012, 
Zarrinkar, et al 2009). 
The aim of this chapter was to examine the effect of ATRA on 
the OCI-AML3 cell line, which harbours mutant NPM1, and 
other cell lines which are wild-type for NPM1. Further studies 
focused on extending the work in Chapter 5 and studying the 
anti-apoptotic proteins following ATRA treatment. 
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6.2 Results: 
6.2.1 Response of NPMc+AML and wild-type NPM1 cell 
lines to ATRA: 
The down-regulation of BCL-2 expression by ATRA has 
previously been associated with CD34 negative cells 
(Bradbury, et al 1996). More recently, it has been revealed 
that NPMc+AML cells are characterised by low expression of 
CD34 (Falini, et al 2005), however there is no evidence linking 
these two studies ± that is ATRA down-regulates BCL-2 
preferentially in NPMc+ cells. Hence, the sensitivity of NPMc+ 
and wild-type NPM1 cell lines to ATRA were evaluated by 
treating cells to different concentrations of ATRA for 72 hours. 
Loss of 50% viable cells in the NPMc+ cell line was achieved at 
10nM of ATRA, while in the MV4-11 cell line, which harbours 
wild-type NPM1 and FLT3-ITD, the concentration required to 
achieve a 50% loss in viability was much higher at 500nM (see 
Figure 6.1). In the MOLM-13 and M-07e cell lines, which are 
wild-type NPM1, 50% loss of viability was not achieved with 
the percentage of viable cells at the highest concentration, 
1µM, being approximately 70%.  
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Figure 6.1: The growth inhibition of AML cell lines upon ATRA treatment; The different 
cell lines were treated with ATRA at different concentration. After 72 hours, the cell viability 
was assessed by using haemocytometer and the percentage of cell viable number was 
calculated from the untreated cells. The experiment was repeated 3 times and the error bars 
represent SD. 
 
6.2.2 ATRA induces differentiation and apoptosis in 
NPMc+AML cell line: 
A decrease in viable cell number could be due to growth 
inhibition, to apoptosis or to both. The effect of ATRA on the 
induction of differentiation and apoptosis in NPM1 mutant and 
wild-type NPM1 cells was examined by treating the cells with 
ATRA at 500nM and incubating for 72 hours. The cells were 
then stained with wright-giemsa and examined for signs of 
myeloid differentiation. Markers of differentiation included a 
decrease in nuclear/cytoplasmic ratio, nuclear segmentation, 
and cytoplasmic granules. As shown in figure 6.2A, the NPMc+ 
cells showed a more lobed nucleus and the ratio of 
nuclear/cytoplasmic ratio could be seen to have decreased 
after the addition of ATRA. In contrast, in M-07e cells, there 
were no signs of differention observed (Figure 6.2B). In order 
to confirm these reuslts CD11b, which is a marker of myeloid 
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cell differention, was evaluted by flow cytometery and the 
percentage of CD11b expression was reported compared to  
untreated cells. The percentage of CD11b-postive cells 
increased in OCI-AML3 to nearly 17% (p-value: 0.025) 
following ATRA compared to MOLM-13 which increased only to 
7% (p-value: 0.014) (Figure 6.2C). In contrast, the CD11b in 
M-07e did not change (p-value: 0.1), and a reduction in MV4-
11 in the CD11b-positive cells was measured following ATRA 
treatment (p-value: 0.026) (Figure 6.2C).  
 
 
Figure 6.2: The effect of ATRA on differentiation in AML cell lines; Cell morphology and 
the CD11b differentiation marker were examined in (A) OCI-AML3 and (B) M-07e. The cell 
lines were treated with 500nM ATRA and incubated for 72 hours. (A) Wright-Giemsa stain was 
used and observed by light microscope in OCI-AML3 and M-07e cell lines. (C) CD11b, a 
differentiation marker, was used to confirm the morphology finding in the OCI-AML3 and M-
07e cell lines. In addition, MV4-11 and MOLM-13 cell lines were also examined for CD11b 
expression. Analysis was by flow cytometry and the percentage of expression was calculated 
by comparing to the untreated cells. The experiments were performed 3 times and the bars 
represent the SD. (* represent p-value<0.05 when compared with the untreated conditions) 
 
0 
20 
40 
60 
80 
100 
120 
140 
M07e OCI-AML3 MV4-11 MOLM-13 
%
 
 
CD
11
b 
ex
pr
es
si
on
 
to
 
u
n
tr
ea
te
d 
ce
lls
 untreated 
500nM ATRA 
C 
* 
* 
* 
Qutob, H  Chapter 6 
133 
 
Apoptosis was also determined by annexin-V staining followed 
by flow cytometery. The annexin-V experiment is more 
sensitive than the cell counting protocol because the annexin-
V identifies changes in the cell membrane during the apoptosis 
process, whereas trypan blue can be excluded from cells in 
early apoptosis stages. Treatment with ATRA was shown to 
induce apoptosis to a significantly greater extent in the NPM1 
mutant cell line by around 5 fold verses the untreated cells (p-
value:0.004) (Figure 6.3B). In addition, the MV4-11 and 
MOLM-13 cell lines showed a 3 and 1.5 fold increase in the 
apoptotic cells, respectively (MV4-11 p-value:0.005, MOLM-13 
p-value: 0.036) (Figure 6.3B). However, the other NPM1 wild-
type cell lines showed a trend for significant increase in the 
apoptotic cells upon ATRA treatment (M-07e p-value: 0.063) 
(Figure 6.3B). The results suggest that following treatment of 
the NPMc+AML cell line with ATRA the cells are more likely to 
undergo differentiation and apoptosis than the other leukaemic 
wild-type NPM1 cell lines. 
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Figure 6.3: The effect of ATRA on apoptosis in AML cell lines; The apoptosis level was 
determined by staining M-07e, OCI-AML3, MV4-11 and MOLM-13 cell lines with annexin-V 
FITC with and without the cell lines had been treated with 500nM ATRA for 72 hours. (A) 
FACS plots showed the cell population in untreated cells is located in the lower left quadrant of 
dot plot (Q3) indicating that the cells are negative for the early or late apoptosis process; cells 
in the lower right quadrant (Q4) and upper right quadrant of dot plots (Q2) depict cells in 
early and late apoptosis stages, respectively. (B) The apoptosis level is shown as percentage 
of the treated cells to untreated. The experiments were performed 3 times and the error bars 
represent the SD. (* indicates p-value <0.05, while   represents p-value<0.005 when 
compared with the untreated conditions) 
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6.2.3 The effect of ATRA on BCL-2 mRNA and protein 
levels: 
According to these results, which showed a much greater 
induction of differentiation and apoptosis in the mutant NPM1 
cell line compared to the wild-type NPM1 cell lines, and also 
the work by Bradbury et al. which demonstrates the down-
regulation of BCL-2 protein levels in CD34 negative AML cells 
treated with ATRA (Bradbury, et al 1996), the transcript and 
protein levels of BCL-2 after the dose of ATRA were assessed. 
Interestingly, the BCL-2 mRNA expression was reduced to 1% 
of its basal level following ATRA treatment of OCI-AML3 cells 
(p-value: <0.00005). In addition, the MV4-11 and MOLM-13 
cell lines, which harbour homozygous or heterozygous FLT3-
ITD, respectively, showed an 80% reduction in BCL-2 
transcripts (p-value for MV4-11 and MOLM-13 cells: 0.001) 
(Figure 6.4A). However, M-07e showed a non-significant 
reduction in the level of BCL-2 mRNA (p-value: 0.114) (Figure 
6.4A). The protein level of BCL-2 in OCI-AML3, MV4-11 and 
MOLM-13 cell lines were also decreased to around 35% 
compared to the basal level (p-value: <0.005 in OCI-AML3, 
MV4-11, and MOLM-13 cell lines), while the M-07e cell line 
was not significantly altered (p-value: 0.151) (Figure 6.4B). 
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Figure 6.4: Anti-apoptotic BCL-2 levels upon ATRA treatment; (A) the BCL-2 mRNA 
levels were measured by real-time PCR after the cell lines were treated with 500nM ATRA for 
72 hours. BCL- WUDQVFULSW OHYHOVZHUHQRUPDOLVHG WRǃ0KRXVHNHHSLQJJHQHDQG WKHQ WKH
percentage of the expression was calculated by comparing to the control cells. (B) The BCL-2 
protein level was analysed by flow cytometry. The MFI was calculated as described previously 
in the material and methods chapter. The chart represents the percentage of the protein 
levels to untreated cells. The mean of 3 experiments was calculated and the bars represent 
the SD. (   represents p-value<0.005 when compared with the relevant untreated conditions) 
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6.2.4 The effect of ATRA on MCL-1 mRNA and protein: 
Myeloid cell leukaemia-1 (MCL-1), which is highly expressed in 
OCI-AML3 cells - as shown in Figure 5.5, is one of the BCL-2 
anti-apoptotic family molecules. It has previously been 
reported that the transcripts and protein level of MCL-1 were 
up-regulated in FLT3-ITD AML cells (Yoshimoto, et al 2009). 
Therefore, the level of MCL-1 following ATRA treatment was 
evaluated in the selected cell lines. The result showed that 
MCL-1 mRNA levels were reduced in all cell lines following 
incubation with ATRA, but the MCL-1 mRNA expression in 
ATRA-treated OCI-AML3 decreased to 40% of the untreated 
cells (p<0.005),  in comparison the three wild-type NPM cell 
lines reached a level of approximately 75% of untreated cells 
(p-value: 0.023, 0.043 and 0.018 in M-07e, MV4-11 and 
MOLM-13 cell lines, respectively) (Figure 6.5A). In contrast, 
20% of the protein level was depressed in OCI-AML3 (p-value: 
0.073), whereas MV4-11 cells showed 40% reduction in MCL-1 
protein level (p-value: 0.039) (Figure 6.5B). on the other 
hand, M-07e showed no decrease in levels of MCL-1, while 
MOLM-13 had a trend of increase (Figure 6.5B). 
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Figure 6.5: The effect of ATRA on MCL-1 mRNA and protein expression; (A) MCL-1 
mRNA level was measured by qPCR after the cell lines were treated with 500nM ATRA. The 
ǃ0KRXVHNHHSLQJJHQHZDVXVHGWRQRUPDOLVHWKHJHQHH[SUHVVLRQDQGWKHQWKHSHUFHQWDJH
of expression was calculated using the untreated cell value (B) MCL-1 protein level was 
analysed by flow cytometry. The MFI was calculated as described previously in the material 
and methods chapter. The chart represents the percentage of the protein levels compared to 
untreated cells. The mean of 3 experiments was calculated and the bars represent the SD. (* 
indicates p-value <0.05, while    represent p-value<0.005 when compared with the untreated 
conditions) 
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6.2.5 The effect of ATRA in combination with the FLT3 
inhibitor AC220: 
Due to the effects of ATRA on BCL-2 and MCL-1 levels and also 
taking into account previous work that has shown FLT3-ITD 
mutations to drive MCL-1 (Yoshimoto, et al 2009), we chose 
look at the effect of a FLT3 inhibitor on the cell lines. The 
FLT3-ITD inhibitor chosen for the study was AC220 which is a 
second-generation FLT3 inhibitor with high potency and 
selectivity (Zarrinkar, et al 2009). Therefore, the viability of 
the different cell lines was assessed after exposure to different 
concentrations of AC220. In the FLT3-ITD cell lines, the IC50 
was 1nM and 5nM in MV4-11 and MOLM-13 cells, respectively 
(Figure 6.6A),  whereas in wild-type FLT3 cell lines 25% cell 
death was achieved at a much higher concentration 1000nM 
(Figure 6.6B), but the IC50 was not achieved. Therefore, the 
MOLM-13 IC25 was used in the following experiments in the 
wild-type FLT3 cell lines. 
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Figure 6.6: The viability of AML cell lines upon AC220 treatment; The four different cell 
lines were treated with AC220 at different concentration and incubated for 72 hours.(A) The 
concentration of AC220 in MV4-11 and MOLM-13 ranged from 0.5nM and 15nM, (B) While for 
OCI-AML3 and M-07e cell lines were between 0.5nM to 1000nM. The cell viability was 
assessed by cell counting using a haemocytometer, and the percentage viability was 
calculated by calculating the viability of the treated cells and comparing to the untreated cells.  
The experiments were repeated 3 times and the bars represent the SD.  
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6.2.6 The effect of ATRA and AC220 on differentiation 
marker and apoptosis: 
FLT3 inhibitors block the abnormal signal transduction 
pathways that contribute to malignancy in cells harbouring the 
FLT3-ITD mutation. AC220 has been shown to prevent the 
constitutive FLT3 phosphorylation present in FLT3-ITD cells; 
this results in an inhibition of cell proliferation in the MV4-11 
cell line and induced differentiation and apoptosis in the 
MOLM-13 cell lines (Sexauer, et al 2012, Zarrinkar, et al 
2009). Hence, M-07e, OCI-AML3, and MOLM-13 cell lines were 
treated with AC220 at 2nM and/or with ATRA at 500nM, while 
due to the sensitivity of the MV4-11 cell line to AC220, these 
cells were treated with 0.5nM AC220 and 500nM ATRA. 
Following treatment, differentiation and apoptosis were 
evaluated. As shown in figure 6.7, there was no significant 
difference between untreated and AC220 treated cell lines with 
respect to either the level of CD11b expression or induction of 
apoptosis. When AC220 was added to ATRA-treated cells, 
there was no significant difference in when compared to ATRA-
treatment alone. These results suggest that only ATRA has 
activity against the studied cell lines and the addition of AC220 
has no effect either alone or when used in combination with 
ATRA. 
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Figure 6.7: The effect of AC220, alone or in combination with ATRA, on 
differentiation and apoptosis in AML cell lines; The differentiation marker CD11b and 
apoptosis were examined in the cell lines which were treated with AC220 at 2nM for M-07e, 
OCI-AML3, and MOLM-13 cell lines, whereas MV4-11 cell line was at 0.5nM. In addition, the 
cells were treated with 500nM ATRA combined with the aforementioned concentration of 
AC220. (A) CD11b was used to evaluate differentiation of the cells. It was analysed by flow 
cytometry and the percentage of expression was compared to untreated cells. (B) The 
apoptosis level was determined by staining the cells with annexin-V FITC and represented as a 
percentage change by comparing treated and untreated cells. The experiments were 
performed 3 times and the bars represent the SD. (* indicates p-value <0.05, while              
   indicates p-value<0.005 when compared with the untreated condition) 
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6.2.7 The effect of ATRA and AC220 on BCL-2 and MCL-1 
mRNA and protein levels: 
Subsequently, the cells were examined for BCL-2 and MCL-1 
levels after treatment with AC220 alone or in combination with 
ATRA. The BCL-2 mRNA level in the NPMc+/FLT3-wt cell line 
and in the NPM1-wt/FLT3-ITD cell lines were decreased, 
although the decrease is not statistically significant upon 
AC220 treatment in OCI-AML3 (p-value: 0.092) and MV4-11 
(p-value: 0.081), while in MOLM-13 is statistically significant 
(p-value: 0.034). In contrast, the NPM1-wt/FLT3-wt cell line 
showed no change in BCL-2 mRNA levels after AC220 
treatment (p-value: 0.633) (Figure 6.8A). When AC220 was 
combined with ATRA, however, the BCL-2 mRNA expression 
was reduced to the same level seen as when treated with 
ATRA alone in the OCI-AML3, MV4-11 and MOLM-13 cell lines 
(see section 6.2.3) (p-value in OCI-AML3, MV4-11, and MOLM-
13 cell lines: <0.005), whilst there was no effect of combining 
AC220 and ATRA on the level of BCL-2 mRNA in M-07e cell line 
(p-value: 0.506) (Figure 6.8A). The MCL-1 mRNA level was 
reduced in MV4-11 and MOLM-13 upon AC220 treatment by 
around 25% and 50%, respectively (p-value: 0.048, and 
0.021), whereas in OCI-AML3 and M-07e cell lines no 
significant decrease was shown in MCL-1 mRNA levels with 
AC220 alone (p-values: (OCI-AML3) 0.114, and  (M-07e) 
0.166) (Figure 6.8C). Combining AC220 and ATRA showed no 
additional significant reductions in MCL-1 levels when 
compared to ATRA alone (OCI-AML3) (p-value: 0.001), or 
AC220 alone (MV4-11 (p-value: 0.058), and MOLM-13 (p-
value: 0.01)) (p-value: 0.001, 0.058, 0.01, and 0.078) and 
the p-values are the reduction in MCL-1 mRNA levels following 
ATRA and AC220 treatment compared to the untreated cells 
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(Figure 6.8B). When looking at the level of BCL-2 and MCL-1 
protein in the AML cell lines treated with AC220 alone there 
was no significant difference to the level seen in untreated 
cells (p-values of BCL-2 protein levels: OCI-AML3 (0.099), 
MV4-11 (0.201), MOML-13 (0.158), and M-07e (0.157), while 
the p-values of MCL-1 protein levels: OCI-AML3 (0.835), MV4-
11 (0.678), MOML-13 (0.489), and M-07e (0.567)) (Figure 
6.8B,D).  
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Figure 6.8: The effect of AC220 alone or combined with ATRA on BCL-2 and MCL-1 
mRNA and protein levels in the AML cell lines; (A) BCL-2 mRNA and (B) BCL-2 protein 
levels were measured by real-time PCR and by flow cytometry, respectively, after the cell 
lines were treated with 500nM ATRA, 2nM AC220 for M-07e, OCI-AML3 and MOLM-13, 0.5nM 
AC220 for MV4-11, or 500nM ATRA and 2nM or 0.5nM AC220. (C) MCL-1 mRNA and (D) MCL-
1 protein levels were analysed by real-WLPH3&5DQGE\IORZF\WRPHWU\UHVSHFWLYHO\7KHǃ0
housekeeping gene was used to normalise the gene expression and then the percentage of 
the expression was divided and the control cells were calculated. The MFI was calculated as 
described previously in the material and methods chapter. The charts represent the 
percentage of the proteins level to untreated cells. The mean of 3 experiments was calculated 
and the bars represent the SD. (* indicates p-value <0.05, while     represent p-value <0.005 
when compared with the untreated conditions) 
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6.2.8 Response of primary AML cells to ATRA and/or 
AC220: 
It is known that around 40% of AML patients with the NPMc+ 
mutation co-express a FLT3-ITD mutation, this results in a 
poorer clinical prognosis than for those patients harbouring 
NPM mutant only (Falini, et al 2005). The anti-apoptotic 
protein MCL-1 has been shown to be up-regulated in FLT3-ITD 
cell lines (Yoshimoto, et al 2009), thus, targeting BCL-2 and 
MCL-1 anti-apoptotic proteins by ATRA, and AC220, 
respectively, lead to down-regulate these two major apoptotic 
proteins which would prime the NPMc+/FLT3-ITD cells for 
apoptosis. Therefore, we examine the effect of adding a FLT3 
inhibitor to ATRA in AML patients that have the NPM1 and 
FLT3-ITD mutations and the work on the samples was done 
blind without knowing the mutation status of the samples until 
the experiments have completed.  
Cells from a total of 8 patients were analysed for the effect of 
ATRA and AC220 on cell viability and BCL-2 and MCL-1 mRNA 
expression (there was not enough material to also look at the 
protein level). 10 further patient samples were thawed but 
these had to be excluded from the analyses because the post-
rest viability was less than 80% or the cell viability was 
affected by DMSO, this was primarily due to the length of time 
the samples had been stored in liquid nitrogen (>10 years). 
The cell viability in samples with wild-type NPM1 and wild-type 
FLT3 showed a reduction after being treated with 500nM ATRA 
of approximately 40%, 15% and 30%, in patient samples 
number 1, 2, and 3 respectively (Figure 6.9A). NPMc+ cells 
showed only a 15%-20% reduction in cell viability in 4 out of 5 
samples and the fifth sample demonstrated a 40% reduction 
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(Figure 6.9B,C). In addition, the combination treatment of 
patient cells with ATRA and AC220 showed a decrease in the 
cell viability to a similar level as detected after treatment with 
ATRA only (Figure 6.9B,C). In the absence of a co-expressed 
FLT3-ITD mutation, neither wild-type or mutant NPM1 patient 
cells were sensitive to the FLT3 inhibitor (AC220) alone. 
However, FLT3-ITD/NPMc+ cells demonstrated a decrease in 
the cell viability of around 20% in one sample out of two 
(Figure 6.9C).  
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Figure 6.9: The viability of primary cells upon ATRA, AC220, or ATRA/AC220 
treatment; Primary cells were treated with 500nM ATRA, 2nM AC220 or a combination of the 
two drugs. The cell viability was evaluated by flow cytometry as described in the material and 
methods chapter (2.5.3). (A) Represents the NPM1-wt/FLT3-wt samples, (B) NPMc+/FLT3-
wt, and (C) NPMc+/FLT3-ITD samples. 
 
Because only one patient sample showed a reduction in cell 
viability upon AC220, FLT3-ITD patient samples were further 
examined and treated with different concentrations of AC220 
and, in addition, a second FLT3 inhibitor CEP-701 to evaluate 
the protocol and the activity of the inhibitors. The FLT3-ITD 
cell lines were run in parallel to test that the drug activity had 
not deteriorated during storage. The concentration of CEP-701 
was chosen dependent on previous work which used a broad 
range (10±100nM) of CEP-701 concentrations on primary cells 
(Levis, et al 2002). The cells, which were treated with CEP-
701, showed an 80% cell death at 100nM, whereas with 
AC220, cell viability was reduced by approximately 20% at 
1000nM, a concentration 50x greater than that required to kill 
more than 80% of cells within the MV4-11 and MOLM-13 cell 
lines (Figure 6.10). These results show that the AC220 drug is 
active in the cell lines, but not effective on the patient sample 
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at the level of cell viability. However, the real-time patient 
results showed differences in the levels of BCL-2 and MCL-1, 
which indicate that AC220 was active in the patient cells. In 
addition, AC220 was used because of the evidence that it may 
also induce differentiation of FLT3-ITD cells (Sexauer, et al 
2012). 
 
 
Figure 6.10: Primary cell lines in response to FLT3 inhibitors at different 
concentrations; Primary cells harbouring a FLT3/ITD were treated with two different FLT3 
inhibitors, while the FLT3-ITD cell lines were only treated with AC220. The cells were treated 
with (A) CEP-701 at low (100nM) and high (1000nM) for 72 hours, or (B) with AC220 at 
different concentration (1nM ± 100nM). The viability was determined by flow cytometry.  
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With regards to the anti-apoptotic mRNA expression levels, 3 
out of 5 NPMc+AML cells (60%) showed a decrease more than 
25% in BCL-2 mRNA upon ATRA treatment and one of these 
samples also had a FLT3-ITD mutation. BCL-2 mRNA level was 
reduced in 1 out of 3 NPM1-wt/FLT3-wt samples (33%). In 
contrast, the MCL-1 mRNA expression decreased in 2 out of 3 
samples that are NPM1-wt/FLT3-wt, whereas if an NPMc+ 
mutation was present a decrease in MCL-1 was seen in each 
sample (5/5) (Table 5.1).  
The BCL-2 and MCL-1 mRNA levels, upon adding AC220 in 
these patient samples, showed down-regulation of BCL-2 
mRNA in 3/5 samples with an NPMc+ mutation and 1 sample 
with NPM1-wt/FLT3-wt, whereas the MCL-1 mRNA level 
decreased in 5/5 samples with mutant NPM1 and 2/3 samples 
with wild-type NPM1 (Table 5.1). This data indicates that ATRA 
down-regulates BCL-2 and MCL-1 mRNA levels in AML cells, 
harbouring NPM1 mutations more than in NPM1-wt/FLT3-wt 
cells. In addition, in combination with AC220, a reduction was 
observed in NPMc+ cells. However, because of the difficulty in 
the culture of primary cells and the majority of these cells did 
not survive, the number of patient samples was not sufficient. 
Therefore, further work in the department is going on and 
more samples are being recruited. 
Table 6.1: BCL-2 and MCL-1 mRNA expressions in patient samples after exposed to 
ATRA and/or AC220 treatment 
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6.3 Discussion: 
The NPMc+AML cells are characterised by low expression of 
CD34, and down-regulation of BCL-2 by ATRA was shown to 
be more frequent in CD34 negative cells than CD34 positve 
(Bradbury, et al 1996). In addition, NPMc+AML cell line 
showed high expression of anti-apoptotic mRNA which could 
be a result of delocalization of mutant and wild-type NPM1 to 
the cytoplasm (chapter 5). For that reason, in this chapter the 
effect of ATRA on the levels of BCL-2 and MCL-1 in the mutant 
NPM1 cell line were evaluated and compared to levels in wild-
type NPM1 cell lines, in addition primary AML samples were 
also studied.  
Previously ATRA was found to down-regulate BCL-2 levels in 
the HL-60 cell line and AML samples, particularly in the CD34 
negative patient cells which showed decline in the protein level 
upon ATRA treatment (Bradbury, et al 1996, Pisani, et al 
1997). Treatment of the OCI-AML3 cell line with ATRA has 
previously been shown to result in an increase in cell 
differentiation and apoptosis (Balusu, et al 2009, Kutny, et al 
2010). In keeping with this, our results confirmed the increase 
in CD11b positive cells and increase in apoptosis in the OCI-
AML3 NPMc+ cell line treated with ATRA compared with the 
NPM1 wild-type cell lines. This indicates that the OCI-AML3 cell 
line, which harbours an NPM1 mutation, is more sensitive to 
ATRA-induced differentiation and apoptosis than the other AML 
cell lines studied. We next examined the effect of ATRA on 
BCL-2 levels in NPM1 mutant and wild-type cell lines. It was 
found that the level of BCL-2 mRNA decreased in the MV4-11 
and MOLM-13 cells following ATRA treatment, but the 
reduction in the OCI-AML3 cells was greater, whereas in M-
07e cell line did not shown a change. Thus, down-regulation of 
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BCL-2 mRNA level in OCI-AML3, which harbours NPMc+, is 
more likely to be achieved by ATRA. Although the huge 
reduction in the expression of BCL-2 mRNA was demonstrated, 
the BCL-2 protein level in OCI-AML3 cells decreased to 
approximately the same levels as the MV4-11 and MOLM-13 
cell lines. The reasons behind this finding have not been 
elucidated but it seems that the long half-life of BCL-2 protein 
and other post-translational factors may affect the protein 
level (Gao and Dou 2000). However, the protein levels are 
going to be evaluated by western blot to confirm the flow 
cytometry results. In primary AML cells, 60% of the 
NPMc+AML cells with wild-type FLT3 showed a reduction in 
BCL-2 mRNA level in response to ATRA, and 50% of 
NPMc+/FLT3-ITD cells also responded to the drug. When 
considering MCL-1 mRNA and protein levels, these were 
decreased in OCI-AML3 upon ATRA treatment, and in 66% of 
NPMc+AML patient samples. The exact molecular mechanism 
through which ATRA has an effect on NPMc+AML cells is not 
completely clear. However, it was noted that NPMc+AML cells, 
when treated with ATRA, showed a down-regulation of the 
NPM1 mutant protein. As a result, the NPM1 wild-type is re-
located in the nucleus and this leads the cell to initiate cell 
cycle arrest and apoptosis (Martelli, et al 2007). 
Internal tandem duplication in the FLT3 juxtamembrane region 
cause constitutive kinase activation and signal for 
hematopoietic growth (Dohner and Dohner 2008). 40% of 
NPMc+ mutated AML samples also have a FLT3-ITD and the 
presence of the two mutations converts the good prognosis 
associated with NPMc+ into an intermediate prognosis (Falini, 
et al 2007b). FLT3-ITD cells show up-regulation of MCL-1 
protein and transcript levels (Yoshimoto, et al 2009), thus we 
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evaluated the effect of adding AC220, which is a highly 
selective inhibitor of FLT3, to down-regulate MCL-1 levels in 
FLT3-ITD cell lines. Treating the MV4-11 and MOLM-13 cell 
lines with AC220 only showed a decrease in MCL-1 mRNA 
level, while the protein level did not change. In addition, the 
MCL-1 protein level in MOLM-13 cell line did not correspond to 
the MCL-1 mRNA expression level which was suppressed after 
treatment with ATRA. This conflict could be a result of other 
biological factors which cooperate in MCL-1 levels, particularly 
it is known that MCL-1 protein has a short turnover and there 
are other pathways that fine-tune MCL-1 expression (Gores 
and Kaufmann 2012). At the N-terminal domain of MCL-1, 
there are 2 sequences called PEST (proline, glutamic acid, 
serine, and threonine) sequences which are targeted by E3 
ubiquitin ligases for rapid proteasomal degradation (Gores and 
Kaufmann 2012)  Thus, deubiquitination or inactivation of E3 
ligases molecules are expected to increase MCL-1 protein 
stabilisation (Schwickart, et al 2010, Wertz, et al 2011).  
At the level of cell survival, none of the primary AML samples 
responded to AC220, even at high concentrations except one 
sample bearing NPMc+AML/FLT-ITD. Therefore, a FLT3-ITD 
sample was tested using two different FLT3 inhibitors. We 
IROORZHGWKHVDPHSURWRFROZKLFKZDVXVHGE\WKH=DUULQNDU¶V
group and the AC220 (IC5o) in their patient samples varied 
between 0.8nM and 2nM but our patient samples were not 
killed by these concentrations (Zarrinkar, et al 2009). Pauwels 
et al. and Smith et al. found that mutations in the kinase 
domain of FLT3 (F691, Y842, G697R, and N676D) can cause a 
resistance to AC220 (Pauwels, et al 2012, Smith, et al 2012). 
However, these mutations have been identified at relapse 
which means that resistance to FLT3 inhibitors are developed 
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after treatment with this inhibitors (Smith, et al 2012). 
Moreover, Pratz et al. found that some FLT3-ITD AML samples 
showed no cytotoxic effect from AC220 because AC220 is a 
highly selective FLT3 inhibitor, while the same samples were 
sensitive to CEP-701, which is a multi-targeted kinase inhibitor 
(Pratz, et al 2010). They reported that incubation of FLT3-ITD 
AML primary cells with IL-3 has decreased the cytotoxicity 
effect of AC220 to FLT3-ITD primary cells in vitro (Pratz, et al 
2010). Thus, it is suggested that our FLT3-ITD sample has 
been affected by IL-3, which should not be incubated with 
AC220 in FLT3-ITD AML cells in vitro. 
The effect of ATRA, in combination with AC220 on the cell lines 
and patient samples, did not enhance the reduction in BCL-2 
and MCL-1 mRNA level significantly, but by adding AC220 
alone a trend of decline in the level of BCL-2 and MCL-1 mRNA 
was seen in OCI-AML3, MV4-11, and MOLM-13 cell lines. At 
the protein level, the decrease in BCL-2 level in OCI-AML3 and 
homozygous FLT3-ITD cell lines followed the decrease in 
mRNA expression after adding ATRA and AC220. As results, 
the FLT3 inhibitor does not have a negative impact on ATRA in 
down-regulation of BCL-2 and MCL-1 mRNA in NPMc+AML cell 
lines. 
Clinically, the administration of ATRA to NPMc+AML patients 
was investigated in combination with intensive chemotherapy. 
In the German group, ATRA was given after the induction 
therapy with idarubicin, cytarabine and etoposide on day 3 
through to day 28. The complete remission rate in the NPMc+ 
patients was significantly improved after addition of ATRA. In 
addition, the relapse-free and overall-survival rates were 
better in those patients than in patients with other genetic 
markers (Schlenk, et al 2011, Schlenk, et al 2009). On the 
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other hand, the Medical Research Council UK trial data do not 
agree with the previous study and they found that the addition 
of ATRA to chemotherapy had no significant effect on the 
outcome of NPMc+AML patients (Burnett, et al 2010). In the 
MRC protocol, however, ATRA was given from the first day 
with the induction therapy, which consists of daunorubicin, 
Ara-C and thioguanine, while it was given on the third day of 
the therapy in the Schlenk protocol (Burnett, et al 2010, 
Schlenk, et al 2009). Moreover, there is evidence, which 
confirms that when ATRA was given after Ara-C, it showed a 
significant decline in BCL-2 protein and elevated apoptosis in 
AML patients (Andreeff, et al 1999). In APL cells, 
administration of ATRA before chemotherapy was shown to 
induce the trans-membrane drug transporter ABCB1 (MDR1) 
and lead to up-regulation doxorubicin resistance (Tabe, et al 
2006). Therefore, it has been suggested that the effect of 
ATRA can be observed after the leukaemic cells are treated 
with cytotoxic agents (Schlenk, et al 2009). 
In summary, the OCI-AML3 cells are more sensitive in 
response to ATRA at a lower concentration than the NPM1 
wild-type cell lines that were tested in this work. In addition, 
the reduction of BCL-2 and MCL-1 levels was greater in 
NPMc+AML following ATRA than in the other cell lines. As a 
result, the percentage of apoptosis and the differentiation 
marker level both increased. However, further studies are 
required with more primary AML samples in order to confirm 
the effect of ATRA on BCL-2 and MCL-1 in NPMc+AML cells.   
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7. General discussion: 
NPM1 is an abundant phosphoprotein and is highly expressed 
in all tissues (reviewed in (Grisendi, et al 2006)). Although 
NPM1 is predominantly localised in the nucleolus, it shuttles 
continuously between the nucleus and cytoplasm and 
transports ribosomal components to the cytoplasm, 
participating in ribosomal assembly (reviewed in (Falini, et al 
2007b)). NPM1 is involved in the cell proliferation process and 
acting as a molecular chaperone in protein synthesis, histone 
assembly, and nucleic acid interactions (reviewed in (Falini, et 
al 2007b, Grisendi, et al 2006)). In contrast, NPM1 is also 
considered as a tumour suppressor protein through the 
mediation of P53 activation by binding to the P53 negative 
regulator (HDM2), and ARF (Colombo, et al 2002, Kurki, et al 
2004b). 
NPM1 mutations are the most common mutation in AML with a 
normal karyotype. NPM1 mutations cause a frame-shift in the 
C-terminus which results in the deletion of two tryptophan 
residues, 288 and 290 (or at least 290 only) leading to the 
disruption of the nuclear localization signal (NLS) while, an 
additional leucine-rich nuclear export signal (NES) is 
generated causing delocalisation of NPM1 into the cytoplasm 
(Falini, et al 2006, Falini, et al 2007b). NPM1 mutations mainly 
occur in exon 12, but they can also be present in exons 9, 10 
or 11 (Falini, et al 2005). The most common type is mutation 
A, which is a duplication of the TCTG tetra-nucleotide at 
positions 956 to 959 (Falini, et al 2005, Falini, et al 2007b). 
NPM1 mutations coincidence with other mutations and the 
presence of internal tandem duplication (ITD) mutations in the 
tyrosine kinase receptor FLT3 in NPMc+ AML accounts for 
around 40% of NPMc+ cases (Rau and Brown 2009, Verhaak, 
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et al 2005). In NPMc+AML, the prognosis is categorised as 
favourable with a complete remission rate around 80%, while 
in the presence of FLT3-ITD, the CR is reduced and considered 
as an intermediate prognosis (Dohner, et al 2005, Schnittger, 
et al 2005, Thiede, et al 2006). 
In our experiments, five different leukaemic cell lines were 
used: OCI-AML3, M-07e, MOLM-13, MV4-11, and HL-60. OCI-
AML3 is the only cell line known to harbour the NPMc+ 
mutation and so is widely used as a model of NPMc+AML in 
the literature (Quentmeier, et al 2005). M-o7e, MV4-11, 
MOLM-13, and HL-60 cell lines were used as cell lines that 
express wild-type NPM1, whilst OCI-AML3, M-07e, MV4-11 and 
MOLM13 are P53 wild-type. HL-60 cells have a deletion in the 
P53 genes and were therefore only used in APE1 subcellular 
localisation experiments as a control for our results because 
the subcellular localisation of APE1 had been previously 
detected in the cytoplasm of HL-60 cells (Yoshida, et al 2003). 
MV4-11 and MOLM-13 cell lines were used in evaluating the 
effect of AC220 ± FLT3 inhibitor - on BCL-2 and MCL-1 levels 
because they harbour FLT3-ITD mutations (Quentmeier, et al 
2003). We would have used isogenetic cell lines expressing 
NPM1-wt/NPMc+ with or without FLT3-ITD, but these were 
unfortunately not available.  
NPM1 is associated with the regulation of DNA repair and has 
been shown to induce proliferating cell nuclear antigen 
(PCNA), which acts as a platform for many enzymes in the 
response to DNA damage (Wu, et al 2002). In addition, ARF 
stability, which is a tumour suppressor protein, is achieved by 
its interaction with NPM1 via subsequent protection of ARF 
from degradation by blocking its ubiquitination (Khan, et al 
2004, Korgaonkar, et al 2005, Kuo, et al 2004). ARF 
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translocates in the nucleoplasm and promotes P53 stabilisation 
by binding to HDM2, while the subcellular localisation of ARF in 
nucleoli is sequestered by NPM1 resulting in increased HDM2 
binding to P53 and inactivation of P53 function (Korgaonkar, et 
al 2005). In NPMc+AML cells, ARF is delocalised into the 
cytoplasm by the mutant NPM1 leading to attenuation of ARF 
activity and hence P53 destabilisation and consequent 
reduction of activity (Colombo, et al 2006, den Besten, et al 
2005). It has therefore been hypothesised that the favourable 
outcome in NPMc+AML cases could be a result of perturbation 
of DNA damage response.  
In response to DNA damage agents, our assays showed that 
the DNA damage process was activated efficiently in 
NPMc+AML cells indicating that delocalisation of NPM1 into the 
cytoplasm has not impaired global repair of DNA. However, 
the protein level of NPM1 was elevated in NPMc+ cells in the 
nuclear and cytoplasmic fractions but relatively much more in 
the nucleus, whereas the NPM1 mRNA expression has not 
changed. The up-regulation in NPM1 protein level may 
contribute to the DNA damage response and the increase in 
NPM1 protein production and re-localisation of wild-type NPM1 
into the nucleolus. The up-regulation in NPM1 protein level 
would appear that NPM1 expression is regulated at the level of 
translation. It has been found that NPM1 protein level depends 
on activation of mTOR signalling, which is a serine-threonine 
protein kinase that controls translation efficiency, cell cycle 
progression, and ribosomal biogenesis through its ability to 
integrate nutrient and mitogenic signals (Pelletier, et al 2007).  
TSC1 ± an upstream inhibitor of mTOR ± was found to repress 
NPM1 protein level, while deletion of TSC1 resulted in NPM1 
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protein induction through increased translation of existing 
nucleophosmin mRNAs (Pelletier, et al 2007).  
As a result, It has been suggested that the subcellular 
localisation of wild-type NPM1 and mutant NPM1 should be 
identified using antibodies that only recognise wild-type NPM1 
without interference with the mutant NPM1, in addition to 
using antibodies specifically against the mutant NPM1 after 
DNA damage response, in order to evaluate the subcellular 
localisation of wild-type and mutant NPM1 in response to DNA 
damage agent. Moreover, further studies are required to 
evaluate the mRNA and protein levels of NPM1 in response to 
stress at different time points. Previous data showed that 
NPM1 protein production is dependent on mTOR activation and 
rapamycin decreases NPM1 protein level without affecting 
NPM1 mRNA level (Pelletier, et al 2007). Thus, in order to 
evaluate the translational control of NPM1, we suggest treating 
NPMc+AML and wild-type NPM1 cell lines with rapamycin, 
which inhibits mTOR signalling pathway, and then the levels of 
NPM1 mRNA and protein are measured. Finally, with the aim 
of determine the important role of NPM1 in DNA repair 
function in NPMc+ cells, the mutant NPM1 and wild-type NPM1 
or the mutant NPM1 only should be knocked-down in 
NPMc+AML cells, followed by exposure of the cells to DNA 
damage agents and evaluation of the repair activity in NPMc+ 
and wild-type NPM1 cells. We knocked-down NPM1 for only 48 
hours, while about 96 hours of NPM1 down-regulation are 
required to study the repair assay after NPM1 siRNA 
nucleofection. Thus, it is recommended to use stable 
transfectants rather than transient ones to perform this 
experiment. 
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APE1 is an essential protein involved in the response to DNA 
damage. APE1 functions in the BER pathway and participate in 
the repair of certain DNA lesions and also acts as a redox co-
activator of many transcription factors such as P53, and NF-ǉ%
by inducing their DNA binding (reviewed in (Fishel and Kelley 
2007)). NPM1 is considered to fine-tune APE1 functions 
through binding to the N-terminal of APE1 and increasing its 
endonuclease activity (Vascotto, et al 2009). Recently, 
Vascotto et al. have demonstrated that NPM1 is essential for 
subcellular localisation of APE1 within nucleoli (Vascotto, et al 
2013). In haematological cell lines, Vascotto et al. assessed 
the presence of APE1 in the cytoplasm of NPMc+AML cells by 
using OCI-AML3 cells and compared the results with OCI-AML2 
cell line, which expresses wild-type NPM1 (Vascotto, et al 
2013). They showed that the APE1 subcellular localisation is 
delocalised into the cytoplasm in OCI-AML3 cells due to the 
presence of NPMc+ compared with wild-type NPM1 cell line 
(Vascotto, et al 2013). However, we found that APE1 is 
localised in the cytoplasm of OCI-AML3, M-07e and HL-60 cell 
lines and because M-07e and HL-60 cells are NPM1 wild-type 
this suggests that cytoplasmic localisation is not independent 
of an NPMc+ mutation. The presence of APE1 in the cytoplasm 
has been seen in fibroblasts, lymphocytes, macrophages, and 
hepatocytes (Tell, et al 2009, Yoshida, et al 2003) and so is a 
common finding. In response to DNA damaging agents - 
etoposide and MMS, we showed that APE1 is translocated into 
the nucleus where it presumably participates in the DNA 
damage response.  
A reduction in APE1 level or blocking of APE1 DNA repair 
function is associated with hypersensitivity of cells to 
alkylating agents (McNeill and Wilson 2007, Wang, et al 2004). 
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The sensitivity of NPM-/- mouse embryonic fibroblasts to a DNA 
damage inducer known to produce DNA lesions which are 
repaired by BER, is greater than NPM+/+ cells (Vascotto, et al 
2013). In addition, OCI-AML3 cells and bone marrow 
NPMc+AML patient cells were more sensitive than wild-type 
NPM1 cell lines and blast cells from healthy donor (Vascotto, et 
al 2013). Furthermore, the level of AP sites was higher in OCI-
AML3 cell than in OCI-AML2 (Vascotto, et al 2013). In 
contrast, our work showed that MMS treatment of NPMc+AML 
cell line and other haematological cell lines with wild-type 
NPM1 showed no differences in sensitivity to the methylating 
agent. Vascotto et al. treated OCI-AML3 and OCI-AML2 cells 
with MMS at different concentrations for 8 hours and evaluated 
the cell viability without assessing the cells during the 
recovery (Vascotto, et al 2013). Whereas Our MMS sensitivity 
protocol was performed on three different leukaemic cell lines, 
which are OCI-AML3, MV4-11, and M-07e, and these cells 
were treated for 1 hour with MSS at different concentrations 
and then incubated for 3 days with free-drug medium to allow 
cell recovery in order to assess the ability of cells to survive 
after the DNA damage inducer. In addition, OCI-AML3 cells are 
the only cell line bearing NPMc+ mutations and the results 
were compared with no isogenetic control cells. Therefore, 
further work should be done on a large number of patient 
samples. 
As a result, our work suggests that the repair of MMS in 
NPMc+AML cells when compared with the selected wild-type 
NPM1 cell lines has not been perturbed, this may either be due 
to a functional BER pathway or other DNA repair pathways 
which also act on this class of DNA damage. In BER, for 
example, inhibition of APE1, which is a protein involved in BER 
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process, leads to the formation and accumulation of DSB from 
unrepaired single strand breaks (Sultana, et al 2012). As a 
result, Homologous recombination pathway attempts to repair 
the DNA damage (Rehman, et al 2010, Sultana, et al 2012). 
In western blot experiments, a lower band was detected by 
APE1 antibodies in the OCI-AML3 ± NPM1 mutated cell line at 
33kDa, in addition to the band at 37KDa which corresponds to 
the expected size of the APE1 protein. In wild-type NPM1 cell 
lines, only the expected APE1 band ± 37KDa was observed. In 
the literature, a lower protein band, which was observed with 
$3( DQWLERG\ KDV EHHQ LGHQWLILHG DV 1Ʃ$3(
(Chattopadhyay, et al 2006, Yoshida, et al 2003)1Ʃ$3(
lacks the first 33 N-terminal residues and it is mainly located 
in the cytoplasm and mitochondria suggesting it may have a 
potential role in DNA repair activity in the mitochondria 
(Chattopadhyay, et al 2006, Yoshida, et al 2003)1Ʃ$3(LV
characterised by higher endonuclease activity than the full-
length APE1 and associated with an apoptotic phenotype 
(Vascotto, et al 2009, Yoshida, et al 2003). The generation of 
this product is by a proteolysis process at Lys31 through 
granzyme A protein, which cleavages APE1 and induces rapid 
cell death, leading to cleavage of the APE1 (Chattopadhyay, et 
al 2006, Guo, et al 2008). Therefore, an investigation of the 
SRWHQWLDO 1Ʃ$3( SURGXFW was undertaken by antibodies 
binding to the N-terminal domain of APE1. The N-terminal 
APE1 antibody reacts with the full-length APE1 at the N-
terminal region, and therefore will QRW UHDFW ZLWK 1Ʃ$3( 
which lacks the N-terminal domain (Yoshida, et al 2003). The 
result shows that the lower band was still present on the 
ZHVWHUQEORWVXJJHVWLQJWKDW LWPLJKWQRWEH1Ʃ$3( but a 
different product containing the N-terminal domain. 
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Furthermore, APE1 mRNA was studied to see if alternative 
splice products could be seen but no such splicing was 
recognised. Whilst this thesis was being prepared Vascotto et 
al. published evidence that the cytoplasmic truncated APE1 in 
NPMc+AML cells is a result of a specific proteolytic activity 
independent of granzyme A protein, which is not expressed in 
OCI-AML3 cells (Guo, et al 2008, Vascotto, et al 2013). 
Apoptosis is a major pathway in DDR which removes 
unwanted or damaged cells. Its deregulation may contribute to 
cancer development. BCL-2 family proteins are an integral part 
of the apoptotic process and either promote or prevent 
apoptosis. Anti-apoptotic BCL-2 expression has been shown to 
play a crucial role in the development of leukaemia and up-
regulation of BCL-2 has been detected in the majority of 
patients with AML (Nagy, et al 2003). Moreover, MCL-1, which 
is another anti-apoptotic protein, has been shown to be 
essential for haematopoietic stem cell and early myeloid 
precursor cell survival and the expression of MCL-1 has been 
shown to be increased in FLT3-ITD AML cases (Yoshimoto, et 
al 2009).  
The expression of BCL-2 and MCL-1 were evaluated in an 
NPMc+AML cell line and the results showed that the mRNA 
level of BCL-2 and MCL-1 were higher in the NPMc+AML 
compared to other cell lines with wild-type NPM1. However, 
when mutant NPM1, or total NPM1, was knocked-down by 
specific siRNAs, there was a reduction in the BCL-2 and MCL-1 
mRNA level in NPMc+AML cells and the protein level of P53 
was increased. Thus, these results revealed that NPM1 may 
participate in the abnormal over-expression of BCL-2 and MCL-
1 in NPMc+AML. P53 negatively regulates BCL-2 expression 
through interaction with the BCL-2 promoter and in 
Qutob, H  Chapter 7 
165 
 
NPMc+AML it is known that ARF, which binds to HDM2 and 
activates P53 function, is delocalised with the NPM1 into the 
cytoplasm (Colombo, et al 2006, Wu, et al 2001). Thus, we 
suggest two possible mechanisms that cause the up-regulation 
of BCL-2 and MCL-1 in NPMc+AML cells. Firstly, the 
delocalisation of NPM1 and ARF into the cytoplasm results in 
the inactivation of P53 function leading to activate the BCL-2 
promoter and increase in BCL-2 level, and the second 
suggestion is that delocalisation of NPM1 into the cytoplasm 
causes NPM1 to interact with the pro-apoptotic BCL-2 family 
proteins and prevents activation of BAX and BAK leading to an 
increase in the level of BCL-2 and MCL-1. Moreover, in 
NPMc+AML, HEXIM1, which is an inhibitor of polymerase II 
transcription elongation, is delocalised in the cytoplasm by the 
mutant NPM1. As a result, the impairment of HEXIM1 function 
induces expression of genes that are associated with anti-
apoptotic family proteins such as MCL-1 (Gurumurthy, et al 
2008). 
Further studies are needed to confirm the basal levels of BCL-
2 and MCL-1 proteins by western blot and to compare these 
results with our flow cytometry measurements which would 
offer further validation of the method. In addition, our knock-
down experiments were used to evaluate the mRNA level of 
BCL-2 and MCL-1, thus it is essential to verify the effect of 
down-regulation of BCL-2 and MCL-1 mRNA on its protein 
level. Thereafter, the impact of the mutant NPM1 on the 
expression of the anti-apoptotic proteins could be assessed by 
knock-down of the mutant NPM1 only in NPMc+AML, followed 
by evaluation of the levels of BCL-2, MCL-1 and P53. 
Moreover, the interaction of the mutant and wild-type NPM1 
with other proteins in the cytoplasm should be studied, 
Qutob, H  Chapter 7 
166 
 
particularly with those proteins involved in the modulation of 
apoptosis such as BH3-only proteins.  
A reduction in the anti-apoptotic BCL-2 and MCL-1 levels in 
NPMc+AML cells after knock-down of NPM1 by siRNA led us to 
treat NPMc+AML with a drug that may target the anti-
apoptotic BCL-2 proteins in NPMc+AML cells. Administration of 
ATRA causes an increase in cell differentiation and apoptosis 
which leads to increased sensitivity of AML blast cells to 
chemotherapy (Andreeff, et al 1999, Pisani, et al 1997). In 
clinical trials, non-APL AML patients have shown variable 
results in response to ATRA. UK-MRC trial failed to 
demonstrate a benefit of adding ATRA to standard 
chemotherapy (Burnett, et al 2010), whereas the Austrian-
German AML study showed that the presence of NPMc+/FLT3-
wt mutations resulted in high complete remission rate, and 
improved relapse-free and overall survival (Schlenk, et al 
2011, Schlenk, et al 2009). Bradbury et al. have shown that 
the expression of BCL-2 is reduced to a greater extent in AML 
cells which are CD34 negative (Bradbury, et al 1996). 
Interestingly, this is a feature of NPMc+AML. Therefore, the 
NPMc+AML cells and wild-type NPM1 cells were treated with 
ATRA and the mRNA and protein expression of BCL-2 and 
MCL-1 were determined. Our results showed that ATRA 
decreased the level of BCL-2 and MCL-1 in all cell lines but a 
near total reduction was observed in NPMc+AML. In addition, 
the NPMc+AML cells were more sensitive to cell differentiation 
and apoptosis. Therefore, it seems that ATRA has a crucial 
impact on the NPMc+AML cells by down-regulation of BCL-2 
and MCL-1 level. However, the exact mechanism has not been 
clarified but it has been noted that the mutant NPM1 in 
NPMc+AML cell line was decreased upon ATRA treatment 
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which is suggested to result in wild-type NPM1 being retained 
in the nucleus leading to induction of cell cycle arrest and 
apoptosis (Martelli, et al 2007). 
Further experiments are needed to confirm the effect of ATRA 
on the anti-apoptotic proteins. Firstly, the levels of BCL-2 and 
MCL-1 proteins were detected by flow cytometry, which should 
be confirmed by western blot as a reference standard method.  
Moreover, we showed a down-regulation of BCL-2 in 
NPMc+AML upon ATRA treatment, thus it is important to 
confirm these results by up-regulating BCL-2 levels in these 
cells then treating the cells with ATRA and assessing the level 
of BCL-2 expression. With regard to the patient samples, the 
experiments were run on a small number of patient cells, 
therefore, to increase the power of the results more patient 
samples must be studied. In addition, the level of BCL-2 and 
MCL-1 mRNA level were detected in the patient samples, the 
protein levels of BCL-2 and MCL-1, and the expression of CD34 
status should also be evaluated to establish the correlation of 
the mRNA with protein level, and the expression of CD34 with 
response to ATRA. 
In NPMc+AML, 40% of the cases co-harbour FLT3-ITD 
mutations. It has been shown that FLT3-ITD play a major role 
to induce MCL-1 expression via activation of PI3K/Akt pathway 
(Yoshimoto, et al 2009). Therefore, we added AC220, which is 
a highly selective FLT3 tyrosine kinase inhibitor and induces 
differentiation of FLT3-ITD cells, to the ATRA-treated cells and 
evaluated BCL-2 and MCL-1 expression (Sexauer, et al 2012, 
Zarrinkar, et al 2009). BCL-2 and MCL-1 mRNA levels were 
decreased in NPMc+AML and FLT3-ITD cell lines upon 
treatment with AC220, while the protein levels did not change. 
In patient samples, the cell survival was not affected by the 
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addition of AC220. However, in combination with ATRA we 
showed the same impact as seen in cells treated with ATRA 
alone. However, more work is required to investigate the 
potential benefits of adding AC220 to ATRA in the treatment of 
NPMc+AML/FLT3-ITD patients by using patient samples 
harbouring both mutations and treating the cells with these 
drugs and evaluating the cell survival and anti-apoptotic 
levels. 
The classic view of protein synthesis (the central dogma) 
states that DNA makes RNA makes protein. This view assumes 
that the production of protein is correlated to the mRNA level, 
but there are other biological factors that affect this relation 
(reviewed in (Maier, et al 2009)). In our results, the weak 
correlation between the mRNA and protein levels of NPM1, 
BCL-2 and MCL-1 could be a result of post-transcriptional 
processes, translational efficiency, the long half life of 
proteins, or other regulatory mechanisms such as miRNA 
which have been found to fine-regulate protein expression 
without causing change in gene expression (Maier, et al 2009, 
Vogel and Marcotte 2012). 
In conclusion, although NPM1 subcellular localisation is 
perturbed in NPMc+AML leading to delocalisation of other 
proteins that are involved in DNA damage response, we have 
not demonstrated the impairment in DNA repair mechanisms 
in cells harbouring NPMc+ mutations. However, an increase in 
NPM1 levels in nuclear lysate has been observed to a similar 
level to that seen in wild-type NPM1 cells. Over-expression of 
anti-apoptotic proteins BCL-2 and MCL-1 in NPMc+AML was 
observed and these are suggested to play an essential role in 
leukaemogenesis development. ATRA has showed a significant 
effect on the level of anti-apoptotic BCL-2 and MCL-1 which 
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could be useful in combination with FLT3 inhibitors in 
NPMc+/FLT3-ITD AML cases. Furthermore, there are potential 
agents which could serve as good targets for leukaemia 
therapy, thus further research should be focused on the 
influence of adding the NPM oligomerization inhibitor, which 
disrupts NPM1 oligomer formation and inhibit aberrant NPM1 
function in NPMc+AML cells, or the anti-apoptotic proteins 
inhibitors to the cytotoxic therapy for NPMc+AML patients. 
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Appendix: 
4.1 APE1 mRNA sequencing results in the leukaemic cell 
lines:  
(A) 1- OCI-AML3 Forward: 
 
2- OCI-AML3 Reverse: 
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(B) 1- M-07e Forward: 
 
2- M-07e Reverse: 
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(C) 1- HL-60 Forward: 
 
2- HL-60 Reverse: 
 
